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ZUSAMMENFASSUNG 
Probiotika sind bakterielle Präparate, die – wenn sie in ausreichender Menge eingenommen 
werden – die Gesundheit eines Wirtes verbessern, indem sie die Mikrobiota bestimmter Habitate 
dieses Wirtes verändern. In den letzten Jahren expandierte der Markt für Probiotika, aber es besteht 
noch immer keine Einigung über die Wirkungsmechanismen dieser Produkte. Die meisten 
probiotischen Eigenschaften scheinen stammspezifisch zu sein. Es besteht demnach Bedarf an neuen 
und gut charakterisierten Stämmen, ebenso wie an der Aufdeckung ihrer funktionellen 
Wirkungsweisen. Ziel dieser Studie war es, Stämme von Lactobacillus aus traditionellen, 
fermentierten afrikanischen Produkten sowie aus dem Stuhl von Säuglingen als mögliche Probiotika in 
vitro zu isolieren, zu identifizieren und zu charakterisieren. Ein bestehendes Model einer Magen-
Darm-Passage wurde optimiert und verwendet um 30 Lactobacillus-Isolate auf ihre 
Überlebensfähigkeiten unter simulierten gastrointestinalen Bedingungen zu testen. Sieben Stämme mit 
guten Überlebensfähigkeiten wurden selektiert und mit Hilfe von pheno- und genotypischen Methoden 
identifiziert. All diese Stämme besaßen Gallensalzhydrolase-Aktivität, welches es Ihnen ermöglichen 
könnte in der Galle zu überleben und möglicherweise Cholesterol zu verwerten. Einige Stämme 
besaßen β-Galaktosidase-Aktivität, die zur Linderung Laktoseintoleranz beitragen könnte. Manche 
dieser Stämme waren in der Lage, auf dem präbiotischen Zucker Raftiline® ST zu wachsen, welches 
die Entwicklung eines synbiotischen Produktes ermöglichen könnte. Darüber hinaus konnten einige 
Stämme das Wachstum von Krankheitserregern aus Nahrungsmitteln durch die Bildung organischer 
Säuren und H2O2 hemmen; auch vermochten sie, mit Pathogenen zu koaggregieren, welches die 
Ansiedlung von Pathogenen durch Blockade ihrer Adhäsionsplätze im Darm verhindern könnte. Die 
Stämme waren zudem in der Lage, an Darmzellen anzuhaften, ein Zeichen dafür, dass sie zumindest 
vorübergehend im Darm verbleiben, und somit ihre probiotischen Wirkungen ausüben können. 
Schließlich regten einige Stämme mittels Lipoteichonsäure die Sezernierung von IL-8 aus Darmzellen 
(HT29-Zellen) an. Diese sanfte  Stimulation könnte dazu beitragen, den Wirt in einen Zustand 
„immunologischer Wachsamkeit” zu versetzen. Mit Hilfe der Durchflusszytomerie konnte somit 
erstmals eine Heraufregulierung von TLR2 und TLR5 in Darmzellen durch Milchsäurebakterien 
nachgewiesen werden. Dieser Mechanismus ermöglicht neue Einblicke in die Kommunikation 
zwischen Bakterien und Darmzellen und unterstreicht die Rolle von Enterozyten als „Wachtposten“. 
L. johnsonii BFE 6128, L. plantarum BFE 1685 and L. rhamnosus GG steigerten die angeborene 
Immunantwort von HT29-Zellen auf S. Typhimurium, indem sie auf synergistische  Weise den IL-8-
Spiegel auf Protein- und mRNA-Ebene erhöhten. Unter Anwendung von real-time RT-PCR-basierten 
Arrays, wurde die Veränderung der TLR-Signalkaskade  durch L. johnsonii BFE 6128 und S. 
Typhimurium eingehend untersucht. Auf mRNA-Ebene wurde zudem die Expression von TLR und 
anderer, in den Wirkungspfad von TLR involvierter Moleküle, verschiedentlich verändert. Diese 
Beobachtung eröffnet neue Möglichkeiten für die Entwicklung probiotischer Produkte, da sie darauf 
hindeutet, dass bestimmte probiotische Stämme die Immunantwort auf Krankheitserreger intensivieren 
können. Andererseits sind Stämme mit diesen Eigenschaften möglicherweise nicht geeignet um 
Darmentzündungen zu behandeln, da sie die Entzündung selbst verstärken könnten. 
Zusammenfassend liefert diese Studie eine Begründung für die weitere Verwendung von vier der 
selektierten Lactobacillus-Stämme (L. plantarum BFE 5759, BFE 1684 and BFE 1685 sowie L. 
johnsonii BFE 6128) als Probiotika für therapeutische oder Krankheitsvorbeugende Zwecke. 
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ABSTRACT 
 Probiotics are bacterial supplements, which, when applied in sufficient numbers, improve the 
health of the host by modifying the microbiota of a particular compartment of this host. The market of 
probiotic products has expanded in the last years, but there is still no consensus about the mechanisms 
of action of these products. Most probiotic effects appear to be strain specific. Thus, there is a need for 
new and well characterised strains, as well as the elucidation of their mode of functional action. The 
objective of this study was to isolate, identify and characterise Lactobacillus strains from traditional 
African fermented milk products and children’s faeces as potential probiotic candidates in vitro. A 
model of the stomach-duodenum passage was optimised and used to screen 30 Lactobacillus isolates 
for their survival under simulated gastrointestinal conditions. Seven strains showing good survival 
were selected, and identified by phenotypic and genotypic methods. All strains possessed bile salt 
hydrolase, as an indicator of survival to bile and of possible cholesterol utilisation, and some also 
hydrolysed lactose, which may serve for alleviating lactose intolerance. Some of these strains were 
able to grow on the prebiotic sugar Raftiline® ST, which would allow the formulation of a synbiotic 
product. Furthermore, some strains could inhibit the growth of food borne pathogens by producing 
organic acids and H2O2 , and also coaggregated with pathogens, which may enhance their removal in 
the gut by blocking their adhesion sites. The strains also adhered well to intestinal cells, indicating that 
they may at least transiently remain in the gut to exert their probiotic effects. They also inhibited 
adhesion of food borne pathogens. Furthermore, some strains stimulated secretion of IL-8 by intestinal 
cells (HT29 cell line) via their lipoteichoic acids. This low stimulation may help maintaining the host 
in a state of immunologic alert. This is the first time that an up-regulation of TLR2 and TLR5 in 
intestinal epithelial cells by lactobacilli was reported, as determined by flow cytometry. This 
mechanism provides new insight in the communication between bacteria and intestinal epithelial cells, 
and underlines the sentinel role of enterocytes. L. johnsonii BFE 6128, L. plantarum BFE 1685 and L. 
rhamnosus GG enhanced the innate response of HT29 cells to S. Typhimurium by synergistically 
increasing IL-8 levels at the protein and mRNA levels. By means of real-time RT-PCR-based arrays, 
the modulation of TLR pathways by L. johnsonii BFE 6128 and S. Typhimurium was further 
investigated. The expression of TLR and other molecules involved in TLR pathways were also 
differentially modulated at the mRNA level. This finding opens new possibilities for probiotic 
development as it indicates that certain probiotic strains may act as adjuvants to increase responses 
against pathogens. On the other hand, strains with these characteristics may not be suitable for 
treatment of inflammatory bowel disease as they may potentiate the inflammatory response. In 
conclusion, this study provides a rationale for the further use of four of the selected Lactobacillus 
strains (L. plantarum BFE 5759, BFE 1684 and BFE 1685 as well as L. johnsonii BFE 6128) as 
probiotics for therapeutic or disease preventive purposes. 
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INTRODUCTION 
1 INTRODUCTION 
 The microbiota of the gastrointestinal tract (GIT) is one of the most complex and 
concentrated groups of organisms in nature (O'Sullivan, 1999) and it can be considered as a 
functionally active organ (Hart et al., 2002). Each segment of the gastrointestinal tract has a 
particular microbial population. This study focuses on bacteria, normally found in the small 
intestine, which may positively influence the health state of the host. The microbiota of the 
small intestine is less stable than that of the colon (Bezkorovainy, 2001), and thus, more 
susceptible to modifications. The composition of these bacterial populations is influenced by 
several factors such as diet, genetic background, age, gender, hygiene practises, 
administration of antibiotics and the physiological state of the host (Holzapfel & Schillinger, 
2002; Isolauri & Salminen, 2005; Tlaskalova-Hogenova et al., 2005). 
1.1 Development of the human gut microbiota 
 During birth, the first bacteria stemming from the mother’s vaginal and faecal bacterial 
populations colonise the gastrointestinal tract of the newborn (Holzapfel et al., 1998). 
Afterwards, genetic factors, but also environmental factors such as the type of milk (breast 
milk or formula) that the newborn receives, determine the composition of the intestinal 
microbiota (McCracken & Lorenz, 2001; Isolauri & Salminen, 2005). Bifidobacterium (B.) 
spp. and to a lesser extend Lactobacillus (L.) spp. are the main genera constituting the 
intestinal microbiota of healthy breastfed infants. The most common lactobacilli constituting 
the gut microbiota of breastfed infants are L. acidophilus, L. gasseri and L. johnsonii, which 
belong to the so-called L. acidophilus-group (Vaughan et al., 2002). Upon introduction of 
solid food, the differences observed between breastfed and formula-fed infants disappear, 
while the numbers of Clostridium, Bacteroides, Escherichia (E.) coli and enterococci increase 
in both groups. After the first year of life, the diversity of the microbiota increases, and it is 
especially during this time when host-microbe interactions are most vital. During this period, 
the newborn, who comes from a sterile environment, establishes the first contact with a huge 
antigen challenge. This implies a strong stimulatory effect for the maturation of the gut 
associated lymphoid tissue (GALT) (Isolauri & Salminen, 2005). In addition, the composition 
of the intestinal microbiota seems to influence the development of autoimmune and atopic 
diseases (Matricardi & Bonini, 2000). Bjorksten et al. (2001) and Watanabe et al. (2003) 
observed that children with atopic dermatitis have differences in the bacterial composition of 
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the gut, with increased numbers of clostridia and Staphylococcus (S.) aureus, and reduced 
numbers of lactic acid bacteria and bifidobacteria. 
 Apart from genetic and environmental factors (air pollution, dietary changes), the 
increased hygiene and life standards associated with western lifestyles have been related to 
the development of atopic and autoimmune diseases in the so-called ‘hygiene hypothesis’ 
(Strachan, 1989). The ‘hygiene hypothesis’ relates the increased incidence, severity and 
prevalence of atopic dermatitis in the past 30-40 years to the decreased exposure to microbial 
antigens associated with a western lifestyle (Bloomfield et al., 2006).  In Finland, where there 
has been an extreme rise in paediatric allergy, diet supplementation with Lactobacillus (L.) 
rhamnosus GG has been implemented to prevent and reduce the severity of atopic dermatitis 
(Baker, 2006). 
1.2 Microbial balance 
 Experiments with germ-free and conventional mice have shown that the microbiota 
strongly influences many biochemical, physiologic and immunologic characteristics of the 
host. In fact, gnotobiotic animals have a lower metabolic rate, high susceptibility to 
pathogens, vitamin deficiencies, less efficient digestion and limited intestinal cell growth 
(Tannock, 2001; Hart et al., 2002). Microbial balance is the key factor that determines 
whether substances in the intestine are converted into compounds that are beneficial or 
detrimental to the host (Percival, 1997). If bacteria expressing virulent properties 
predominate, the host will suffer from disease (e.g. cancer, geriatric diseases, diarrhoea, 
constipation). In contrast, if the resident microbiota has predominantly healthy properties 
(support of the immune system, production of short chain fatty acids and vitamins such as vit. 
K and vit. B12, and protection of overgrowth and/or infection by pathogens) this would help 
maintain a state of good health. Manipulation of this balance for therapy or as a preventive 
measure is a challenge, which makes the use of probiotics an interesting tool as an alternative 
to antibiotics. Another way of influencing the microbial balance in the gut is by means of 
naturally occurring or synthetic sugars, that are normally indigestible in the human gut, but 
that are selectively used as a carbon source for growth and metabolism by certain colonic 
bacteria. These substrates should stimulate growth of Bifidobacterium spp. and Lactobacillus 
spp., but not of potential pathogens such as toxin producing clostridia, proteolytic bacteroides 
and toxigenic E. coli. Substances which fulfil these requisites, such as inuline, 
fructooligosaccharides and lactulose, are called prebiotics. Preparations combining both pro- 
and prebiotics for obtaining synergistic effects are termed synbiotics (Schrezenmeir & de 
Vrese, 2001; Bielecka et al., 2002; Holzapfel & Schillinger, 2002). 
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1.3 Probiotics 
1.3.1 Definition 
 The hypothesis that a shift of the microbial balance towards the beneficial properties would 
improve health was postulated at the beginning of the 20th century by Metchnikoff. He related 
the longevity of the Caucasians to the consumption of fermented milk products (Metchnikoff, 
1907). But the first documentation about health promoting effects of fermented milk dates 
back to a Persian version of the Old Testament (Genesis 18:8) that states that ‘Abraham owed 
his longevity to the consumption of sour milk’. Kollath in 1953 and Vergio in 1954 were 
probably the first to introduce the term ‘Probiotic’ (Holzapfel & Schillinger, 2002). The 
definition of probiotics has been modified and improved several times; a consensus definition 
has been stated by Havenaar and Huis in’t Veld (1992): ‘A preparation of, or a product 
containing viable, defined microorganisms in sufficient numbers, which alter the microflora 
(by implantation or colonisation) in a compartment of the host and by that exert beneficial 
health effects in this host’. 
1.3.2 Postulated mechanisms of action 
 Probiotic strains have beneficial effects on the host by controlling undesirable micro-
organisms and by modulating the immune system (McCracken & Gaskins, 1999; Fuller & 
Perdigon, 2003). However, despite the efforts to elucidate their mechanism of action, it is still 
not well understood how probiotics work (Tannock, 2002). 
 There are several postulated mechanisms through which probiotics exert their beneficial 
effects in the host (Fig. 1.1). Most of the mechanisms have been studied in vitro because of the 
complexity of the gut ecosystem and the numerous interactions taking place in the gut 
(bacteria-bacteria, nutrients-bacteria, nutrients-epithelium, epithelium-bacteria, epithelium-
immune system and bacteria-immune system). Some in vitro experiments can be extrapolated 
to the in vivo situation, as shown in several studies that compare in vitro results with in vivo 
studies (Jacobsen et al., 1999; Cesena et al., 2001). Animal models are also useful tools; 
nevertheless, they have substantial differences in the anatomy of the gastrointestinal tract and 
MALT (mucosa associated lymphoid tissue) and in the microbial composition of the gut 
microbiota, when compared with human beings. In addition, some strains show host-
specificity for adherence and exerting their health effects (Morelli, 2000). 
 Some of the mechanisms through which probiotics may antagonise pathogens include 
production of antimicrobial compounds such as lactic acid, acetic acid, hydrogen peroxide 
and bacteriocins (Alakomi et al., 2000; Annuk et al., 2003). Other functional properties to 
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characterise probiotics are their ability to modulate immune responses and to adhere to gut 
tissues (Holzapfel & Schillinger, 2002) (Fig. 1.1). 
 The ability to adhere to the intestinal epithelium is one of the main criteria for selecting 
new probiotic strains, as this property allows strains to remain, at least transiently, in the 
intestinal tract, and exert their probiotic effects such as excluding pathogenic bacteria by 
competing for adhesion sites (Alander et al., 1999; Blum et al., 1999; Saarela et al., 2000). 
PROBIOTICS
Competitive exclusion of enteric 
pathogens by adhesion 
Maintenance of normal 
intestinal microbiota
Cholesterol lowering
effects
Growth inhibition of pathogen by 
lactic acid and bacteriocins
Immunomodulatory
activity
Nutritional effects
Food allergy 
reduction 
Barrier / Restoration 
effects
Enhancement of 
bowel motility
Neutralization of dietary 
carcinogens such as 
nitrosamines (butyric acid)
Lactose intolerance 
alleviation
 
Fig. 1.1 Postulated mechanisms of action of probiotics.
 
 Lactic acid bacteria have been shown to reduce the symptoms of lactose intolerance. 
Lactose, a disaccharide composed of glucose and galactose, is the main sugar present in milk 
and needs to be cleaved to the monosaccharides in order to be absorbed in the small intestine. 
This enzymatic hydrolysis is catalysed by lactase (β-galactosidase), an enzyme present in the 
brush border of the enterocytes in childhood. Some adults still express this enzyme and can 
benefit from milk as a protein and calcium source, but the expression of this enzyme generally 
decreases with age and is, in some cases, completely lost (Szilagyi, 2002). In individuals with 
low lactase contents, lactose cannot be absorbed and it can be used as fermentable substrate 
by the intestinal microbiota. In addition, water accumulates in the intestinal lumen due to 
lactose osmotic properties. As a result, the patient may suffer from bloating, flatulence, pain, 
nausea and even diarrhoea (Hove et al., 1999; de Vrese et al., 2000). The consumption of 
yogurt and fermented milk containing lactic acid bacteria has been proven to alleviate lactose 
maldigestion symptoms because of the lower lactose content, and its hydrolysis by microbial 
β-galactosidase (Gilliland & Kim, 1984; Mustapha et al., 1997). This enzyme is sensitive to 
low pH and, therefore, bacteria surviving low pH protect the enzyme from activity loss until it 
reaches its site of action, which is the small intestine (Zarate et al., 2000). On the other hand, 
bacteria sensitive to bile salts present a membrane with increased permeability, which allows 
two events which may or may not be exclusive: one is the transport of the substrate at higher 
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rates into the bacterial cell, and the other one is the increased release of the bacterial enzyme 
into the lumen. Probiotic bacteria, with higher resistance to bile salts, release less amounts of 
enzyme into the lumen. Therefore, yogurt starter cultures which do not survive the effect of 
bile, seem to be more effective in alleviation of lactose intolerance (de Vrese et al., 2000). 
 Another desirable property of some probiotic strains is their ability to reduce cholesterol 
levels (De Smet et al., 1998; du Toit et al., 1998). This property has been partly related to bile 
salt hydrolase (Bsh), which deconjugates bile salts by releasing the amino acid (taurine or 
glycine) bound to the side chain of the steroid core. Deconjugated bile salts are less soluble, 
and thus easily excreted via faeces, resulting in decreased reabsorption and recirculation of 
bile salts into the liver. Consequently, more cholesterol is needed for de novo synthesis of bile 
salts (Usman & Hosono, 1999). Bsh activity has also been related to the ability of some 
bacteria to survive bile and colonise the intestine (De Smet et al., 1995; Klaenhammer & 
Kullen, 1999), but this hypothesis is controversial because others have found that 
deconjugated salts are more toxic than their conjugated counterparts (Grill et al., 2000). In 
humans, excess bile deconjugation may lead to adverse effects such as steatorrhea and 
formation of secondary bile salts, which are toxic and/or mutagenic (Marteau et al., 1995). 
 Probiotics have also been shown to modulate the immune system at different levels. They 
may have anti- and/or pro-inflammatory properties. Some strains have shown to influence the 
adaptive immunity, whereas others affect the innate immunity (Fuller & Perdigon, 2000). The 
immunomodulatory activities of probiotics are presented in section 1.4. 
1.3.3 New probiotic strains and sources of isolation 
 There is still no consensus about the need for viability of probiotics to exert health effects 
(Gopal et al., 2001). Some studies maintain that the viability of probiotic strains is necessary 
for stimulation of the gut associated immune system (Lammers et al., 2002) or for anti-
genotoxic effects (Galdeano & Perdigon, 2004; Ma et al., 2004). Others have shown that heat-
killed probiotics (Pool-Zobel et al., 1996), or specific components derived from probiotic 
strains such as DNA (Nagy et al., 2005) or bacterial cell wall (Lammers et al., 2002; Jijon et 
al., 2004), are responsible for some immunomodulatory effects. If this is the case, and live 
microorganisms are not necessary to obtain the desired effects, a revision of the definition of 
probiotics or the development of a new concept defining these probiotic-derived components 
will be needed. 
 A general agreement, among those in favour of the classical definition of probiotics, refers 
to the need of live microorganisms exerting health-promoting effects, and thus, the need of 
survival to host conditions to reach the site of action. The general criteria for selection of 
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strains to be used as probiotics include: safety and origin of the bacteria, their tolerance to the 
hostile conditions of the stomach and the small intestine, and their ability to adhere to gut 
epithelial tissue (Davidkova et al., 1992; Tannock, 2002). The first step in the choice of new 
microbial strains to be used as probiotics should be their safety and origin. GRAS (generally 
recognised as safe) microorganisms include Lactobacillus spp. and Bifidobacterium spp., 
which are bacteria with a long history of safe use as they have been consumed by humans for 
centuries. Selection of other microorganisms must include expensive and time consuming 
short- and long-term toxicological studies (Morelli, 2000; Chesson et al., 2002). Havenaar et 
al. (1992) considered that the origin of the strain regarding host species and location 
specificity play an important role if colonisation is essential for achieving the desired effect of 
the probiotic. In this study, strains from human origin and from fermented milks were 
compared in their in vitro probiotic potential. 
 The bacterial isolates screened to be selected as potential probiotics in this study were 
isolated from African traditionally fermented milk products (Kwerionik and Kule naoto) and 
human faeces. Of special interest because of their background were the strains isolated from 
‘Kule naoto’, a traditional fermented milk that was spontaneously fermented in gourds made 
out of dried calabash by the Maasai people (Chesson et al., 2002). The Maasai are a semi-
nomadic and pastoral tribe living in Kenya and northern Tanzania. Traditionally, the Maasai 
rely on meat, milk and blood (only in special ceremonies) from cattle for protein and caloric 
needs (Mathara et al., 1996; 2004). The Maasai consume Kule naoto daily, because of its 
flavour and its supposed health-promoting properties. As a matter of fact, they believe that 
this product alleviates constipation and prevents diarrhoea (McAdams Wright, 2006). 
Interestingly, in a study of cholesteremia conducted by Mann and Spoerry (1974) in a tribe of 
Maasai, serum cholesterol level of Maasai men decreased after consumption of large amounts 
of milk fermented with a wild Lactobacillus strain. 
1.3.4 Safety considerations 
 Even though Lactobacillus spp. belong to risk group 1 organisms (European Food Safety 
Authority, 2004), which include biological agents that are unlikely to cause human or animal 
disease, it is important to assess the safety of those microorganisms intended for use as food 
additives. Because of the serious concerns about the increasing level of resistance to 
antibiotics in regular use in human medicine, one of the aspects which needs to be analysed is 
antibiotic resistance. Probiotic strains as well as bacteria used in food fermentations may 
harbour resistance genes, which can be transferred to pathogenic bacteria (Havenaar et al., 
1992; Danielsen & Wind, 2003; Franz et al., 2005). Therefore, probiotic strains intended for 
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the market should be screened for transferable resistance genes. A report by the Scientific 
Committee for Animal Nutrition (SCAN) recommended to the European Union commission 
(Teuber, 1999) that the absence of transferable resistance genes should be considered as an 
important pre-requisite for approval of probiotics.  
1.3.5 Site of action of probiotics: the small intestine 
 The small intestine is a long tube of about 3-5 m in length; it begins with the duodenum, 
continues with the jejunum and ends with the ileum. Its main functions are digestion of food 
and absorption of water, electrolytes and nutrients necessary for cellular growth of the whole 
organism. In order to assure a maximal contact with the digested food in a limited place, the 
intestine presents different surface-increasing strategies: circular folds, intestinal villi and 
microvilli. This makes the gut mucosa (with a surface of approximately 200 m2) the largest 
area of the body in contact with the environment (Holzapfel et al. 1998). 
 The intestinal epithelium is a highly organised, single-cell layer covering the interface 
between tissues and the intestinal lumen. This monolayer is mainly constituted of enterocytes, 
which are the cells responsible for taking up nutrients, Paneth cells, which secrete the mucus 
bathing the epithelium, and intra-epithelial lymphocytes, which are part of the MALT. Yet, all 
epithelial cells arise from common non-differentiated precursors present in the epithelium 
(Brandtzaeg, 1995). This monolayer is constantly being renewed as epithelial cells undergo a 
lifecycle, which starts in the deep of the crypts, where they arise, continues with their 
differentiation and migration towards the tip of the villi and ends with apoptosis and 
exfolliation (Stadnyk, 1994; Turner, 2003; Dommett et al., 2005). This cycle takes about 3 to 
5 days in humans and allows epithelial self-renewal. Because of this turn over, the gut surface 
is covered by dead and exfoliating cells, which provide together with the mucus, bathing the 
cells, and the nutrients passing through the lumen an excellent growth substrate for 
microorganisms (Stadnyk, 2002; Tlaskalova-Hogenova et al., 2005). 
1.4 Tolerance and immunity in the gut 
 Mucosal surfaces are constantly exposed to foreign substances and microorganisms from 
the environment; indeed, they are the most common gate of entry for pathogens. All mucosal 
surfaces have similar organised lymphoid tissue collections and are characterised by the local 
presence of IgA. They all share anatomical and functional characteristics, and form the so-
called MALT (Hill, 1995). 
 Mucosal surfaces are connected with each other; stimulation in one anatomical site also 
induces immunity at other mucosal sites. This process occurs because lymphocytes activated 
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at one mucosal site migrate and relocalise selectively in other mucosal sites (“mucosal 
homing”) (Roux et al., 2003). In contrast to other tissues, the intestinal mucosa must react 
against threatening microorganisms, but it must simultaneously tolerate the presence of a 
myriad of commensal microorganisms and their by-products. This presents an immunological 
paradox, which is still not fully understood. The non-responsiveness to harmless food 
antigens and the generation of an adaptive immune response to potentially dangerous 
microorganisms are both vital physiological processes essential for the effective function of 
the intestinal epithelial barrier (Mowat & Viney, 1997; Roux et al., 2003).  
 The usual response to innocuous antigens is the induction of local and systemic tolerance, 
known as oral tolerance. Oral tolerance can be defined as the systemic unresponsiveness to 
previously ingested antigens when encountered in the parenteral route (Brandtzaeg, 1998; 
Strobel & Mowat, 1998; Nagler-Anderson, 2000). This phenomenon may be exploited for the 
immunotherapy of autoimmune and inflammatory diseases, but also presents a hindrance in 
the development of mucosal vaccines. Inappropriate responses to harmless food and other 
luminal (e.g., bacterial) antigens are likely to play a role in the induction of food allergy and 
inflammatory bowel disease (IBD) (Strobel & Mowat, 1998).  
 Innate immunity is also probably involved in the developing of tolerance in the gut. In 
contrast to other epithelia, such as the pulmonary epithelium or uroepithelium, which react 
potently to both pathogens and commensals, the intestinal epithelium seems to be able to 
distinguish them. This discrimination ability is disturbed in IBD as it is shown by the 
immunological reactivity of patients to their own commensal microbiota (Strobel & Mowat, 
1998; Faria & Weiner, 2005). 
 Some members of the family of pattern-recognition receptors (PRRs), e.g. Toll-like 
receptors (TLRs), can be expressed by intestinal epithelial cells. Nevertheless, they are poorly 
responsive to a variety of TLR2 and TLR4 ligands (e.g. peptidoglycan and 
lipopolysaccharide, respectively) when compared to professional immune cells such as 
dendritic cells or macrophages. This seems to be partly due to the low expression of both 
receptors in enterocytes and to the presence of high levels of Toll inhibitory protein (Tollip) 
(Ghosh et al., 2004; Ohkusa et al., 2004). 
 As most pathogens enter the body through mucosae, a strong immune response is required 
to protect these tissues. Therefore, inflammation is the initial and usually adequate phase of 
the immune response against a potentially dangerous agent (Melmed et al., 2003). As a short-
term survival strategy, some pathogen virulence factors alter function and/or functionality of 
host proteins and so pathogens can colonise, enter or survive in the host cell. As a long-term 
survival strategy, pathogens can modify host gene transcription in order to evade the immune 
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system and keep their niches hospitable (Neish, 2003; Beutler, 2004b). Many pathogens are 
able to suppress the inflammatory process, overcoming host defences, as a critical feature of 
their pathogenicity (Rosenberger et al., 2001). As an example, Porphyromonas gingivalis, an 
oral pathogen, is able to ‘paralyse’ chemokine production during infection, and this could 
serve as pathogenic mechanism (Wilson et al., 1998; Neish, 2003). Yersinia enterocolitica is 
another example of a pathogen able to evade, to some extent, the initiation of an inflammatory 
response. Yersinia enterocolitica appears to decrease the amount of IL-8 released by cells, as 
IL-8 levels induced by this microorganism in intestinal epithelial cells were significantly 
lower than those induced by other invasive strains (Darveau et al., 1998). Some strains of 
Yersinia, Bordetella and Salmonella are also able to inhibit the NF-кB pathway at different 
levels, leading either to apoptosis of the infected cell or to a blockade of the innate immune 
responses (Schulte et al., 1996). 
1.4.1 Bridging innate immunity and adaptive immunity 
 The acquired or adaptive immunity is characterised by the exquisite antigen-specificity 
caused by re-arrangement of the genes encoding T-cell receptors and immunoglobulins.  All 
higher vertebrates are able to mount specific immune responses against infectious agents. 
Protozoa also have to deal with microbes; they do it efficiently even though they lack this 
specific immunity. This is possible thanks to the innate immune system, which is present in 
the whole animal kingdom. Innate immunity is specifically inherited in the genome, 
recognises a wide spectrum of pathogens and activates an immediate answer. ‘Innate’ and 
‘adaptive’ immune systems are more an academic classification than two separate systems. 
Therefore, it is very difficult to decide where the one ends and the other begins. They are 
connected at different stages and, to a greater extent, cells of the adaptive immune system 
depend on the signals and cells of the innate immune system to get activated (Collier-Hyams 
& Neish, 2005). 
 The GIT possesses physical and chemical barriers which have to be overcome before a 
microorganism infects the host. These barriers represent obstacles for both potential 
probiotics and pathogens. Indeed, the presence of lysozyme in saliva, the low pH in the 
stomach, the presence of proteolytic enzymes, the abrupt pH change towards the intestine, the 
detergent action of bile salts, the antimicrobial peptides (defensins) secreted by Paneth cells, 
the mucus bathing the intestinal epithelium, the continuous peristaltic movement and the 
presence of normal microbiota are most of the times enough to prevent infection by foreign 
microorganisms (Hoffmann et al., 1999; Janeway & Medzhitov, 2002; Kaufmann et al., 2004; 
Schütt & Bröker, 2006). If these barriers are overcome, a pathogen infects the host, and 
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defences of another kind have to be mobilised in order to prevent further progress of infection 
into disease. Before the elucidation of the sensing pathways involved in the innate immune 
response, there was a lack of knowledge concerning what exactly happens during the first 
twelve hours that the adaptive immune system needs for acting, expanding and generating 
memory cells for long-term responses (clonal expansion). Now it is clear that when the 
immune system contacts the pathogen for the first time, the innate arm protects the host 
during the time needed for the clonal expansion of the adaptive and more specific arm to 
occur (McCracken & Lorenz, 2001; Turner, 2003; Dommett et al., 2005). That is why the 
innate immune response is critical for the immediate combat of invading pathogens at their 
port of entry (skin or mucosae). 
 During a first infection, the recognition of the threat can take from seconds to hours 
(Janeway et al., 2002). The tissue macrophages engulf the intruder and destroy it with an 
arsenal of enzymes and toxic reactive oxygen species. The complement system, present in 
extracellular liquids, can be activated trough the classical or alternative pathways at the 
surface of the pathogens either opsonising them, which increases phagocytosis, or directly 
lysing them by forming channels through their cell walls and/or membranes. If these measures 
are not enough, the phagocytes (and other cells such as epithelial cells, too) send warning 
signals to initiate the process called inflammation. The molecular mediators and regulators of 
immune responses are proteins called cytokines (CK) which mediate cell-to-cell 
communication. Chemokines (CHKs) are special CKs which augment permeability of blood 
vessels, induce the expression of adhesion molecules by endothelial cells and serve as chemo-
attractants that recruit professional immune cells from circulation to the site of infection. 
Interleukin-8 (IL-8), a potent neutrophil attractant and activator, is one of the first messengers 
released (Beutler, 2004b). Natural killer cells also express IL-8 receptors (Morohashi et al., 
1995) and can migrate in response to IL-8 (Campbell et al., 2001). 
 Neutrophils are short-lived effector cells of crucial importance for the resolution of 
infection. Upon activation by CKs and CHKs such as IL-8, they become potent phagocytes 
with an arsenal of ‘weapons’ to effectively destroy pathogens (Moser, 2004; Seiler et al., 
2004; Schütt & Bröker, 2006). Their importance is reflected by the fact that the absence of 
this cellular subset (neutrophils) causes a severe immunodeficiency (Gewirtz et al., 2003; 
Hayashi et al., 2003; Kuijpers & Roos, 2004). In turn, neutrophils further secrete other soluble 
mediators, which activate other immune cells, such as lymphocytes, and the process 
undergoes a positive feed-back. As result of an effective inflammatory process, the invader is 
eliminated and the tissue damage is locally restricted. This complex, non-specific reaction to 
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deleterious stimuli is characterised by erythema (redness), edema (swelling), pain and fever 
(heat) at the site of infection. 
 Macrophages play a central role as nexus between innate and adaptive immunity (Beutler, 
2004b). They are, together with dendritic and mast cells, professional antigen-presenting cells 
(APCs). After destroying the pathogen, they process it and present the antigens (digested 
peptides) in the context of class II major histocompatibility complex molecules (MHC-II) to T 
lymphocytes. If the necessary co-stimulatory stimuli are present, T cells secrete IL-2 and 
proliferate (clonal expansion). T-cytotoxic cells (CD8+) attack and destroy cells invaded by 
pathogens. Activation of naïve CD4+ T cells leads to differentiation into either a Th1 or a Th2 
phenotype. Th1 cells mediate immunity towards pathogens, especially those adapted to 
intracellular life cycles, and release IFN-γ, TNF-α and IL-12. Th2 cells are involved in 
responses against parasites (especially helminths) and produce IL-4, IL-5 and IL-10 and IL-15 
inducing IgE and eosinophil-mediated destruction of the pathogen (Mosmann & Coffman, 
1989). The differentiation into a Th1 or a Th2 phenotype occurs early in the immune response 
and is crucial for the clinical course of infection. The mechanisms of this differentiation 
process are still not fully elucidated and it is also possible that the canonical Th1 and Th2 
global phenotypes only represent two polar extremes of all possible single phenotypes (Kelso, 
1995). 
 Vertebrates rely on innate and adaptive defences to cope with invasive microorganisms, 
which would parasitise or eventually kill them (Hoffmann & Dutton, 1971). Both arms 
interact and cooperate very closely, but activation of innate immunity is a pre-requisite for the 
induction of adaptive immunity (Hoffmann et al., 1999). The recognition of the importance of 
innate immunity arose after the discovery that innate immune cells discriminate between non-
self and self, and have a high degree of specificity (Akira & Takeda, 2004; Beutler, 2004b). 
Toll-like receptors are to a great extent responsible for this discrimination capacity. The 
revolutionary finding of these receptors, and their key role in the innate afferent (sensing) 
arm, has changed the way of thinking about pathogenesis and treatment of cancers, infectious, 
immune and allergic diseases (Janeway & Medzhitov, 2002). 
1.4.2 Toll-like receptors 
 Toll-like receptors belong to a family of PRRs. They recognise foreign microbial products 
and are responsible for the initiation of host defence responses in all multicellular organisms 
investigated to date (Akira & Takeda, 2004). Two main advances in understanding innate 
immunity were first, the discovery that a protein called ‘Toll’ involved in embryogenesis of 
Drosophila also played a role in innate immunity against fungi (Aderem & Ulevitch, 2000; 
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O'Neill, 2004) and second, the finding of similar receptors in mice (Lemaitre et al., 1996). 
Until now 10 TLR homologues have been found in humans. They do not participate in 
embryogenesis, but all of them sense microbial molecules (Fig. 1.2). 
 TLRs and interleukin-1 receptors (IL-1 Rs) share a conserved region of about 200 amino 
acids called the Toll/IL-1R (TIR) domain. In the extracellular domain, TLRs contain 19-25 
tandem copies of leucine rich repeats (LRRs), which form a horseshoe structure. This concave 
structure is thought to be responsible for ligand recognition. When the microbial derived 
ligand binds the LRR, the TIR domain initiates a complex enzyme cascade (see Fig. 1.2) 
including adaptor proteins like myeloid differentiation factor (MyD88), IL-1R-associated 
kinase (IRAK), tumour necrosis factor (TNF) receptor-associated factor (TRAF6), several 
mitogen-activated protein (MAP) kinases and inhibitor кB kinases (IKKs) (Poltorak et al., 
1998; Beutler, 2004a). 
 This cascade ends up in the activation of the transcription factor NF-кB, which regulates 
the inducible expression of key pro-inflammatory mediators such as cytokines, chemokines 
and cationic antimicrobial peptides (defensins) (Aderem & Ulevitch, 2000; Janssens & 
Beyaert, 2003). 
 NF-кB dimmers are kept inactive in the cytoplasm by IKKs. TLRs cascades lead to the 
inactivation of the IKKs by phosphorylation, ubiquitination and proteasome-mediated 
degradation, resulting in the release of NF-кB. In turn, NF-кB translocates into the nucleus 
and induces NF-кB-dependent gene expression. Many of these genes are also up-stream 
activators of NF-кB, which implies a positive feedback for the amplification of the 
inflammatory response. The mechanistic details of NF-кB pathways are still not fully 
elucidated (Schnare et al., 2006). 
 TLRs influence or control the activation of adaptive immunity in several ways, such as 
regulation of dendritic cell maturation, induction of expression of CKs and co-stimulatory 
proteins and reversal of tolerance (van Duin et al., 2006). It also seems that TLR favours Th1 
polarisation of the adaptive immune response (Trinchieri, 2003). 
 The discovery of TLRs has opened new possibilities for treatment and prevention of 
disease. Autoimmunity, sterile inflammation, sepsis and vaccination against malaria or HIV 
are only a few of the still not resolved health problems in which TLR targeting would be 
possibly applied (Ulevitch, 2004; van Duin et al., 2006). Nevertheless, there is still a long way 
to go before it is discovered when, how (i.e. blocking or stimulating) and what should be 
targeted. 
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physical barrier. Because of their strategically located anatomical situation, it also plays an 
active and central role in the so-called ‘trilogue’ between luminal bacteria, epithelium and 
professional immune cells in the lamina propria. IECs scan the gut environment for microbial 
threats, interpret signals from luminal bacteria, transmit this information to professional 
immune cells in the lamina propria and thereby cooperate with the GALT to mount a response 
to certain antigenic stimuli (O'Sullivan, 1999). Because of the continual exposure to the gut 
microbiota, the intestinal epithelium maintains, under normal conditions, a state of controlled 
or physiologic inflammation (Collier-Hyams & Neish, 2005; Shao et al., 2005). It is clear that 
commensal bacteria should not elicit as intense an inflammatory response as a pathogen; 
however, some investigators (Kagnoff, 2003; Jijon et al., 2004; Rakoff-Nahoum et al., 2004) 
have shown that a constant TLR stimulation may be necessary for intestinal health. Gewirtz et 
al. (2004) also pointed out that some degree of low level ‘surveillance’ NF-кB activation may 
be physiological. 
 One of the features that make IEC apt for this role as ‘transducer’ is the expression of 
receptors and antigen-presenting molecules. The receptors allow IECs to sense microbial 
components. They belong to the family of pattern recognition receptors (PRRs) and include 
lectins, adhesins, members of the nucleotide-binding oligomerization domain (NOD) family 
and the Toll-like receptor (TLR) family (Gewirtz et al., 2003). The antigen presenting 
molecules belong both to the classical (HLA-II, HLA-I) and non-classical types (e.g.: CD1d 
β2-m associated and non-β2-m associated) (Cario & Podolsky, 2000; Cario, 2005). These 
molecules enable direct communication with adjacent immune cells of the lamina propria. It 
was assumed that presentation of antigen trough IECs leads to anergy because of lack of co-
stimulatory signals. This was only until non-typical co-stimulatory molecules (e.g.: CD58, 
CD86, ICAM-I), normally present in dendritic cells, were found in IECs, demonstrating once 
again that the rules of the mucosal immune system are different from those of the systemic 
immune system (Dotan & Mayer, 2003; Shi & Walker, 2004; Shao et al., 2005). These data 
strongly suggest that IECs may function as important APCs in the mucosal immune system. 
 IECs are able to further communicate with cells of the immune system indirectly by 
releasing cytokines. In response to pathogens, IECs secrete pro-inflammatory cytokines that 
recruit pro-inflammatory cells from circulation. Apart from that, they also actively participate 
in the defence against infection by secreting antimicrobial peptides called defensins (Dotan & 
Mayer, 2003). The expression of both cytokines and defensins is regulated by TLR signalling 
(Ogle et al., 2002). 
 The expression of β-defensin-2 is regulated by TLR4- and TLR2-dependent pathways 
(Vora et al., 2004). O’Neil et al. (1999) demonstrated that IEC up-regulate β-defensin-2 
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expression in response to IL-1α and invasive enteric bacteria. Expression of TLRs is increased 
in response to Th1 cytokines in IBD mucosa. This increased expression of TLRs may enhance 
reactivity to bacteria resulting in chemokine expression, recruitment of inflammatory cells, 
and secretion of antimicrobial peptides (Vora et al., 2004). The Crohn’s disease associated 
mutations in CARD15/NOD2 (a protein with antimicrobial properties highly expressed in 
Paneth cells) result in decreased responsiveness to bacterial muramyldipeptide. Some studies 
have also suggested that deficiency in antimicrobial peptide (e.g. defensins) expression may 
contribute to the pathogenesis of Crohn’s disease (Abreu et al., 2002; Fellermann et al., 2003; 
Vora et al., 2004). Thus, defects in the innate immune response to pathogens or commensal 
bacteria may contribute to the pathogenesis of IBD. 
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Fig. 1.3 Phases on acute epithelial infection. (1) IECs are central in the coordination of the response 
to infection. They elicit the first warning signals (e.g.: IL-8) to recruit neutrophils (PMN). (2) PMNs 
migrate from neighbouring vessels attracted by the IL-8 gradient and transmigrate through the 
epithelium to the lumen, where they induce secretion of Cl- and fluid transport, which flushes the 
surface of the epithelium. (3) Other epithelium-derived CKs (e.g.: TNF-α) synergises with CKs 
secreted in the lamina propria to accelerate fluid transport. In phase (4), CKs released by intraepithelial 
lymphocytes (IEL) and lamina propria lymphocytes, initiate attenuation of PMNs accumulation. 
Adapted from Colgan et al. (2003). 
 
 A putative model was suggested by Colgan et al. (2003) to summarise and highlight the 
key role of IECs and cytokines in the development and resolution of inflammation (Fig. 1.3). 
Taken together, all these data underline the central role of the enterocytes in orchestrating the 
response to microorganisms. 
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1.5 Probiotics and their effect in the immune system 
 As mentioned before, the microbial load during the first days of life is very important as it 
primes the immune system for the antigens encountered later in life. If microbial stimuli are 
poor, there will be a defective immune maturation leading to disregulation of the innate and 
acquired immune systems. The mechanisms by which microorganisms may influence 
maturation of the host immune response and immune diseases are still poorly understood.  
 Probiotics have been shown to influence both innate and adaptive immunity. Some strains 
have been shown to increase phagocytosis and to modify CK production on different cell 
populations (Erickson & Hubbard, 2000; Haller et al., 2000; McCracken et al., 2002; Wallace 
et al., 2003). The type of modulation required to down-regulate the chronic inflammation in 
Crohn’s disease is quite different from the one required for treatment of allergy or 
gastroenteritis. In inflammatory bowel disease there is an enhanced Th1 response against the 
own microbiota, which is characterised by high levels of pro-inflammatory CKs, e.g. IL-12. 
Therefore, probiotics able to increase levels of downregulating CKs such as IL-10, may be 
used as therapeutic supplements for treatment of IBD. In the case of cancer, the opposite may 
be true. IL-12 enhances the cytotoxicity mediated by NK cells against tumours (Trinchieri, 
1994), which may be relevant for those lactobacilli with claimed anti-tumour activity (Kato et 
al., 1994). Some pathogens are able to induce IL-10, which inhibits neutrophil phagocytic and 
bactericidal activity as a strategy to evade host defences (Fiorentino et al., 1991; Laichalk et 
al., 1996). In this setting, probiotics able to enhance the inflammatory immune response (with 
recruitment of neutrophils, activation of macrophages and NK cells for example by inducing 
IL-12 production) would be more effective for clearance of the infective agent (Hessle et al., 
1999; Ogawa et al., 2006). In mice, L. casei Shirota feeding induced a Th1 rather than a Th2 
response, and this provides a means for reducing IgE when co-fed with the appropriate 
antigen (Matsuzaki & Chin, 2000). Most of the studies have been done on models of 
pathologies such as chronic inflammation, allergies, tumours and gastroenteritis. Healthy 
people, the most important target group of probiotics in the market, have been somewhat 
neglected as there are only few studies done on healthy volunteers, which can be explained by 
the strict safety and human ethic requirements for such studies. 
 Less exploited but very promising fields are the use of probiotic strains or some of their 
components as adjuvants for vaccines, as well as the use of genetically modified strains for 
delivering regulatory molecules (e.g. IL-10) or encoding proteins from pathogenic 
microorganisms for immunisation (Pouwels et al., 1998; Nagy et al., 2005).  
 Probiotic products represent a relatively economical source for boosting the immune 
system and covering some nutritional requirements of children in developing countries, who 
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suffer from immunodeficiency associated with malnutrition, and for whom gastroenteric 
infections are among the main causes of morbidity. In addition, children in developed 
countries suffering from the consequences of living in a ‘too clean environment’ (see 1.1.1) 
may also benefit from the consumption of these products.  
 Some rare clinical reports associate Lactobacillus strains with endocarditis and formation 
of abscesses (Maskell & Pead, 1992; Harty et al., 1994). Therefore, the characterisation and 
safety assessment of new strains and their effect on healthy as well as on immuno-deficient 
patients is very important in order to avoid any negative interaction.  
 
1.6 Probiotics and acute gastroenteritis 
 Acute diarrhoea causes significant morbidity and mortality all over the world. The main 
etiological agents are viruses such as rotaviruses, caliciviruses, adenoviruses, Norwalk and 
Norwalk-like viruses and, to a lesser extent, enteropathogens. Several clinical studies have 
revealed that administration of probiotics such as L. rhamnosus GG reduces the duration of 
diarrhoea (Majamaa et al., 1995; Isolauri et al., 2001; Guandalini, 2002). When used as a 
preventive therapy in healthy infants, the consumption of probiotics reduces the number of 
episodes as well as their duration (Saavedra et al., 1994). These favourable clinical effects 
have been partly explained by the improvement of the intestinal immunological barrier, 
especially IgA responses by L. rhamnosus GG (Isolauri et al., 1993).  
 Bacterial infections of the gastrointestinal tract also cause diarrhoea. Probiotics could thus 
be used as a preventive measure, as support therapy and sometimes also as an alternative to 
the use of antibiotics. The strains with these preventive effects should fulfil some of the 
following requirements: produce antimicrobial metabolites, compete for nutrients, adhere to 
mucus and/or intestinal cells, and modulate the gut associated lymphoid tissue (Lee & Puong, 
2002; Resta-Lenert & Barrett, 2003; Collado et al., 2005; Sherman et al., 2005). In 
experiments with mice, it has been shown that L. casei, L. delbrueckii and S. thermophilus are 
able to protect against Salmonella enterica serovar Typhimurium by inducing an increase in 
the sIgA levels and in the number of IgA producing plasma cells (Perdigon et al., 1991; 
1995).  
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1.7 Study objective 
 Over the last decades, there has been a continuous increase in the consumption of 
functional foods and the market of these products is flourishing. There are already many 
studies about the effects of probiotics, prebiotics and synbiotics on health, but there are still a 
lot of unanswered questions. Not all probiotic bacteria act in the same way, their ability to 
inhibit pathogens and to modulate the immune system (see 1.4) are quite different and these 
differences are not related to the genus or the species but appear to be strain specific. 
Therefore, and because of safety reasons, for each single strain there should first be an 
intensive in vitro investigation of probiotic properties, which report a functional effect that 
justify further in vivo studies, which are associated with high costs and ethical requirements.  
 The general objective of this work was to find new probiotic Lactobacillus candidates to 
be used in functional fermented milks and to characterise the strains in vitro as an initial part 
in their development in order to elucidate their possible mechanisms of probiotic action. The 
partial aims of this work were: 
• To isolate Lactobacillus strains from traditional African fermented milks and children’s 
faeces, select those strains able to survive under simulated gastrointestinal conditions 
and accurately identify them by phenotypic and genotypic methods via a polyphasic 
taxonomic approach. 
• To screen the strains for technological and probiotic properties: antimicrobial activities 
against pathogens, presence of β-galactosidase and bile salt hydrolase, and utilisation of 
prebiotics for a possible application as synbiotics. 
• To study the surface characteristics of selected strains in order to investigate their 
possible interaction with epithelial cells via adhesion or aggregation mechanisms. 
• To investigate the ability of selected strains to adhere to epithelial cells and assess the 
effect of such adhesion properties on possible competitive exclusion of pathogens. 
• To determine whether there is a modulation by Lactobacillus strains or their 
components (LTAs, DNA; cell wall) of pathways involved in innate immunity in 
intestinal epithelial cells. To study the influence of these strains on innate recognition 
and/or responses towards S. Typhimurium in intestinal cells by investigating the RNA 
and protein expression levels. 
• Based on the an evaluation of these results, to recommend probiotic strains for further 
probiotic development. 
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2 MATERIALS AND METHODS 
2.1 Culture media 
 ABTS-Medium for determination H2O2 production. Composition (g/l): Fish extract 
10.0; tryptone 10.0; yeast extract 5.0; Tween® 80 1.0; dipotassium hydrogen phosphate 2.0; 
diammonium hydrogen citrate 2.0; magnesium sulphate 0.2, manganese sulphate 0.05, sodium 
acetate 5.0, D(+)-glucose 15.0; agar 13.0; pH 6.5. Supplemented with 0.5 mM ABTS (2,2-
azino-bis-3-ethylbenzothiazoline-6-sulfonic acid, Boehringer, Mannheim) and 0.3 U/ml 
horse-radish peroxidase (Sigma, Taufkirchen).  
 
 Basal medium for sugar fermentation test (API50CH; Biomerieux, Nürtingen). 
Composition (g/l): Peptone from casein 5.0; meat extract 5.0; yeast extract 5.0; dipotassium 
hydrogen phosphate 2.0; Tween® 80 1.0; magnesium sulphate 0.2; manganese sulphate 0.05.  
 
 Basal medium for prebiotic fermentation test of probiotic strains. Composition 
(g/l): Peptone from casein 5.0; meat extract 5.0; yeast extract 5.0; dipotassium hydrogen 
phosphate 2.0; Tween® 80 1.0; magnesium sulphate 0.2; manganese sulphate 0.05.  
 
 DMEM used for culturing of HT29 colon carcinoma cells. Dulbecco’s modified 
Eagle’s medium (Invitrogen Technologies, Karlsruhe). 
 
 M17 broth (Difco, Heidelberg) for testing lactose utilisation. Composition (g/l): 
Peptone from soymeal 5.0; peptone from meat 2.5; peptone from casein 2.5; yeast extract 2.5, 
meat extract 5.0; lactose monohydrate 5.0; ascorbic acid 0.5; sodium β-glycerophosphate 19.0 
and magnesium sulphate 0.25.  
 
 MacConkey agar (Oxoid, Wesel). Composition (g/l): Peptone 20.0; lactose 10.0; bile 
salts 1.5, NaCl 5.0; neutral red, 0.03; crystal violet 0.001; agar, 15.0.  
 
 MRS (De Man, Rogosa and Sharpe) broth (Merck, Darmstadt). Composition (g/l): 
Peptone from casein 10.0; meat extract 8.0; yeast extract 4.0; D(+)-glucose 20.0; dipotassium 
hydrogen phosphate 2.0; Tween® 80 1.0; diammonium hydrogen citrate 2.0; sodium acetate 
5.0; magnesium sulphate 0.2; manganese sulphate 0.04.  
 
MRS agar: MRS broth containing 15.0 g/l agar. 
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 MRS-Arginine broth. Composition (g/l): universal peptone 10.0; yeast extract 5.0; 
D(+)-glucose 0.5; dipotassium hydrogen phosphate 2.0; Tween® 80 1.0; diammonium 
hydrogen citrate 20.0; sodium acetate 5.0; magnesium sulphate 0.1; manganese sulphate 0.05; 
arginine 3; pH 7.0 ±0.1.  
 
 PALCAM agar supplemented with Listeria selective supplement (Oxoid). 
Composition (g/l): Peptone 23.0; starch 1.0; sodium chloride 5.0; agar 13.0; yeast extract 3.0; 
D(-)-mannitol 10.0; ammonium iron (III) citrate 0.5; esculin 0.8; glucose 0.5; lithium chloride 
15.0; phenol red 0.08. pH: 7.2±0.2. The sterile medium was cooled to 45-50°C and 
supplemented with 5.0 mg/l polymixin-B-sulphate; 10.0 mg/l ceftacidim and 2.5 mg/l 
acriflavine.  
 
 Rogosa agar (Oxoid). Composition (g/l): Peptone from casein 10.0; yeast extract 5.0; 
D(+)-glucose 20.0; potassium dihydrogen phosphate 6.0; ammonium citrate 2.0; Tween® 80 
1.0; sodium acetate 15.0; magnesium sulphate 0.575; iron (II) sulphate 0.034; manganese 
sulphate 0.12; agar-agar 15.0; pH adjusted to 5.5 with acetic acid 96% (v/v). This medium 
was not autoclaved. 
 
 Salmonella/Shigella agar (Oxoid). Composition (g/l): Peptone 10.0; lactose 10.0; ox 
bile 8.5; sodium citrate 10.0; sodium thiosulphate 8.5; ammonium iron(III) citrate 1.0; 
brilliant green 0.0003; neutral red 0.025; agar 12.0. This medium should not be autoclaved. 
Oxoid Ltd. Usage: for the isolation of Salmonellae and Shigellae. 
 
 Standard I broth (Merck). Composition (g/l): Peptone 15.0; yeast extract 3.0; sodium 
chloride 6.0; D(+)-glucose 1.0; agar (not present in the broth) 15.0. Merck, Darmstadt.  
 
Standard I agar (Merck). Standard I broth containing 15 g/l agar. 
 
2.2 Buffers and solutions 
2.2.1 Buffers and solutions used in molecular biology 
 Denaturing solution. 4 M guanidinium isothiocyanate (Ambion, Huntigdon, 
Cambridgeshire) 25 mM sodium citrate (0.75 M; pH 7; Sigma); 0.1 M β-mercaptoethanol 
(Sigma); 0.5 % N-lauryl sarcosinate (Sigma). 
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 DEPC-H2O. DEPC (diethylpyrocarbonate, Sigma) was added to redistilled water to a 
concentration of 0.1 % to eliminate RNases. The solution was agitated overnight and then 
autoclaved to eliminate DEPC. DEPC-H2O is free of RNases. 
 
 EDTA (0.5 M). 181.6 g EDTA.2H2O in 800 ml distilled water, adjusted to pH 8 with 
approx. 20 g NaOH to solubilise the EDTA and then adjusted to 1 l. 
 
 GES solution. 5 M guanidinium thiocyanate (Sigma); 100 mM EDTA (Roth, 
Karlsruhe); 0.5% Sarkosyl; pH 8. 
 
 Loading buffer. 2.5 mg/ml bromophenol blue dye, 50 % (v/v) glycerol in 1 x TE (pH 
8.9). 
 
 MOPS (10 x) buffer. 41.8 g 3 -(N-morpholino)-propane sulfonic acid (Sigma) was 
dissolved in 800 ml DEPC-H2O and adjusted to pH 7.0 with NaOH. After this, 16.6 ml 3 M 
sodium acetate (prepared in DEPC- H2O) and 20 ml 0.5 M EDTA (prepared in DEPC- H2O, 
pH 8.0) were added and the final volume was adjusted to 1 l. The buffer was sterilised by 
filtration (0.2 µm) and kept protected from light at RT. 
 
 Sample buffer for RNA electrophoresis. 2 µl 10 x MOPS, 3.5 µl formaldehyde 
(Merck), 10 µl deionised formamide (Sigma), 1 µl 400 ng/µl ethidium bromide (Roth). Daily 
prepared. 
 
 TE (10 x). Composition in (g/l): Tris-HCl, 121.1; Boric acid (Roth), 61.83; EDTA, 
0.76; final pH 8. 
 
 TERMLS. 10 mM EDTA, 0.2 g/l D(+)glucose; 0.015 g/ml lysozyme (L3790, Sigma); 
100 U/ml mutanolysin (M9901, Sigma); 25 µg/ml RNase (R6513, Sigma). 
 
 Tris-HCl. 121.1 g Tris base (Merck) dissolved in 800 ml H2O, adjusted to pH 8 with 
approx. 42 ml HCl, adjusted to 1 l and autoclaved. 
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2.2.2 Buffers and solutions required for sandwich ELISA  
 Activation reagents for TGF-β. 1 N HCl and 1.2 N NaOH/0.5 M Hepes (Sigma). 
 
 Blocking buffer for detection of TGF-β. 5 % Tween®20, 5 % sucrose in PBS pH 7.2-
7.4. Freshly prepared. 
 
 Blocking buffer. 1 % Bovine serum albumin (BSA) (Roche, Mannheim, Germany) in 
0.05% Tween®20 in PBS pH 7.2-7.4. Freshly prepared. 
 
 Reagent diluent for detection of TGF-β. 1.4 % delipidised bovine serum (Opticlear, 
Biocell laboratories), 0.05% Tween®20 in PBS pH 7.2-7.4. Freshly prepared. 
 
 Reagent diluent for IL-10 and TNF-α detection. PBS. (See 2.2.4) 
 
 Reagent diluent for IL-8 detection. 0.1 % BSA, 0.05 % Tween®20 in Tris-buffer 
saline (20 mM Trizma base, 150 mM NaCl) pH 7.2-7.4. The Tris-buffer can be autoclaved, 
the reagent diluent was freshly prepared. 
  
 Reagent diluent. 1 % BSA in PBS, pH 7.2-7.4. Freshly prepared 
 
 Stop solution. 1 N H2SO4. 
 
 Substrate solution. 1:1 mixture of colour reagent A (H2O2) and colour reagent B 
(Tetramethylbenzidine) from R&D Systems. 
 
 Wash buffer. 0.05 % Tween®20 (Sigma) in PBS pH 7.2-7.4. 
 
 Working solution of streptavidin-horse radish peroxidase. A 1:400 dilution of 
streptavidin in the corresponding reagent diluent was used. 
 
2.2.3 Buffers and solutions required for FACS (fluorescence activated cell sorter) 
analysis 
 Antibodies. Monoclonal antibody to TLR9 FITC labelled (0.5 µg/µl, no. IMG-305C, 
Biomol, Hamburg), monoclonal antibody to TLR5 PE labelled (0.5 µg/µl, no. IMG-663D, 
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Biomol), mouse antibody to human TLR2 FITC labelled (supplied as 100 tests in 1 ml 
PBS/NaN3, no. 11000-09, Biozol, Eching), mouse IgG2a istotype control PE-labelled antibody 
(supplied as 100 tests in 1 ml PBS/NaN3, no. 0103-09, Biozol) and mouse IgG1 isotype 
control FITC-labelled antibody (supplied as 100 tests in 1 ml PBS/NaN3, no. MCA982F, 
Serotech, Oxford). 
 
 Cleaning and transport solutions for FACS. FACS Clean, FACS Flow and FACS 
Rinse (BD Biosciences). 
 
 Lysis solution. FACS lysing solution (10 x) dilute 1:10 in steril dH2O. (BD 
Biosciences, Heidelberg). 
 
 Saponin buffer. Wash buffer added with 0.5% saponin (Sigma). 
 
 Wash buffer. 1 %BSA, 0.1 % NaN3 PBS. 
 
2.2.4 Other buffers and solutions  
 Artificial duodenum solution. 6.4 g/ l NaHCO3, 0.239 g/l KCl, 1.28 g/l NaCl, 0.5 % 
bile salts (Oxgall, Merck) and 0.1 % pancreatin (no. 77160, Fluka, Taufkirchen). 
 
 Disruption buffer. 0.05M Tris-HCl pH 8.0 containing 1 mM MgCl2, 0.2 mM 
dithiothreitol and 50 µg/ml of each RNAse and DNAse (no. R6513 and 31135, respectively) 
(Sigma). 
 
 Electrolyte solution. 6.2 g/l NaCl, 2.2 g/l KCl, 0.22 g/l CaCl2 and 1.2 g/l NaHCO3, pH 
2.5. 
 Phosphate buffered saline (PBS). 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4 and 0.24 g 
KH2PO4 (adjusted to pH 7.4 with 1 N HCl) dissolved in 1 l water and autoclaved. For cell 
cultures endotoxin-free PBS was purchased from Gibco, Invitrogen. 
 
 Quarter-strength Ringer (QSR) solution. Prepared by dissolving tablets as indicated 
by the supplier (Merck) and diluting 1:4 in dH2O. Solutions were autoclaved and stored at 
8°C. 
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2.3 Isolation, selection and identification of Lactobacillus strains 
2.3.1 Isolation of bacterial strains 
 One gram of freshly collected faeces from a 3-year-old and a 4-year-old child were 
suspended (10-1 dilution) in 9 ml quarter-strength Ringer solution (QRS) and diluted further in 
a ten-fold dilution series with QRS. One hundred microlitre aliquots of suitable ten-fold 
dilutions were spread plated onto Rogosa and MRS agar to enumerate bacteria and isolate 
predominant colonies. Plates were incubated anaerobically (Anaerocult®, Merck) for 48 h at 
37°C. Several randomly selected colonies were picked from plates of the highest dilution of 
each sample. The morphology of strains was checked by microscopy (1000x magnification) 
and twenty strains with rod-shaped morphology were further sub-cultured in MRS broth and 
streaked out three times to check for purity. Stock cultures were kept at -80°C in MRS broth 
containing 20 % (v/v) glycerol. 
 
2.3.2 Strain selection and identification 
 Gram-positive, catalase-negative rods from infant faeces were selected for further 
studies to determine if they were able to survive a successive passage through solutions 
mimicking saliva, gastric juice and intestinal juice (see below). In addition, strains deposited 
in the BFEL culture collection, which were previously isolated from two traditional fermented 
milk products ‘Kule naoto’ and ‘Kwerionik’ from Kenya and Uganda, respectively, were also 
used in this study (Table 2.1). Strains with good survival rates were further identified using 
phenotypic and genotypic characterisation and identification techniques as described below. 
 
2.3.3 Phenotypic characterisation 
2.3.3.1 Growth at different temperatures 
 Overnight cultures were inoculated (1 %) in MRS broth and incubated in a water bath 
at 15°C and 45°C for 5 days. Turbidity indicated growth. 
 
2.3.3.2 Production of gas from glucose 
 Overnight cultures were inoculated (1 %) in MRS broth (ca. 1 x 106 CFU/ml) in an 
assay tube containing an inverted Durham’s tube and incubated at 37°C for 48 h. The 
presence of gas in the Durham’s tube indicated a heterofermentative metabolism. 
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Table 2.1 Strains used in this study. 
Genus Species Strain Origin Use/Reference 
Lactobacillus spp. BFE 5759 Kwerionik This study. Isolates deposited by Dr. J. Nakavuma. 
(L.)  BFE 5878 Kule naoto 
  BFE 5092 Kule naoto 
  BFE 6128 Kule naoto 
  BFE 6154 Kule naoto 
This study. Isolates deposited by Dr. J. M. Mathara. 
This study. Isolates deposited by Dr. J. M. Mathara. 
This study. Isolates deposited by Dr. J. M. Mathara. 
This study. Isolates deposited by Dr. J. M. Mathara. 
  BFE 1684 Human faeces This study. 
  BFE 1685 Human faeces This study. 
 johnsonii LA1 
(BFE663) 
Nestlé Good gastrointestinal survival, diminishes H. pylori 
colonisation and improves oral vaccination (Link-
Amster et al., 1994; Salminen et al., 1998; Felley et 
al., 2001; Holzapfel et al., 2001). 
 rhamnosus GG Valio Ltd. Reduces duration of rotavirus and traveller’s 
diarrhoea, immunomodulation, treatment of allergies, 
improvement of IBD (Kaila et al., 1992; Guandalini, 
2000; Gupta et al., 2000; Kalliomaki et al., 2001). 
High binding to IEC (Blum et al., 1999). 
 paracasei BFE 675 Danone Low binding to IEC  (Tuomola & Salminen, 1998). 
 casei DSM20011 DSMZ Type strain. 
 casei Shirota (BFE 
688) 
Yakult Low binding to IEC (Tuomola & Salminen, 1998). 
Immunmodulation (Yasui et al., 1999). 
 sakei DSM20017 DSMZ Arginine positive control strain.  
Enterococcus faecalis DSM20409 DSMZ Indicator strain for agar spot test.  
(Ent.) faecalis FAIR-E155 BFEL Bsh-positive control strain. (Franz et al., 2001) 
 faecium DSM13590 DSMZ Pathogenic strain, vancomycin resistant (Klein, 2003). 
Indicator strain for agar spot test. Assays of inhibition 
of adhesion. 
 faecium FAIR-E179 BFEL Bsh-negative control strain. (Franz et al., 2001) 
innocua WS2258 Weihenstephan 
Inst. 
Indicator strain for agar spot test. Listeria 
(List.) 
monocytogenes Scott A BFEL Indicator strain for agar spot test. Coaggregation test. 
Assays of inhibition of adhesion. 
Staphylococcus 
(S.) 
aureus ATCC 25923 ATCC     Coaggregation test. Clinical isolate 
Streptococcus mutans DSM6178 DSMZ Indicator strain for agar spot test. 
coli ATCC 43895 ATCC Indicator strain for agar spot test.  Escherichia 
(E.) coli ATCC 25922 ATCC      Clinical isolate. Enterotoxigenic strain. Assays of 
inhibition of adhesion. Coaggregation test. 
Salmonella 
(S.) 
enterica 
serovar 
Typhimurium 
S 5489 BFFF Indicator strain for agar spot test. 
 enterica 
serovar 
Typhimurium 
ATCC 14028 ATCC     Clinical isolate. Pathogenic strain. Assays of 
inhibition of adhesion. Coaggregation test. 
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2.3.3.3 Hydrolysis of arginine  
 Overnight cultures were inoculated (1 %) in MRS-arginine broth at 37°C for 24-72 h. 
For detection of ammonia, 100 µl were spotted onto a white spotting tile and an equal volume 
of Nessler’s reagent was added. If ammonia was present, a dark orange colour appeared 
immediately. L. sakei DSM 20017 (Table 2.1) was used as an arginine positive control strain. 
 
2.3.3.4 Presence of meso-diaminopimelic acid (mDAP) in the cell walls 
 One and a half millilitre of an overnight culture was centrifuged (7,500 x g, 10 min; 
Megafuge 1.0 R, Heraeus) in Eppendorf tubes, resuspended in 200 µl 4 N HCl and hydrolysed 
at 100°C in a heating block overnight in tightly closed tubes. HCl was removed by gently 
streaming nitrogen at 40 to 50°C into the solution for 1 h. The dry residue was collected in a 
drop of water and spotted onto a thin layer chromatography plate (pre-coated cellulose plastic 
sheets 20 cm x 20 cm, Merck, no. 5577). A mDAP standard (5 mg/ml) was also spotted as a 
positive control. The ascending one-dimensional chromatography was run in a solvent 
solution containing methanol:pyridine:10 N HCl: water (32:4:1:7). After drying, the 
chromatograms were developed with an acidic ninhydrin spray (0.5 % wt/v ninhydrin in 1-
butanol:acetic acid [13:1]) and heated at 100°C in an oven for 5 min. mDAP is characterised 
by a low Rf (retention factor) and an olive green colour which changes to yellow with time 
and light exposure.  
 
2.3.3.5 Determination of lactic acid enantiomers produced 
 Lactic acid enantiomers were determined using an enzymatic kit (Boehringer 
Mannheim) based on the oxidation of D-lactate or L-lactate into pyruvate in the presence of 
NAD+, which in turn reduces to NADH, by the corresponding enzymes D-lactate-
dehydrogenase or L-lactate-dehydrogenase. The equilibrium of these reactions lies on the side 
of lactate. By trapping pyruvate in a subsequent reaction catalysed by glutamate pyruvate 
transaminase in the presence of L-glutamate, the equilibrium can be shifted in favour of 
pyruvate and NADH. The amount of NADH formed in the mentioned reactions is 
stoichiometric to the amounts of lactic acid oxidised by the lactate-dehydrogenases. The 
increase of NADH was determined spectrophotometrically (spectrophotometer Bioad 
SmartSpecTM Plus, Munich) by measuring the increase in light absorbance at 340 nm over 
time. 
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2.3.3.6 Sugar fermentation profiles 
 Overnight cultures grown in MRS broth were washed twice in QRS (7,500 x g, 10 
min) and resuspended in basal medium for API 50 CH (bioMeriéux, Nürtingen). The API 50 
CH strips consist of 50 microtubes containing dehydrated carbohydrates and its derivatives 
(heterosides, polyalcohols, uronic acids). The microtubes are inoculated with the bacterial 
suspension, which rehydrates the substrates. When fermentation occurred, it was revealed by 
a color change in the tube, caused by the anaerobic production of acid which is detected by 
the pH indicator present in the medium. The first tube, which does not contain any substrate, 
was used as negative control. Fermentation profiles were determined according to 
manufacturer’s instructions.  
 
2.3.4 Genotypic characterisation 
2.3.4.1 Isolation of genomic DNA from bacteria 
 The total genomic DNA of selected Lactobacillus strains was isolated according to the 
guanidinium isothiocyanate method of Pitcher et al. (1989) as modified by Björkroth and 
Korkeala (1996) for Gram-positive bacteria. Briefly, 5 ml of an overnight culture (grown in 
MRS) were centrifuged (17,860 x g, 10 min) and the pellet was resuspended in 1.5 ml 1 x TE 
containing 0.5 % NaCl and centrifuged again. The pellet was resuspended in 100 µl TERMLS 
(see 2.2.1) and incubated at 37°C for an hour. To degrade bacterial peptidoglycan, cells were 
lysed and protein denatured by adding 500 µl GES to the suspension and gently mixing by 
inversion. The preparation was incubated on ice for 5 min after which 250 µl 7.5 M 
ammonium acetate was added and the tubes were gently inverted before incubating for 10 min 
and centrifuging at 15,000 x g for 10 min. The upper phase was carefully removed and placed 
in a new Eppendorf tube. The DNA was precipitated by adding 460 µl ice cold 2-propanol 
and centrifuging at 15,000 x g for 10 min at 4 °C. The supernatant was discarded and two 
washes with 400 µl ethanol followed. The pellet was vacuum-dried (Vacuum-drier, 
Eppendorf, Hamburg) at 45°C for about 3-5 min. The DNA was resuspended in 200 µl of 10 
mM Tris-HCl (pH 8). 
 
2.3.4.2 Determination of DNA and RNA concentration and purity 
 The concentration of DNA and RNA in solution was determined 
spectrophotometrically by measuring the light absorbance (A) at 260 nm in UV-cuvettes 
(VWR International, Bruchsal). An A260 of 1 corresponds to approximately 50 μg/ml of 
dsDNA and 40 μg/ml of ssRNA (Sambrook et al., 1989). The ratio between the readings at 
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260 nm and 280 nm (A260/A280) provides information on the purity of the nucleic acid, with 
pure preparations of DNA and RNA having A260/A280 ratios of 1.7 to 2.0. Appropriate 
dilutions were prepared for measurements. DNA solution was diluted 1:200 and RNA was 
diluted 1:100 before measurements. Aliquots were stored at -20°C and -80°C until use. 
 
2.3.4.3 Rep-PCR 
 Rep-PCR using the primer GTG5 (5`-GTG GTG GTG GTG GTG-3`) was used for 
identification of strains according to methods as previously described by Gevers et al. (2001). 
DNA was amplified in a 50-µl volume containing 100 ng template, 1 X Taq DNA polymerase 
buffer (Amersham Pharmacia, Freiburg, Germany), 200 µM dNTPs (BioRad, München, 
Germany), 50 pM primer GTG5, 4 % dimethylsulphoxide (Sigma) and 1.5 U Taq DNA 
polymerase (Amersham Pharmacia). PCR products were separated by electrophoresis on 1.8 
% (wt/v) agarose gels in 1 x TBE puffer (Saambrook et al., 1989). Rep-PCR products were 
subjected to electrophoresis for 16.5 h at 48 V. The gels were stained with ethidium bromide 
and gel images were captured using the Fluorchem Imager 5500 system (Alpha Innotech, 
USA). The digitised images were normalised and subsequently analysed using the 
Bionumerics (version 2.5) software package (Applied Maths, Sint-Martens-Latem, Belgium). 
Groupings of the rep-PCR fingerprints were performed by means of the Pearson product-
moment correlation coefficient (r) and the unweighted pair-group method using arithmetic 
averages clustering algorithm (UPGMA)(Sneath & Sokal, 1973). 
 
2.3.4.4 16 S rDNA sequence  
 The almost complete 16S rDNA of selected strains was amplified by PCR using the 
primers 16Sseqfw (5’-AGA GTT TGA TCM TGG CTC AG-3’) and 16Sseqrev (5’-GGN 
TAC CTT GTT ACG ACT TC-3’) corresponding to positions 8 to 27 and 1511 to 1491 of the 
16S rDNA gene of E. coli (Brosius et al., 1978), respectively. DNA was amplified in 32 
cycles (94°C, 1 min; 56°C, 1 min, 72°C, 2 min) in a 50 µl reaction volume containing Taq 
DNA polymerase (Amersham Pharmacia), 1 x polymerase buffer (Amersham Pharmacia), 
primers and dNTPs at the same concentrations as described for rep-PCR. The PCR products 
were cleaned using quantum prep PCR clean columns (see below) and sequenced 
bidirectionally at GATC Biotech (GATC, Konstanz, Germany). 
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2.3.4.5 Analytical scale purification of PCR products 
 Quantum Prep PCR Kleen spin columns (BioRad) were used to purify PCR products. 
The resin contained in the column was resuspended by vortexing for 5 s. The column was 
placed in a 2 ml wash tube and spun for 1 min in a micro-centrifuge at 735 X g. After this, the 
column was placed in a clean 1.5 ml collection tube and 25-100 µl sample was applied at the 
top centre of the column without disturbing the resin. The tube was spun again at 735 X g for 
2 minutes. The purified PCR product was recovered in the bottom of the collection tube. 
 
2.4 Testing Lactobacillus strains for in vitro probiotic properties 
2.4.1 Studies on resistance to gastrointestinal conditions 
2.4.1.1 Evaluation of parameters which affect survival of probiotic strains during 
simulated stomach passage 
 The Plackett–Burman (PB) statistical design was used to select parameters that can 
affect the survival of probiotic strains during simulated stomach passage. This statistical 
design allows the identification of variables responsible for main effects in a model study with 
relatively few experiments (Plackett & Burman, 1946).  
 For testing five variables at two levels in their various combinations, theoretically 25 
tests would have to be done. The PB design, however, allows to determine the significance of 
these parameters on bacterial survival in only eight experiments (Plackett & Burman, 1946). 
The PB matrix for planning the eight experiments is shown in Table 2.2.  
 
 Table 2.2 Plackett-Burman matrix for 8 experiments 
 
A B C D E F G Run no.  
1 + - - + - + +  
2 + + - - + - +  
3 + + + - - + -  
4 - + + + - - +  
5 + - + + + - -  
6 - + - + + + -  
7 - - + - + + +  
8 - - - - - - -  
A to G: indicate the variables. + or - : indicate one of the two levels at which each variable 
is tested. Run no.: indicates the experiment number. 
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 The variables tested included: protective effect of 15 % (w/v) skim milk (Merck), 
medium composition (MRS or electrolyte solution), presence of lysozyme (100 ppm; Merck), 
presence of pepsin (0.3%; Fluka Biochemika, Steinheim), and pH of the medium. Each 
variable was tested at two levels: either presence or absence of each enzyme, two different pH 
values, using MRS broth or an electrolyte solution (see 2.2.4) resembling artificial gastric 
solution and finally, the probiotic candidates were either inoculated into skim milk as food 
matrix or into MRS broth (Table 2.3). In order to allow calculation of variance and standard 
error, two variables defined as “dummy” because they do not really exist, were used following 
the PB design (Stowe & Mayer, 1966; Lavilla et al., 1998; Fonseca et al., 2001).  
 
 Table 2.3 Variables used in the PB-design 
  Code A B C D E F G 
 Protective 
effect of 
milk 
Variable/ 
Level 
 Solution 2 pH Dummy Pepsin Dummy Lysozyme
 
- MRS MRS absent 2.5 - absent -  
 Saline 
solution 
+ Milk present 3.0 - present - 
 
 
 L. johnsonii LA1 (BFE 663) was used as reference strain (Table 2.1), because of its 
well documented tolerance to gastrointestinal conditions (Salminen et al., 1998; Holzapfel et 
al., 2001), while other reference strains were not used. Milk or MRS broth were inoculated 
with an overnight culture to reach a final concentration of approximately 5 × 106 to 1 ×107 
CFU/ml. One millilitre samples were taken at the beginning of each assay (T0) and after one 
hour (T60). The response was calculated as the difference between the log units of the initial 
and final counts (inhibition: log CFU/mlT0−log CFU/mlT60). The effect of each individual 
variable, the variance and the standard error were calculated as described by Stowe and Mayer 
(1966) and shown below. 
 The effect of each variable on the inhibition of L. johnsonii LA1 can be calculated as 
the difference between the mean of the inhibition values for the four experiments at the (+) 
level and the mean of the inhibition values for the experiments at the (-) level. As an example, 
the equation for calculation of the effect of variable A is shown below: 
 
EA= [I exp1+ I exp2 + I exp 3 + Iexp5] / 4 - [I exp4+ I exp6 + I exp 7 + Iexp 8] / 4 
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EA: Effect of variable A 
I expx: inhibiton (log CFU/ml T0 – log CFU/ml T60) in experiment no. i 
i: 1 to 8 
 
 The variance is calculated as the average of the squares of the inhibition values when 
analysing the dummy variables (E and G). The standard error is equal to the square root of the 
variance (Stowe and Meyer, 1966). 
  
Variance= (EE + EG) / 2             S.E.: √ variance 
 
 The significance of variable A was tested by means of the t-test for individual effects, 
which allows the evaluation of the probability (P) of finding an effect merely by chance.  
 
T = EA / S.E. 
 Probability (P) can be read from distribution tables using the calculated T values. If P 
is sufficiently small, it can be assumed that the inhibition was caused by the change of levels 
of variable A. The same calculations were also done for each variable (A, B, C, D and F). For 
this kind of test, a 85 % confidence level is considered significant (Stowe & Mayer, 1966; 
Lavilla et al., 1998; Fonseca et al., 2001). 
 
2.4.1.2 Survival of Lactobacillus strains after the successive passages through artificial 
saliva, gastric juice and intestinal juice 
 The parameters determined as important for bacterial survival in the PB design were 
adopted in a model stomach/intestinal passage experiment in order to compare the survival of 
potential probiotic strains. Reconstituted skim milk (15 % wt/v, Merck) was inoculated with 
approximately 2 x 108 CFU/ml of an overnight culture. A 1-ml aliquot was removed, serially 
diluted in QSR (ten-fold dilution series) and spread-plated onto MRS agar to determine the 
CFU/ml at time 0. To simulate the dilution and possible hydrolysis of bacteria in the human 
oral cavity, the suspension was diluted 1:1 in a sterile electrolyte solution (see 2.2.4) to which 
lysozyme was added to a final concentration of 100 ppm, and incubated for 5 min at 37°C. 
The sample was subsequently diluted 3:5 with an artificial gastric fluid, consisting of the 
electrolyte solution mentioned above, adjusted to pH 2.5 and to which pepsin (no. 76190, 
Fluka) was added to a final concentration of 0.3 %. If required, the pH was readjusted to pH 
2.5 with 5 N HCl. After 1 h of incubation at 37°C, another 1-ml aliquot was removed, serially 
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diluted in QSR and spread-plated onto MRS agar. To simulate the dilution in the small 
intestine, the remaining volume was diluted 1:4 using an artificial duodenal secretion (pH 7.2, 
see 2.2.4) (Zarate et al., 2000; Fernandez et al., 2003). One-millilitre aliquots were again 
removed after 2 and 3 h, serially diluted in QSR and spread-plated onto MRS agar to 
determine the CFU/ml in duplicate. Experiments were conducted in triplicate. Only strains 
which survived this passage were further characterised. 
 
2.4.1.3 Resistance to 0.4 % phenol 
 Some aromatic amino acids derived from dietary or endogenously produced proteins 
can be deaminated in the gut by bacteria leading to the formation of phenols (Suskovic et al., 
1997). These compounds can exert a bacteriostatic effect against some Lactobacillus strains. 
Thus, testing for the resistance to phenol may generate further information on the potential for 
survival of lactobacilli in gastrointestinal conditions (Xanthopoulos et al., 2000). Therefore, 
the ability of Lactobacillus strains to grow in the presence of phenol by inoculating cultures (1 
% of an overnight culture) in MRS broth with and without 0.4 % phenol was tested. Serial 
dilutions were spread-plated (100 μl aliquots) onto MRS agar at time 0 and after 24 h of 
incubation at 37°C to enumerate surviving bacteria as described by Xanthopoulos et al. 
(2000). 
 
2.4.2 Determination of antimicrobial potential of probiotic strains 
2.4.2.1 Production of H2O2 
 Ten microlitres of overnight cultures were spotted onto ABTS-agar plates (see 2.1) and 
incubated anaerobically at 37°C for 72 h. After anaerobic incubation, plates were exposed to 
the atmosphere. Oxidative coloration of ABTS by H2O2 was visible as a violet halo 
surrounding the colony of H2O2 producer Lactobacillus strains,  indicating H2O2 production 
(Marshall, 1979).  
 
2.4.2.2 Screening for antagonistic activity 
 The agar spot test as described by Schillinger and Lücke (1987) was used for screening 
the antagonistic activity of the selected Lactobacillus strains. Ten microlitres of an overnight 
lactobacilli culture were spotted onto modified MRS agar (2 g/l glucose and 13 g/l agar) and 
incubated at 37°C for 24 h. These plates were overlayered with MRS soft agar (7.5 g/l agar) 
inoculated with ca. 1 x 108 CFU/ml of indicator strains (shown in Table 2.1).  
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 The agar spot test method of Uhlman (1992) was used to test whether the inhibition 
zones observed in the screening for antagonistic activity were due to bacteriocin production or 
as a result of acid inhibition. Briefly, cell-free neutralised supernatants were obtained from 
overnight producer cultures grown in MRS broth at 37°C. After centrifuging the culture at 
7,200 x g for 10 min, the supernatants were neutralised with sterile 5 M NaOH and then 
boiled for five min to inactivate residual viable cells. The supernatants were tested against the 
same indicator strains mentioned above. 
 
2.4.3 Bile salt hydrolase activity 
 Bile salt hydrolase (Bsh) activity of the cultures was detected using the procedure 
described by du Toit et al. (1998). Briefly, ten microliters of overnight cultures were spotted 
onto MRS agar plates supplemented with 0.5 % (wt/v) taurodeoxycholic acid sodium salt 
(T0875, Sigma) and 0.37 g/l of CaCl2. The plates were incubated anaerobically for 72 h, after 
which those strains with a white precipitation zone surrounding the colony were considered as 
positive (du Toit et al., 1998; Franz et al., 2001).  
 
2.4.4 Production of β-galactosidase 
 The o-nitrophenyl-β-D-galactopyranoside (ONPG) substrate (N1127, Sigma) was used 
to determine β-galactosidase activity as described by Zárate et al. (2000), with modifications 
as described below. Those strains able to grow in M17 medium (Merck), which contains 
lactose as only carbon source, were harvested by centrifugation and washed twice in 
phosphate buffered saline (PBS) at pH 7.4. Strains growing on M17 were thought to have β-
galactosidase activity, which enables utilisation of lactose and hence growth on this type of 
medium. The samples were adjusted to an A580nm of 1.0. Hundred-µl aliquots of each of the 
bacterial suspensions were incubated in the presence of 2 mmol/l ONPG for 40 min in a water 
bath at 37°C. The reaction was stopped by addition of 1ml 0.25 M Na2CO3. The samples were 
centrifuged at 7,200 ×g for 10 min at 4°C and the supernatants were recovered to measure the 
A420nm. A standard curve was obtained with o-nitro-phenol (ONP, Sigma) (concentrations of 
0.05 to 0.5 μmol/ml in 0.05 μmol/ml increments). In order to compare the activity of those 
strains able to hydrolyse ONPG, cell-free extracts were prepared by disruption using a French 
pressure cell (SLM Aminco, SLM Instruments Inc., Lorch, Germany). Briefly, 10 ml of 
overnight cultures grown in M17 broth were harvested by centrifugation (7,200 × g at 4°C for 
10 min) washed twice with buffer KH2PO4/Na2HPO4  (50 mM pH 7.25) and resuspended in 
the same buffer. The cell suspension was passed through the French pressure cell at 1,000 psi 
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pressure for at least two times. Cell debris was separated by centrifugation at 10,000 × g at 
4°C for 10 min. Cell extracts were kept on ice until incubation with the substrate as 
previously described. Protein contents were determined by the method of Bradford (1976), 
using bovine serum albumin (Roche, Mannheim) as standard. One enzymatic unit was defined 
as the micromoles of ONP liberated from ONPG per milligram of protein and per min. 
 
2.4.5 Growth on prebiotics 
 Overnight cultures grown in MRS were washed twice in QSR (750 x g) and inoculated 
into basal medium containing either 1 % wt/v prebiotic sugars or 1 % wt/v prebiotics together 
with 0.1 % wt/v glucose. The following prebiotics from Orafti (Belgium) were used: 
Raftilose®P95 (> 93 % oligofructose, 2-8 polymerisation degree, ≤ 6.8 % content of glucose + 
fructose + sucrose); Raftiline®LS (> 99 % oligofrustose, 2-60 polymerisation degree, ≤ 1 % 
content of glucose + fructose + sucrose); Raftiline®ST (> 90 % oligofructose, >10 
polymerisation degree, ≤ 4 % content of glucose + fructose and ≤ 8 % + sucrose) and 
Raftiline®HP (> 99.5 % oligofructose, 2-60 ploymerisation degree, ≤ 0.5 % content of glucose 
+ fructose + sucrose). One hundred µl of each suspension was added to each well of a 100-
well-Biocreen plate and incubated at 37°C to determine growth kinetics. The A580nm was 
measured automatically every 15 min in an automatic spectrophotometer plate reader 
(Bioscreen C200, Applied Biosystems). 
 
2.5 Safety considerations: antibiotic resistance profiles of Lactobacillus strains 
 The selected strains were investigated for their antibiotic resistance profile using the E-
test (Viva Diagnostika, Cologne, Germany) using MRS agar and anaerobic incubation 
conditions and following the manufacturer’s instructions. The minimum inhibitory 
concentration (MIC) values used to determine whether strains were susceptible or resistant 
were those as suggested by the scientific Commission on Animal Nutrition (SCAN) for 
Lactobacillus spp. (Chesson et al., 2002). 
 
2.6 Adhesion properties of selected Lactobacillus strains 
2.6.1 Microbial adhesion to solvents 
 Microbial adhesion to solvents was measured using the methods described by 
Rosenberg et al. (1980) and Bellon-Fontaine et al. (1996) with slight modifications. Overnight 
cultures of lactobacilli were harvested by centrifugation at 5,000 x g for 5 min, washed twice 
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in PBS (pH 7.4), resuspended and diluted in PBS to reach an absorbance (A0) of approx. 0.5 
at 580 nm. Two ml of test solvent were added to 2 ml of the suspension and mixed by 
vortexing for one minute. The three test solvents used were n-hexadecane (Sigma), which is 
an apolar solvent, chloroform (Merck), which is a monopolar and acid solvent, and ethyl 
acetate (Merck), which is a monopolar and basic solvent. The aqueous phase was taken after 
20 min incubation at RT and its absorbance at 580 nm was measured (A1). The percentage of 
bacterial adhesion to solvent was calculated as (1 - A1/A0) x 100. 
 
2.6.2 Aggregation  
 The auto-aggregation assay was performed as described by Del Re et al. (2000) with 
modifications. Overnight cultures were washed as described above and the cells were 
suspended in either PBS pH 7.4, PBS pH 4.0, supernatant of bacteria grown overnight in 
MRS or in neutralised supernatant (neutralised with 1 N HCl). Two ml of each of these 
suspensions were vortexed for 10 s and auto-aggregation was determined after 2 h at RT. For 
determination of auto-aggregation, 100 µl were removed from the top of the suspension and 
were transferred to a cuvette containing 900 µl PBS pH 7.4. The absorbance (A1) was 
measured at 580 nm. The auto-aggregation percentage is expressed as: (1 - A1/A0) x 100, 
where A0 represents the absorbance at time = 0. 
 
2.6.3 Coaggregation 
 Overnight cultures of lactobacilli and pathogenic strains (Table 2.1) were washed 
twice with PBS pH 7.4. To each well of a 24-well microtray (Costar, VWR Int.), 500 µl of the 
Lactobacillus suspension (109 CFU/ml) and 500 µl of the pathogen suspension (109 CFU/ml) 
were added. After mixing, the trays were incubated at 37°C with shaking at 100 rpm for 2 h. 
The scoring system of 0 to 4 (0, for no coaggregation, 1 for small and dispersed clumps, 2 for 
medium-sized and dispersed clumps, 3 for abundant and medium sized clumps and 4 for very 
big clumps and clear supernatant) as described by Reid et al. (1988) was used. Each 
suspension was examined for aggregation microscopically at 200x and 400x magnification 
with an inverted microscope, though clumping at score levels of 3 and 4 could be seen 
macroscopically. 
 
2.6.4 Lactobacilli adhesion to HT29 cells 
 Overnight cultures (2 ml) were washed twice with the same volume of PBS pH 7.4 and 
the bacterial cells were resuspended and diluted to a concentration of 2 x 108 CFU/ml in 
DMEM. Prior to the adhesion assays, confluent HT29 cell monolayers (see section 2.8.1) 
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grown on 8-well-chamber slides (Falcon, VWR Int.) were washed twice with PBS (pH 7.4) to 
remove cellular debris, FCS and antibiotics. Bacterial suspensions (2 x 108 CFU/ml, 363 µl 
per chamber) were added to the monolayers (approx. 7 x 10  HT29 cells, resulting in a ratio of 
100 bacterial cells per HT29 cell) and incubated for o
5
ne hour at 37°C and 5 % CO2. After 
incubation, the cells were washed three times with 1 ml PBS (pH 7.4) to remove non-adherent 
bacteria. Slides were allowed to air dry for 30 min at RT, fixed with methanol (100 %, Merck) 
for 10 min and Gram stained (Del Re et al., 2000; Gopal et al., 2001; Nam et al., 2002). Each 
chamber measured 28 microscopic fields in length and 18 microscopic fields in width. Nine 
photographs were taken with a Leitz Camerasystem for automatic microscopy (Leitz, Wetzlar, 
Germany) fitted to a Leitz Aristoplan microscope. Photographs from nine different length-
width co-ordinates (for different chamber wells the same coordinates were used) were taken at 
1000x magnification. All HT29 cells, as well as attached bacteria, were counted and the 
number of adherent bacteria per 100 HT29 cells was calculated. Adherence of strains was 
classified according to the criteria reported by Del Re et al. (2000) as follows: non-adhesive, 
fewer than 5 bacteria per 100 cells; adhesive, 6 to 40 bacteria to 100 cells; strongly adhesive, 
more than 40 bacteria per 100 cells. 
 
2.6.5 Competitive exclusion: adhesion inhibition assays 
 Changes in adherence to epithelial cells of List. monocytogenes Scott A, Ent. faecium 
DSM 13590, S. Typhimurium ATCC 14028 and E. coli ATCC 25922 (Table 2.1) were 
determined using an in vitro epithelial binding assay. HT29 cells were grown to 100 % 
confluence on 24-well plates (Falcon, VWR Int., Bruchsal) and washed twice with 1 ml 
PBS/well (pH 7.4). One ml of a suspension of approx. 1 x 108 CFU/ml lactobacilli in DMEM 
(without FCS and without antibiotics) was added to the wells and incubated for an hour at 
37°C and 5% CO2 to allow adhesion of the probiotic candidates. Control wells without 
lactobacilli were treated in the same way and incubated with DMEM without bacteria. 
Following the one hour incubation, List. monocytogenes Scott A, Ent. faecium DSM 13590, S. 
Typhimurium ATCC 14028 or E. coli ATCC 25922 were inoculated to the wells (1 x 105 
CFU/well) and incubated under the same conditions. After a further hour incubation, non-
adherent bacteria were removed by washing three times with 1 ml PBS (pH 7.4). Cells with 
adherent bacteria were lysed with 1.5 ml of 1 % (v/v) Triton 100-X (Merck), serial diluted 
and plated on to differential media (Palcam Agar for List. monocytogenes with Listeria 
selective supplement, MacConkey Agar for E. coli, Salmonella-Shigella Agar for S. 
Typhimurium. and MRS supplemented with 64 µg/ml erythromycin (for Ent. faecium). 
-36- 
MATERIALS AND METHODS 
2.7 Interaction of Lactobacillus strains with intestinal epithelial cells: activation of 
 innate responses 
2.7.1 Co-culture of HT29 cells with bacteria for induction of cytokines 
 In order to see if the selected Lactobacillus strains and control strains were able to 
induce secretion of cytokines by HT29 cells, bacterial suspensions and HT29 cells were co-
cultured for 24 h at 37°C and 5 % CO2. 
 HT29 cells (1 x 106 per well) were seeded in 6-well-plates (Falcon, VWR 
International) and allowed to attach and grow for 48 h. Sub-confluent monolayers (because it 
was shown in previous pilot studies that this was the optimal condition for studying CK 
induction) were washed twice with endotoxin-free PBS pH 7.4 before adding new culture 
medium without FCS or antibiotics to the control wells, and 2 ml of bacterial suspensions 
containing 5 x 106 CFU/ml to trial wells. These co-cultures were incubated for 24 h after 
which supernatants were collected, centrifuged and stored at –80°C until assayed 
 
2.7.2 Co-culture of HT29 cells with bacteria, LPS, LTA and TNF- α for induction of 
 cytokines 
 In a similar experimental set as indicated in 2.7.1, HT29 cells were treated with 
bacteria (same conditions as above) and 0.1 µg/ml LPS from E. coli (no. L4516, Sigma), 
0.1µg/ml LTA from S. aureus (no. L2515, Sigma) or 0.1 µg/ml TNF-α (no. C63720, 
PromoKine, Heidelberg). These co-cultures were incubated for 24 h after which supernatants 
were collected, centrifuged and stored at –80°C until assayed. 
 
2.7.3 Co-culture of HT29 cells with bacterial cell components, supernatant and 
bacteria pre-treated with proteinase K and KIO4 
 In a similar experimental set as in 2.7.2, HT29 cells were treated with bacterial crude 
cell wall extracts, cell walls isolated with SDS, lipoteichoic acids, DNA, the sterile-filtered 
supernatant of bacteria grown for 24 h in DMEM. HT29 cultures were incubated for 24 h, 
after which supernatants were collected, centrifuged and stored at –80°C until assayed (see 
details below). 
 When isolating cellular components, one-way endotoxin free material or material 
treated with 1 N NaOH (for elimination of endotoxin) was used in order to avoid possible 
contaminations with endotoxin. 
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2.7.3.1 Isolation of crude cell walls from selected Lactobacillus strains 
 When disrupting Gram-positive bacteria with the French pressure cell, the cell walls 
retain functional fragments of cytoplasmic membrane and lipoteichoic acid. Since this 
disruption process does not shear nucleic acids, it is essential to treat the broken cell 
suspension with nucleases before purification of cell walls (Hancock & Poxton, 1988) 
 Harvested bacteria were washed twice in ice-cold 0.9 % NaCl and frozen overnight at -
20°C. The thawed bacteria were resuspended in approx. 30 ml disruption buffer (see 2.2) to a 
final concentration of 20-30 % wet wt/v. The cell suspension was passed through the French 
pressure cell (SLM Aminco) at 1000 psi. Two passages were necessary to provide adequate 
disruption. Unbroken bacteria were removed by centrifugation at 17,000 x g for 1 h at 0°C 
and washed twice with the disruption buffer added with 0.2 M KCl. Cell walls were frozen at 
-80°C and lyophilised for 24 h. A 0.1 µg/ml fresh suspension was prepared in DMEM before 
performing the assays as described in 2.10.3. 
 
2.7.3.2 Isolation of cell walls with SDS 
 Crude cell wall extracts were obtained as mentioned above and treated with boiling 
SDS to simultaneously inactivate autolysins and remove contaminating membrane, proteins, 
LTA and cytoplasmic material as described below. 
 The crude wall was suspended in the minimum volume possible of cold water and 
poured into approx.20 ml boiling 4 % SDS to a final concentration of 30 mg dry w/ml, with 
stirring. The suspension was kept in a boiling water bath for 15 min before recovering the 
walls by ultracentrifugation (45,000 x g for 15 min at 20°C). If the pellet remained pigmented 
or inhomogeneous, the SDS treatment was repeated. The wall pellet was washed repeatedly, 
by resuspension and centrifugation, first with 0.9 % NaCl and then with water at 20°C to 
remove traces of SDS. After washing, SDS-treated wall was suspended in 0.01 M Tris-HCl, 
pH 8.2, to 30 mg wt/ml, for trypsin digestion. 
 The wall suspension was mixed with trypsin to 40 U/ml and incubated with gentle 
mixing at 30°C overnight, with the addition of a drop of toluene to prevent microbial 
contamination. 
 Walls were recovered by ultracentrifugation (45,000 x g for 15 min) and washed once 
with boiling 1 % SDS to remove insoluble peptides. The residue was washed repeatedly with 
water. Cell walls were lyophilised and a 0.1 µg/ml fresh suspension was prepared in DMEM 
before performing the assay as explained in 2.7.3. 
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2.7.3.3 Isolation of LTA 
 Bacteria were grown in 2 l MRS and harvested by centrifugation at 10,000 x g for 10 
min at 4°C. Pellets were washed twice in PBS and lyophilised. The lyophilisates were brought 
to the laboratory group of Dr. Corinna Hermann at the ‘Forschungszentrum für den 
wissenschaftlichen Nachwuchs’, University of Constance. The purification protocol (Morath 
et al., 2002) consisted in adding an equal volume of n-butanol (Merck) to a defrosted 
suspension of bacteria (in 100 ml PBS) under stirring for 30 min at RT. After centrifugation at 
13,000 x g for 20 min, there were two phases: an upper organic and a lower aquatic phase. 
The aquatic phase, which contained the LTAs, was transferred to a new tube and lyophilised. 
The lyophilisate was resuspended in starting chromatographic buffer (15 % n-propanol in 0.1 
M ammonium acetate, pH 4.7) and centrifuged at 45,000 x g for 15 min. The supernatant was 
filtered (0.22 µm) and applied onto an octyl-Sepharose column for a hydrophobic interaction 
chromatography. After loading the column (2.5 x 11 cm), a linear elution gradient (15 % to 60 
% n-propanol in 0.1 M ammonium acetate, pH 4.7) was used. Eight-ml fractions were 
collected at a flow rate of 0.5 ml/min and analysed for LTA-phosphate (Ames, 1966). LTA 
containing fractions were pooled and lyophilised. This lyophilisate was again resuspended in 
starting buffer and applied onto a previously equilibrated column (1 x 5 cm, equilibrated with 
35 % n-propanol in 0.1 ammonium acetate, pH 4.7). The column was eluted at a flow rate of 
0.5 ml/min. After elution of the first 20 ml starting buffer, a linear salt gradient was started 
(0.1 M to 0.8 M ammonium acetate). Each collected aliquot was measured for phosphate 
(Ames, 1966) and for absorption at 260 nm; aliquots with no absorption at 260 nm but high 
levels of phosphate contained LTA. These LTA-containing aliquots were lyophilised and kept 
frozen at -80 °C until use. During the whole procedure extreme care was taken in order not to 
contaminate the samples with exogenous endotoxin. Therefore endotoxin-free water, 
endotoxin-free one-way material or materials treated with 1 N NaOH were used. 
 
2.7.3.4 Isolation of DNA 
 Bacterial DNA was isolated using the same procedure explained in section 2.3.4.1 but 
at a larger scale. The DNA precipitate was resuspended in 200 µl ddH2O and added to 3 ml 1 
x TE. The DNA solution was transferred to the pre-cooled French pressure cell and disrupted 
by 1000 psi. DNA solutions were passed 2-3 times through the press. Short-chain DNA was 
recovered by precipitating with 2 volumes of ethanol and 1/9 vol of ammonium acetate 
overnight. Tubes were centrifuged (10,000 x g for 11 min at 4°C) and the supernatant was 
discarded. The precipitate was washed twice with ice-cold ethanol as explained in section 
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2.3.4.1. Stock DNA solutions containing 250 µg/ml were prepared. A volume of 8 µl of these 
solutions was added to the cell cultures as explained before (2.7.3) to reach a final 
concentration of 1 µg/ml. 
 
2.7.4 Flow cytometric detection of TLRs in non-stimulated HT29 cells and HT29 cells 
stimulated with lactobacilli 
 Both TLR2 and TLR5 are transmembrane proteins present in the plasma membrane, 
whereas TLR9, also a transmembrane protein, is present in the endosomic membranes of 
certain cells, i.e. an intracellular receptor. For that reason, the detection of TLR9 includes an 
extra step for permeabilisation of the cells to allow access of the antibody to TLR9 (see 
below). All buffers and solutions needed for detection of TLRs by means of a fluorescence 
activated cell sorter (FACS) are described in section 2.2.3. 
 HT29 cells (1 x 106 cells/well) were allowed to attach and grow in 6-well plates for 48 
h until subconfluency and were co-incubated with suspensions (1 x 107 CFU/well) of L. 
rhamnosus GG, L. johnsonii BFE 6128 or L. plantarum BFE 1685 or S. Typhimurium for 20 
h, after which cells were washed in PBS and incubated for 16 h with DMEM (10 % FCS and 
1 % penicillin / streptomycin). 
 Single cell suspensions were prepared by adding 250 µl trypsin/EDTA per well and 
incubating for 3-5 min to detach monolayers and obtain single HT29 cells. A volume of 1.8 
ml DMEM (10 % FCS ad 1 % P/S) was added to stop trypsin activity. Cell suspensions were 
centrifuged (200 x g for 5 min), the supernatant was aspirated and new medium was added. 
Cell counts were determined in a Neubauer chamber. 1 x 106 HT29 cells were transferred to 
FACS tubes, centrifuged (200 x g for 5 min) and the supernatant was aspirated. Hundred µl 
PBS were added to the tubes to re-suspend the cell pellet. An individual tube containing 1 x 
106 cells was prepared for each particular antibody staining. HT29 cells were fixed by adding 
2 ml ‘lysis’ solution (see 2.2.3), shortly vortexed and incubated for 10 min at RT protected 
from light. HT29 cells were centrifuged (200 x g for 5 min) and washed with 2 ml wash 
buffer. For staining steps, 10 µl of antibody to TLR2 (no amount in µg specified by the 
manufacturer), 5 µl of antibody to TLR5 (=2.5 µg), 5 µl antibody to TLR9 (=2.5µg) or 7 µl of 
the isotypes controls (IgG1-FITC for TLR9-Ab or IgG2-PE for TLR2-Ab and TLR5-ab) were 
added to each fixed cell suspension and incubated at RT for 1 h protected from light. Cells 
were centrifuged (200 x g for 5 min) and washed with 2 ml wash buffer twice. The 
supernatant was aspirated and the cells were resuspended in 500 µl wash buffer. The labelled 
cell suspensions were vortexed for 5 sec and passed through the flow cell of a flow cytometer 
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(FACS, Calibur fluorescence associated cell sorter, BD Biosciences). Twenty thousand events 
(cells) were analysed in each run. Each cell passes individually through a highly focused laser 
beam of the flow cytometer. The fluorochrome of each labelled monoclonal antibody attached 
to the cell is excited by the laser light and emits light of a certain wavelength. The cells also 
scatter light at multiple angles. Photodetectors placed a forward angle and at right angles to 
the axis of the laser beam collect the emitted or scattered light. Forward and right angle scatter 
signals, and the fluorochrome signal can be detected from each cell (multiparametric 
analysis). For FITC-coupled antibodies, channel FL1 (absorption maximum 485 nm and 
emission minimum 501 nm) was used. For PE-coupled antibodies, channel FL2 (absorption 
maximum 488 nm and emission minimum 578 nm) was used. The intensity of the specific 
fluorescence can be directly related to expression of the target receptor being investigated. 
 For TLR9 staining the same procedure as described above was used with an additional 
permeabilisation step, which was done before staining the cells. This step consisted in 
suspending the cells in 190 µl saponin buffer (see 2.2.3) and incubating cells at RT for 20 min 
protected from light. As permeabilisation with saponin is a reversible phenomenon, all 
subsequent wash and staining steps were done in saponin buffer. 
 Three experiments were done; a representative histogram (obtained with the software 
provided with the instrument) of one such experiment is presented in the results section. 
 
2.7.5 Treatment of HT29 cells with lactobacilli before challenge with S. Typhimurium 
 The aim of these experiments was to determine if treatment of HT29 cells with 
selected lactobacilli (L. johnsonii BFE6128 and L. plantarum BFE 1685) or a known 
probiotic strain (L. rhamnosus GG) changed the way in which HT29 cells respond to 
challenge with a pathogenic S. Typhimurium strain. In the first experimental set, cells were 
treated with lactobacilli or medium without bacteria for 2 h, followed by a four-hour treatment 
with medium without bacteria. In the second experimental set, cells were treated also for 2 h 
with lactobacilli or medium without bacteria but cells were afterwards challenged with S. 
Typhimurium ATCC 14028 for 4 h. 
 HT29 cells grown under the same conditions as explained in 2.7.1 were treated with 2 
ml of suspensions containing 5 x 106 CFU/ml of L. rhamnosus GG, L. plantarum BFE1685 
and L. johnsonii BFE6128 in DMEM or DMEM alone (negative control). After 2 h incubation 
(37°C, 5% CO2), wells were washed twice with PBS and culture media (DMEM without 
penicillin/streptomycin nor serum) was added to the wells and incubated for further 4 h (1st 
experimental set) or 2 ml of a 5 x 106 CFU/ml (=1 x 107/well) suspension of S. Typhimurium 
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(2nd experimental set). Cell supernatants were collected, centrifuged to separate bacteria and 
freezed at -80 °C for later measurement of IL-8 and LDH. The supernatant pH was 
immediately measured after collecting the sample with pH strips (Merck). Total RNA was 
also immediately isolated from the cells by means of a modified ‘Single step’ protocol as 
described below. 
 
2.7.6 Treatment of HT29 cells with L. johnsonii BFE 6128 before challenge with S. 
Typhimurium components 
 The aim of these experiments was to determine the components of S. Typhimurium to 
which L. johnsonii BFE 6128 enhanced the response of HT29 cells. Cells were treated with L. 
johnsonii BFE 6128 (1 x 107 CFU/well) for 2 h, followed by a four-hour treatment with 
medium containing different components of S. Typhimurium. The following components 
were tested: flagellin (no. tlrl-dtfla, Invivogen, San Diego) at a final concentration of 0.1 
µg/ml; LPS form S. Typhimurium (no. L6143, Sigma); DNA from S. Typhimurium (isolated 
in this study as described in section 2.7.3.4) at a final concentration of 0.1 µg/ml and 
ODN2006 (no. tlrl-hodnb, Invivogen) at a final concentration of 1µM. 
 
2.8 Cell culture conditions and isolation of peripheral blood mononuclear cells 
2.8.1 Culturing of HT29 cells 
 The enterocyte-like HT29 cell line was obtained from the German collection of micro-
organisms and cell cultures (DSMZ, Braunschweig, Germany). This cell line expresses 
certain differentiation features which are characteristic of mature intestinal cells: tight 
junctions and a typical brush border. Cells were routinely cultured in T80 culture flasks 
(Nunclon TM ∆ Surface, Nunc, Roskilde) containing DMEM supplemented with 10 % (v/v) 
heat-inactivated (56°C, 30 min) fetal calf serum (FCS, PAA Laboratories GmbH, Cölbe) and 
which contained 100 U/ml penicillin G (Invitrogen) and 100 µg/ml streptomycin sulphate 
(Invitrogen). Cultures were incubated at 37°C under 5 % CO2.  The medium was changed 
every other day and cells were sub-cultured every 4 to 8 days. All media, solutions and 
enzymes given to the cells are pre-warmed to 37°C before use. 
 In order to disrupt the monolayer and detach the cells from the plastic surface of 75 
cm2 culture flasks, cells were treated with 1 ml trypsin/EDTA (0.25 % trypsin with EDTA 
4Na; Invitrogen, Karlsruhe) for 3-5 min at 37°C. This incubation time is critical because a 
longer incubation time would be detrimental for the cells as trypsin also attacks the cell 
plasma membrane. In order to facilitate the activity of this proteolytic enzyme, cells were pre- 
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washed with PBS to eliminate serum remnants. To stop trypsin activity, cells were suspended 
in fresh medium containing serum. Cells were washed once, by centrifuging (200 x g, 5 min, 
37°C) to eliminate trypsin containing medium, and the pellet was resuspended in fresh 
medium. Cells cannot be vortexed and therefore the careful mixing with the pipette is crucial 
for disaggregating cell clumps. 
 To determine the number of cells per ml, 20 µl of a cell suspension were mixed with 
40 µl of a trypan blue solution (diluted 1:3 in PBS; Sigma-Aldrich). This vital stain allows the 
differentiation between dead (blue stained) and live (refractive) cells. Cells were counted 
under the microscope (200x) using a modified Neubauer chamber. 
 
2.8.2 Isolation of peripheral blood mononuclear cells (PBMC) 
 PBMC constitutively express TLRs (Zarember & Godowski, 2002; Hayashi et al., 
2003). Therefore, PBMC were isolated in order to extract their RNA as control for TLR 
expression. 
 Seven ml heparinised venous whole blood collected from healthy volunteers were 
carefully mixed with 3 ml PBS in 15 ml-polystyrene tubes at room temperature (RT). Four ml 
Ficoll-Hypaque (Sigma), which has a specific density of 1.077 g/l were carefully overlayered 
with 10 ml of the whole blood-PBS suspension. The tubes were centrifuged at 400 x g for 10 
min at RT. The interfacial layer containing the PBMC was carefully removed with a sterile 
Pasteur pipette and collected in a new tube. RNA was isolated using the same procedure as for 
HT29 cells (see 2.10.2). 
 
2.8.3 Cell vitality assays 
2.8.3.1 LDH cytotoxicity test 
 Lactate dehydrogenase (LDH) is a stable cytoplasmatic enzyme in eukaryotic cells 
which is released to the cell culture supernatant only upon damage of the plasma membrane. 
The activity of this enzyme was measured in the collected supernatants with a cytotoxicity 
detection kit (Roche, Mannheim, Germany) using a spectrophotometric microtiter plate reader 
(ThermoMax). After incubating HT29 cells with lactobacilli, LPS, LTA, other bacterial 
components or TNF-α, supernatants were collected. Hundred µl of each cell-free supernatant 
were mixed in a 96-well microtiter plate with 100 µl substrate mixture. This mixture is 
provided in the kit and contains a catalyst (diaphorase/NAD+) and a dye solution [2-p-
(iodophenyl)-phenyltetrazolium chloride and sodium lactate]. Two enzymatic reactions take 
place. In the first one, LDH reduces NAD+ to NADH by oxidation of lactate to pyruvate; in 
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the second reaction the catalyst (diaphorase) transfers H/H+ to the tetrazolium salt, which 
turns from pale yellow into red. The formazan dye can be spectrophotometrically quantified at 
λ=500 nm. 
 
2.8.3.2 MTT Test 
 In parallel experiments, the vitality of HT29 cells treated with bacterial suspensions 
was studied by means of a MTT test which relies on the reduction of 3-(4,5-dimethyldiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (no. M5655, Sigma) by the metabolically active 
mitochondrial dehydrogenases into formazan salts. HT29 cells grown in 96-well plates to 80-
90 % confluence were treated with 100 µl of a suspension of each probiotic strain (5 x 106 
CFU/ml) for 24 h. At the end of the treatment period, cells were washed with PBS three times 
and 100 μl of MTT (0.5 mg/ml in DMEM) were added to each well at 37°C for 4 h protected 
from light. Formazan salts were dissolved in 100 µl of a solution containing 10 % (v/v) SDS 
and 0.3 % (v/v) HCl and measured colorimetrically at 560 nm. 
 
2.9 Cytokine ELISA 
 Culture supernatants were analysed for IL-1, IL-8, IL-6, MCP-1, and TGF-β, by means 
of sandwich ELISA with the capture antibodies, detection antibodies, standards and 
streptavidin-horse radish peroxidase provided by DuoSet® (R&D Systems Europe, Abingdon, 
U.K). In addition, culture supernatants were also analysed for IL-10 and TNF-α by means of 
sandwich ELISA with the capture antibodies, detection antibodies, standards and 
streptadividin-horse radish peroxidase provided by ELISA CytoSets® (Biosource Europe 
S.A., Nivelles, Belgium). All solutions not provided in the kits are listed in section 2.2.2. The 
procedure used is described below. 
 Capture antibody was diluted to the working concentration in PBS without carrier 
protein or in reagent diluent as suggested by the supplier for each antibody. A 96-well 
microplate was coated with 100 µl of the diluted capture antibody. Wells were decanted and 
washed 3 times with wash buffer. The liquid was completely removed every time to assure 
good washing performance. After the last wash, liquid had to be completely removed by 
inverting the plate and blotting it against clean paper towels. Plates were then blocked by 
adding 300 µl of blocking buffer into each well and incubated for 2 h at RT. After this, plates 
were washed as described above.  
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 For TGF-β, a further activation step is needed. 160-µl samples were treated with 32 µl 
HCl. After 10 min incubation, 32 µl of Hepes/NaOH were added to neutralise the samples. 
 Hundred µl of samples or standards diluted in the corresponding reagent diluent were 
added to each well, and incubated for 2 h at RT. An eight point standard curve was made in 
duplicate using 2-fold serial dilutions in reagent diluent. For calibration curves the following 
highest concentrations were 2,000 pg/ml for IL-10, IL-8, TNF-α and TGF-β, 600 pg/ml for 
IL-6, and 250 pg/ml for IL-1. Plates were washed again as indicated above. 
 Hundred µl of detection antibody, diluted in reagent diluent according to the supplier’s 
suggestions for each case, was added to each well and incubated for 2 h at RT after which 
plates were washed as indicated above. Then, 100 µl of working solution of streptavidin were 
added to each well and plates were incubated for 20 min at RT protected from light. Plates 
were then washed again as previously indicated and 100 µl of substrate solution were added 
to each well and incubated for 20 min at RT protected from light. Next, 100 µl of stop 
solution were added to each well. Immediately afterwards, the absorbance of each well was 
measured by using a microplate reader (ThermoMax, Molecular Devices, MWG Biotech, 
Freiburg) set to 450 nm with wave length correction set at 570 nm. All samples were 
measured in duplicate. For each set of samples assayed, a 4 parameter logistic standard curve 
was generated. 
 
2.10 Transcriptomics 
2.10.1 Working with RNA 
 RNases are very stable omnipresent enzymes and therefore, careful handling of RNA 
containing samples is necessary to avoid losses of RNA. All glass material was baked at 200 
°C before use. Plastic ware was treated with RNase Away® (Roth, Karlsruhe) for 10-15 min 
to eliminate contaminating RNases and washed before use with DEPC-H2O. Prior use, gel 
box, combs and chambers were thoroughly cleaned with RNase Away® or 3 % H2O2 for 15 
min, rinsed with DEPC-H2O and dried with ethanol. All working surfaces were treated with 
RNase Away® before use. Gloves were used in all cases as skin contains RNases. 
 
2.10.2 Isolation of RNA from HT-29 cells by a modified ‘Single-step’ method 
 Chomczynski and Sacchi (1987) established a method for isolation of RNA from 
eukaryotic cells which was later modified by Meltzer et al. (1990). When trying this protocol, 
genomic DNA traces could still be detected. Therefore, a second treatment with DNase 
(Recombinant Bovine RNase free DNase 1; Ambion, Huntigdon, Cambridgeshire) to 
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hydrolyse genomic DNA and a second phenol-chloroform (125:24:1, pH 4.3-4.7; Sigma-
Aldrich, Taufkirchen) treatment, two precipitation steps with isopropanol (Roth) and two 
wash steps with ethanol (Merck) were added to the modified protocol. 
 HT29 cells were grown in 6-well plates (as indicated before), the medium covering the 
cells was aspirated and the cells were lysed by adding 500 µl of the ice cold denaturing 
solution (see 2.2.1) and kept for about 5 min at RT. Cell lysates were homogenised at least 10 
times with a one-way syringe and needle by aspiration and discharge of the homogenates. 
Homogenates were transferred into Eppendorf tubes, 650 µl of acidic phenol-chloroform-
isoamylalcohol (Sigma) was given to the tubes, mixed by end-over-end rotation for at least 30 
s and placed on ice for 15 min (in between steps, samples were kept on ice). The emulsion 
was centrifuged (11,000 x g, 20 min, 4 ºC) to accelerate the separation of phases. The upper 
aqueous phase containing RNA was carefully removed in order not to disturb the interphase 
where proteins, and DNA are trapped and transferred into a new Eppendorf tube carefully. An 
equal volume of ice cold 100 % isopropanol was added, and the tubes were kept at -20°C 
overnight to precipitate RNA. Tubes were centrifuged (11,000 x g, 20 min, 4 ºC), the 
supernatant was aspirated and the RNA precipitate was washed twice with 700 µl 75% 
ethanol. The RNA precipitate was collected by centrifugation (12,000 x g, 20 min, 4 ºC). 
Ethanol was removed with a disposable pipette tip and dried in a vacuum extractor. RNA was 
dissolved in 90 µl DEPC-H2O. The RNA solution was treated for 30 min with RNase-free 
DNase I (Ambion Inc.) at 37°C (90 µl RNA solution, 4 µl 2 U/µl DNase and 10 µl 10x DNase 
I buffer) to eliminate possible DNA contamination. DNase I buffer was supplied with the 
enzyme and contained 100 mM Tris-HCl pH 7.5, 25 mM MgCl2 and 5 mM CaCl2. The DNA 
digestion was stopped by addition of 396 µl denaturing solution (4°C). A phenol-chloroform-
isoamylalcohol extraction was repeated to eliminate DNase traces. As indicated above, RNA 
was precipitated again by addition of isopropanol, washed twice with ethanol, allowed to dry 
and resuspended in 50 µl DEPC-H2O. RNA concentration was measured as explained in 
2.3.4.2. Aliquots adjusted to 400 ng/µl were stored at -80°C until use.  
 
2.10.3 RNA gel electrophoresis under denaturing conditions 
 RNA electrophoresis under denaturing conditions in formaldehyde was performed 
according to Schulte et al. (1994) using the MOPS buffer system. RNA under these conditions 
is fully denatured and migrates according to the log10 of its molecular weight.  
For 100 ml of a 1.2 % agarose gel, 1.2 g agarose in 5 ml 10 x MOPS (see 2.2.1) and 75 ml 
DEPC-H2O were melted in a microwave. After cooling to approximately 60°C (hand hot) 15 
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ml formaldehyde were added. The samples (4.5 µl of aliquots containing 400 ng/ml) were 
given to 16.5 µl sample buffer for RNA (see 2.2.1) and incubated for 15 min at 65°C. 
Immediately after, the samples were cooled by placing them on ice for 2 min. Before loading, 
2 µl loading buffer was added. Samples were loaded onto the gel and electrophoresed 90 min 
at 90 V in 1 x MOPS buffer until the leading bromophenol blue dye front had migrated 
approximately three quarters of the length of the gel. Because of the formation of toxic gases 
through evaporation of formaldehyde, the gel had to be run in a fume hood. Visualisation of 
RNA was achieved by irradiation with UV light and photographed with a video 
documentation system (Fluor Chem 5500, Alpha Innotech Corporation, Biozym scientific 
GmbH, Oldendorf). 
 mRNA quality has historically been assessed by electrophoresis of total RNA stained 
with ethidium bromide. This method relies on the assumption that rRNA quality and quantity 
reflect that of the underlying mRNA population. Total RNA preparations from human cells 
contain 95 % rRNA (28S, 18S and 5S). Quality indicators are the absence of fluorescence in 
the wells, the absence of smearing and the presence of two bands being the 28S RNA band 
twice as fluorescent as the 18S RNA one (Fig. 2.1 ) (Sambrook et al., 1989). 
 
 
Fig.  2.1 RNA electrophoresis. S1: RNA from HT29 cells incubated with DMEM. S2: RNA from 
HT29 cells incubated with S. Typhimurium and S5: HT29 cells incubated with L. johnsonii BFE 6128 
as explained in section 2.7.5. 
 
 S1a   S1b    S1c   S2a   S2b   S2c  S5a   S5b   S5c 
← 28S rRNA (4.8 kb) 
 
← 18S rRNA (1.8 kb) 
 
2.10.4 One step protocol for RT-PCR 
 Retrotranscriptase PCR was performed with the Ready-to-go™ kit (Amersham 
Biosciences, Freiburg), which utilizes Moloney Murine Leukemia Virus (M-MuLV) and Taq 
polymerase to generate a PCR product from an RNA template. When brought to a final 
volume of 50 µl, each individual RT-PCR reaction contained 2 U of Taq DNA polymerase, 
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10 mM Tris-HCl (pH 9.0), 60 mM KCl, 1.5 mM MgCl2, 200 µM of each dNTP, M-MuLV 
Reverse Transcriptase (concentration not provided by the supplier), RNAguard™ 
(ribonuclease inhibitor) and stabilisers, including RNase/DNase-free BSA. In each reaction a 
first-strand DNA synthesis was primed with an oligo(dT)primer (1 µg/µl) and the target gene 
was primed with a gene-specific primer (10 pmol/µl; Thermo Electron GmbH Biopolymers, 
Ulm). The thermal cycling parameters are specified in Table 2.4 
 
Table 2.4 Thermal cycling parameters for RT-PCR 
 Temperature (°C) Time Step 
1.  42 30 min Reverse transcription 
2.  95 7 min Retrotranscriptase inactivation 
3.  95 45 sec 
4.  Annealing T° * 45 sec 
5.  72 1 min 
30-40 PCR-cycles 
6.  8  End 
 * Annealing temperatures are given for each individual pair of primers in Table 2.5. 
 
Table 2.5 Primers of the target genes amplified by RT-PCR 
Name, annealing 
temperature and size 
of amplicon 
Fw primer Rw primer Source 
HBD 2 (51 ºC) 
254 bp 
5´ CCA GCC ATC AGC CAT 
GAG GGT 3´ 
5´ GGA GGC CTT TCT 
GAA TCC GCA 3´ 
(O'Neil et 
al., 1999) 
IL8 (52 ºC) 
220 bp 
5´ TTG GCA GCC TTC CTG 
ATT TCT 3´ 
5´ TTT CCT TGG GGT CCA 
GAC AGA 3´ 
(Li et al., 
1998) 
GAPDH (54 ºC) 
306 bp 
5´ CGG AGT CAA CGG ATT 
TGG TCG TAT 3´ 
5´ ACG CTT CTC CAT GGT 
GGT GAA GAC 3´   
(Otte et al., 
2004) 
TLR2 (50 ºC) 
638 bp 
5´ CGC CAG CAA ATT ACC 
TGT GTG 3´ 
5´ CTG AGC CTC GTC CAT 
GGG CCA CTC C 3´ 
(Schaefer 
et al., 
2004) 
TLR4 (50 ºC) 
449 bp 
5´ TGC AAT GGA TCA AGG 
ACC AGA GGC 3´ 
5´ GTG CTG GGA CAC 
CAC AAC AAT CAC C 3´ 
(Schaefer 
et al., 
2004) 
TLR9 (50 ºC) 
511 bp 
5´ GCG AGA TGA GGA TGC 
CCT GCC CTA CG 3´ 
5´ TTC GGC CGT GGG TCC 
CTG GCA GAA G 3´ 
(Schaefer 
et al., 
2004) 
 
2.10.5 Real-time RT-PCR 
 Real-time PCR is one of the most sensitive and reliable quantitative methods for gene 
expression analysis. Data derived from real-time RT-PCR are quantified absolutely and 
relatively. Relative quantification is sufficient for most pathological and physiological studies. 
This method relies on the comparison between expression of a target gene in a control sample 
and the expression of the same target gene in reference samples (Yuan et al., 2006). The 
experimental system used in this study involved a control sample (RNA from cells incubated 
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in DMEM) and seven treatment samples (RNA from cells incubated as explained in 2.7.5 and 
summarised in Table 2.6). Real time RT-PCR was done in duplicate for each sample. The 
experimental set was done in triplicate. The experimental system also included the 
investigation of target genes (e.g. TLR2, TLR9, TLR4) and a reference gene for internal 
control (a housekeeping gene, here GAPDH) for each sample. 
 
Table 2.6 Experimental set for gene expression studies 
Sample name Pre-treatment (2h) Post-treatment (4h) 
S1 (control) DMEM DMEM 
S2 DMEM S. Typhimurium 
S3 L. rhamnosus GG DMEM 
S4 L. rhamnosus GG S. Typhimurium 
L. johnsonii BFE 6128 S5 DMEM 
S6 L. johnsonii BFE 6128 S. Typhimurium 
S7 L. plantarum BFE 1685 DMEM 
S8 L. plantarum BFE 1685 S. Typhimurium 
 
2.10.5.1 Synthesis of cDNA 
 cDNA was synthesised with the Omniscript Transcriptase Kit (Qiagen). Each RT-PCR 
reaction contained 2 µl 10 x RT Buffer, 2 µl dNTP mix, 2 µl oligo(dT) primer (10 pmol/µl), 1 
µl RNase inhibitor (9.8 U/µl; diluted 1:4 in RT Buffer), 1µl Omniscript Reverse 
Transcriptase, 4 µl RNA-free water and 8 µl (400 ng/µl) RNA template. The reaction took 
place at 37°C for 1 h. 
 
2.10.5.2 Real time-PCR general protocol 
 Real time-PCR was performed in MicroAmp Optical Tubes (sealed with ABIPrism 
optical caps, both from Applied Biosystems, Darmstadt) using a reaction volume of 25 µl and 
a real-time PCR kit (SYBR Green PCR Core Reagents, Applied Biosystems, Darmstadt). 
Each reaction consisted in 1 µl RT-PCR product (obtained as indicated in 2.10.5.1), 2.5 µl 
10x SYBR Green PCR Buffer, 3 µl 25 mM MCl2, 2 µl dNTP-mix, 1 µl of each forward and 
reverse primers (10 pmol/µl), 14.125 µl DEPC-H2O, 0.25 AmpErase UNG and 0.125 µl 
AmpliTaq gold. Master mixes were prepared on ice and templates were added last. All 
reagents were supplied by the kit, with exception of primers (Table 2.7) and templates. The 
reactions were performed with the programme shown in Table 2.8 in a thermal cycler with 
fluorescence detection (GeneAmp® 5700 Sequence Detection System, Applied Biosystems). 
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A no template control (NTC) as well as a no reverse transcriptase control (NRT) were used to 
check for contamination of the master mix with foreign nucleic acids or for the presence of 
genomic DNA in RNA samples, respectively. 
 
 Table 2.7 Primers used for real-time RT-PCR. 
Name, annealing 
temperature and size
Fw primer Rev primer Source 
Int GAPDH (55 ºC) 
207 bp 
5´ CTG GAA GAT GGT 
GAT GGG AT 3´ 
5´ GGA TTT GGT CGT 
ATT GGG CG 3´ 
This study 
Int TLR 2b (54 ºC) 
300 bp 
5´ GCA GAA GCG CTG 
GGG AAT GG 3´ 
5´ GGA TGC CTA CTG 
GGT GGA GAA 3´ 
This study 
Int TLR 4b (53 ºC) 5´ GGT GGA AGT TGA 
ACG AAT GG 3´ 
5´ CCA GCA AGA AGC 
ATCAGG TG 3´ 
This study 
182 bp 
Int TLR9b (54 ºC) 
132 bp 
5´ GAG CGC AGT GGC 
AGA CTG GGT G 3´ 
5´ CAC AGG TTC TCA 
AAG AGG GT 3´ 
This study 
 
 
 Table 2.8 Real-time PCR programm 
 Temperature Time Reaction 
1 50°C 2 min AmpErase UNG activity 
2 95°C 10 min 
Inactivation of RT-
Transcriptase  
AmpliTaq Gold activation 
4 95°C 20 sec 
5 See annealing temperature for each primer pair in Table 3.67  20 sec 
6 72°C 30 sec 
Real-Time PCR (35-40cycles)
 
 
2.10.5.3 Calibration curves for real time PCR 
 TLRs are known to be expressed constitutively in PBMC (peripheral blood 
mononuclear cells). For this reason, PBMC were isolated from blood (2.8.2) for RNA 
isolation and further amplification of the mRNA coding for TLR2, TLR4, TLR9 and 
GAPDH. These RNA molecules were amplified with the ready-to-go one step RT-PCR. The 
products were purified using Quantum Prep® PCR Kleen Spin columns (See 2.3.4.5). The 
purified RT-PCR products were sent to GATC Biotech (Constance) for sequencing. The 
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identities of these products were confirmed and the sizes also correlated with the expected 
amplicon size. 
 The RNA concentration of the purified RT-PCR products was determined 
spectrophotometrically by measuring the A260nm of a 1:40 dilution (see 2.3.4.2). A suspension 
containing 107 copies/µl of each target gene was prepared and 10-fold serial dilutions were 
made until 102 copies/µl. A real-time PCR was done using this serial dilution and a calibration 
cure was constructed by relating the Ct and the log of the number of copies as shown in Fig. 
2.2.  
 The threshold cycle (Ct) for each well was calculated using the instrument’s software. 
 
 
 
 
 
 
Ct 
Log amount of standard 
Threshold 
 
 
 
 
 
 
fluorescense 
Fig. 2.2 Real-time RT-PCR calibration curve for TLR9. The Ct was plotted in function of the log 
of numbers of copies of template. 
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2.10.6 RT2Profiler® PCR Array 
 The modulation of expression of genes involved in TLR pathways in HT29 cells 
stimulated with DMEM (negative control) or with L. johnsonii BFE 6128 alone, S. 
Typhimurium alone or after a pre-treatment with L. johnsonii BFE 6128 (experiment set as 
explained in 2.7.5) was investigated using a PCR-based TLR-pathway-focused gene 
expression profiler (no. APH-018A, SuperArray, Biomol) and SuperArray’s RT2 Real Time® 
SYBR Green PCR kit. 
 First strand cDNA synthesis was done using Omniscript reverse transcriptase as 
explained before (2.10.5.1). The cDNA synthesis reaction was diluted 1:5 (20 µl cDNA 
synthesis reaction + 80 µl DEPC-H2O) and kept on ice until use. 
 The array consisted of a 96-well plate with 84 wells each containing specific primer 
pairs to detect 84 different target genes and 4 different control genes (housekeeping genes). In 
addition, 5 wells contained primers to detect ACTB gene expression that were used to make 
the standard curves to calculate the PCR efficiency of each array. Two extra wells, each 
containing a primer pair to detect housekeeping genes, were used for the NTC and NRC. For 
detection of target and control gene expression, a 1 x array master mix was prepared by 
mixing 1,255 µl 2 x SuperArray PCR master mix, 98 µl diluted 1st cDNA strand reaction and 
1,127 DEPC-H2O. Then, 25 µl of this array master mix were added to each well. The standard 
curve for ACTB was prepared by preparing 10-fold serial dilutions in the array master mix. 
 The plate was carefully sealed with the corresponding optical thin-wall 8-cap strips 
provided by the kit. All these steps were done on ice. To remove bubbles, plates were shortly 
centrifuged. The following real-time PCR programme was run: 1 cycle: 95 °C (necessary to 
activate the HotStart DNA polymerase), 10 min; 40 cycles: 95°C, 15 sec and 60°C 1 min.  
 The threshold cycle (Ct) for each well was calculated using the instrument’s software.  
 Genes included in the RT2Profiler PCR®Array are described in Table 2.9. 
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Table 2.9 Genes investigated by means of RT2Profiler® PCR Array 
 
Group Symbol UniGene RefSeq Description Gene Name 
BTK Hs.159494 NM_000061 Bruton agammaglobulinemia tyrosine kinase AGMX1/AT 
CD14 Hs.163867 NM_000591 CD14 antigen CD14 
HMGB1 Hs.434102 NM_002128 High-mobility group box 1 DKFZp686A04236/HMG1 
HRAS Hs.37003 NM_005343 V-Ha-ras Harvey rat sarcoma viral oncogene 
homolog 
HRAS1/K-ras 
HSPA1A Hs.520028 NM_005345 Heat shock 70kDa protein 1A HSP70-1/HSP72 
HSPD1 Hs.471014 NM_002156 Heat shock 60kDa protein 1 (chaperonin) CPN60/GROEL 
LY86 (MD-1) Hs.567394 NM_004271 Lymphocyte antigen 86 MD-1 
LY96 (MD-2) Hs.69328 NM_015364 Lymphocyte antigen 96 MD-2 
MAPK8IP3 Hs.207763 NM_015133 Mitogen-activated protein kinase 8 interacting 
protein 3 
DKFZp762N1113/JIP3 
MYD88 Hs.82116 NM_002468 
Adaptors 
and 
interacting 
proteins 
Myeloid differentiation primary response gene 
(88) 
MyD88 
PELI1 Hs.7886 NM_020651 Pellino homolog 1 (Drosophila) pellino 
RIPK2 Hs.103755 NM_003821 Receptor-interacting serine-threonine kinase 2 CARD3/CARDIAK 
SARM1 Hs.532781 NM_015077 Sterile alpha and TIR motif containing 1 SAMD2/SARM 
TICAM2 Hs.278391 NM_021649 Toll-like receptor adaptor molecule 2 TICAM-2/TIRAP3 
TIRAP Hs.537126 NM_052887 Toll-interleukin 1 receptor (TIR) domain 
containing adaptor protein 
Mal/wyatt 
TOLLIP Hs.368527 NM_019009 Toll interacting protein IL-1RAcPIP 
TICAM1 
(TRIF?) 
Hs.29344 NM_014261 Toll-like receptor adaptor molecule 1 PRVTIRB/TICAM-1 
CASP8 Hs.369736 NM_001228 Caspase 8, apoptosis-related cysteine 
peptidase 
FLICE/MACH 
EIF2AK2 Hs.131431 NM_002759 Eukaryotic translation initiation factor 2-alpha 
kinase 2 
EIF2AK1/PKR 
FADD Hs.86131 NM_003824 Fas (TNFRSF6)-associated via death domain GIG3/MORT1 
IRAK1 Hs.522819 NM_001569 Interleukin-1 receptor-associated kinase 1 IRAK/pelle 
IRAK2 Hs.449207 NM_001570 Interleukin-1 receptor-associated kinase 2 IRAK-2 
MAP3K7 Hs.485968 NM_003188 Mitogen-activated protein kinase kinase kinase 
7 
TAK1/TGF1a 
MAP3K7IP1 Hs.507681 NM_006116 Mitogen-activated protein kinase kinase kinase 
7 interacting protein 1 
TAB1 
NR2C2 Hs.549074 NM_003298 Nuclear receptor subfamily 2, group C, 
member 2 
TAK1/TR2R1 
PPARA Hs.103110 NM_005036 Peroxisome proliferative activated receptor, 
alpha 
NR1C1/PPAR 
PRKRA Hs.405537 NM_003690 Protein kinase, interferon-inducible double 
stranded RNA dependent activator 
HSD14/PACT 
SITPEC Hs.515146 NM_016581 Signaling intermediate in Toll pathway, 
evolutionarily conserved 
ECSIT 
TRAF6 Hs.444172 NM_004620 TNF receptor-associated factor 6 MGC:3310/RNF85 
UBE2N Hs.524630 NM_003348 Ubiquitin-conjugating enzyme E2N (UBC13 
homolog, yeast) 
UBC13/UbcH-ben 
Effectors 
UBE2V1 Hs.420529 NM_021988 Ubiquitin-conjugating enzyme E2 variant 1 CIR1/CROC-1 
HPRT1 Hs.412707 NM_000194 Hypoxanthine phosphoribosyltransferase 1 
(Lesch-Nyhan syndrome) 
HGPRT/HPRT 
RPL13A Hs.546356 NM_012423 Ribosomal protein L13a RPL13A 
GAPDH Hs.544577 NM_002046 Glyceraldehyde-3-phosphate dehydrogenase G3PD/GAPD 
House-
keeping 
genes 
ACTB Hs.520640 NM_001101 Actin, beta b-Actin 
CXCL10 Hs.413924 NM_001565 Chemokine (C-X-C motif) ligand 10 C7/IFI10 
IFNA1 Hs.37026 NM_024013 Interferon, alpha 1 IFL/IFN 
IFNB1 Hs.93177 NM_002176 Interferon, beta 1, fibroblast IFB/IFF 
IFNG Hs.856 NM_000619 Interferon, gamma IFG/IFI 
IRF1 Hs.436061 NM_002198 Interferon regulatory factor 1 IRF-1/MAR 
IRF3 Hs.75254 NM_001571 Interferon regulatory factor 3 IRF-3 
IRF 
Pathway 
TBK1 Hs.505874 NM_013254 TANK-binding kinase 1 NAK/T2K 
-53- 
MATERIALS AND METHODS 
      
ELK1 Hs.181128 NM_005229 ELK1, member of ETS oncogene family Elk1 
FOS Hs.25647 NM_005252 V-fos FBJ murine osteosarcoma viral 
oncogene homolog 
c-fos 
JUN Hs.525704 NM_002228 V-jun sarcoma virus 17 oncogene homolog 
(avian) 
AP1 
MAP2K3 Hs.514012 NM_002756 Mitogen-activated protein kinase kinase 3 MAPKK3/MEK3 
MAP2K4 Hs.514681 NM_003010 Mitogen-activated protein kinase kinase 4 JNKK/JNKK1 
MAP3K1 Hs.508461 XM_042066 Mitogen-activated protein kinase kinase kinase 
1 
MAPKKK1/MEKK 
JNK/p38 
pathway 
MAPK8 Hs.522924 NM_002750 Mitogen-activated protein kinase 8 JNK/JNK1 
CLEC4E Hs.236516 NM_014358 C-type lectin domain family 4, member E CLECSF9/MINCLE 
NF/IL6 
pathway 
PTGS2 Hs.196384 NM_000963 Prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 
COX-2/COX2 
CCL2 Hs.303649 NM_002982 Chemokine (C-C motif) ligand 2 GDCF-2/GDCF-2 HC11 
CHUK Hs.198998 NM_001278 Conserved helix-loop-helix ubiquitous kinase IKBKA/IKK-alpha 
CSF2 Hs.1349 NM_000758 Colony stimulating factor 2 (granulocyte-
macrophage) 
GMCSF 
CSF3 Hs.2233 NM_000759 Colony stimulating factor 3 (granulocyte) G-CSF/GCSF 
IFNA1 Hs.37026 NM_024013 Interferon, alpha 1 IFL/IFN 
IFNB1 Hs.93177 NM_002176 Interferon, beta 1, fibroblast IFB/IFF 
IFNG Hs.856 NM_000619 Interferon, gamma IFG/IFI 
IKBKB Hs.413513 NM_001556 Inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase beta 
IKK-beta/IKK2 
IL10 Hs.193717 NM_000572 Interleukin 10 CSIF/IL-10 
IL12A Hs.673 NM_000882 Interleukin 12A (natural killer cell stimulatory 
factor 1, cytotoxic lymphocyte maturation factor 
1, p35) 
CLMF/IL-12A 
IL1A Hs.1722 NM_000575 Interleukin 1, alpha IL-1A/IL1 
IL1B Hs.126256 NM_000576 Interleukin 1, beta IL-1/IL1-BETA 
IL2 Hs.89679 NM_000586 Interleukin 2 IL-2/TCGF 
IL6 Hs.512234 NM_000600 Interleukin 6 (interferon, beta 2) BSF2/HGF 
IL8 Hs.624 NM_000584 Interleukin 8 3-10C/AMCF-I 
LTA Hs.36 NM_000595 Lymphotoxin alpha (TNF superfamily, member 
1) 
LT/TNFB 
MAP3K1 Hs.508461 XM_042066 Mitogen-activated protein kinase kinase kinase 
1 
MAPKKK1/MEKK 
MAP4K4 Hs.431550 NM_004834 Mitogen-activated protein kinase kinase kinase 
kinase 4 
FLH21957/HGK 
NFKB1 Hs.431926 NM_003998 Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 (p105) 
DKFZp686C01211/EBP-1 
NFKB2 Hs.73090 NM_002502 Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 2 (p49/p100) 
LYT-10/LYT10 
NFKBIA Hs.81328 NM_020529 Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha 
IKBA/MAD-3 
NFKBIL1 Hs.2764 NM_005007 Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor-like 1 
IKBL/LST1 
NFRKB Hs.530539 NM_006165 Nuclear factor related to kappaB binding 
protein 
DKFZp547B2013 
REL Hs.370620 NM_002908 V-rel reticuloendotheliosis viral oncogene 
homolog (avian) 
C-Rel 
RELA Hs.502875 NM_021975 V-rel reticuloendotheliosis viral oncogene 
homolog A, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 3, p65 
(avian) 
NFKB3 
TNF Hs.241570 NM_000594 Tumor necrosis factor (TNF superfamily, 
member 2) 
DIF/TNF-alpha 
NF-кB 
pathway 
TNFRSF1A Hs.279594 NM_001065 Tumor necrosis factor receptor superfamily, 
member 1A 
CD120a/FPF 
CD80 Hs.838 NM_005191 CD80 antigen (CD28 antigen ligand 1, B7-1 
antigen) 
CD28LG/CD28LG1 Regulation 
of adaptive 
immunity CD86 Hs.171182 NM_006889 CD86 antigen (CD28 antigen ligand 2, B7-2 
antigen) 
B7-2/B70 
-54- 
MATERIALS AND METHODS 
RIPK2 Hs.103755 NM_003821 Receptor-interacting serine-threonine kinase 2 CARD3/CARDIAK 
TRAF6 Hs.444172 NM_004620 TNF receptor-associated factor 6 MGC:3310/RNF85 
CD180 Hs.87205 NM_005582 CD180 antigen LY64/Ly78 
SIGIRR Hs.501624 NM_021805 Single immunoglobulin and toll-interleukin 1 
receptor (TIR) domain 
TIR8 
TLR1 Hs.111805 NM_003263 Toll-like receptor 1 DKFZp547I0610/DKFZp564I06
82 
TLR2 Hs.519033 NM_003264 Toll-like receptor 2 TIL4 
TLR3 Hs.29499 NM_003265 Toll-like receptor 3 TLR3 
TLR4 Hs.174312 NM_003266 Toll-like receptor 4 TOLL/hToll 
TLR5 Hs.114408 NM_003268 Toll-like receptor 5 TIL3 
TLR6 Hs.366986 NM_006068 Toll-like receptor 6 TLR6 
TLR7 Hs.443036 NM_016562 Toll-like receptor 7 TLR7 
TLR8 Hs.272410 NM_016610 Toll-like receptor 8 MGC119599 
TLR9 Hs.87968 NM_017442 Toll-like receptor 9 TLR9 
TLRs 
TLR10 Hs.120551 NM_030956 Toll-like receptor 10 MGC104967 
 
 
2.10.7 Data analysis of gene expression modulation detected with the RT2Profiler® PCR 
Array: the ΔΔCt method 
 The NTC tested for DNA contamination in the PCR system, while the NRT control 
tested for contamination of the original RNA with genomic DNA. If no DNA was present, 
both threshold cycles should be greater than 35. Thus, if a PCR product was formed reaching 
the detection threshold at a cycle <35, it could be assumed that the sample was contaminated 
with DNA. 
 For calculation purposes, all Ct values reported as greater than 35 or as N/A (not 
detected) were arbitrarily set to 35. The replicates of the same gene measured in three 
different arrays were used to calculate the average Ct. 
 ΔCt for each pathway-focused gene in each treatment group was calculated as follows: 
 
ΔCt(control group)= average target gene Ct – average of housekeeping genes Ct 
for control group (HT29 cells treated only with DMEM) 
 
ΔCt(treatment  group)= average target Ct – average of housekeeping genes Ct 
for treatment group (e.g. HT29 cells pre-treated with DMEM or L. johnsonii BFE 6128 and treated 
with S. Typhimurium or DMEM) 
 
 The ΔΔCt for each gene across to PCR arrays was calculated as follows: 
ΔΔCt = ΔCt (treatment group) - ΔCt (control group) 
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The fold-changes in expression (increases or decreases) for each gene from control group to 
treatment group was calculated as: 2- ΔΔCt
 Statistical analysis was done by comparing the ΔCt(control group) and ΔCt(treatment). Two non-
parametrical tests were used: the Wilcoxon test for two-sample comparisons as suggested by 
Yuan et al. (2006) and the Kruskal-Wallis, which is identical to the Wilcoxon test but for 
multiple comparisons. Both tests were done with the SAS 9.1 software. 
 
2.11 Statistical analysis 
 Data are expressed as mean ± standard error of the mean of at least three experiments 
done in duplicate. Statistical significance between groups was assessed by 2-way ANOVA 
followed by Dunnett’s test for multiple comparisons to a control. In some cases, the t-test for 
multiple comparisons was used. For analysis of real-time data non-parametrical tests were 
used. Probability values P of <0.05 or <0.01 were taken as criteria for a significant difference 
as indicated in each case. Statistical analyses were performed using SAS® 9.1 Software. 
 
 
 
 
 
 
 
 
 
 
 
-56- 
RESULTS 
3 RESULTS 
3.1 Survival of lactobacilli under gastrointestinal conditions 
3.1.1 Effect of parameters which affect survival of probiotic strains during a simulated 
stomach passage 
The most commonly used tests for selection of bacteria to be used as probiotics are 
resistance to acid and to bile. These tests are mostly done in MRS broth pH 2.0 to 3.5 and in 
MRS broth with bile salts (Chesson et al., 2002). In order to see which parameters should be 
included in an in vitro test of simulated stomach conditions, the Plackett-Burman design was 
used to test the effect of the presence of milk, the media in which the bacteria are tested, the 
pH and the presence of enzymes on survival of a commercial control strain (L. johnsonii LA-
1) with known good survival to gastrointestinal conditions. The analytical results of the PB-
test are summarised in Table 3.1. Confidence values corresponding to the calculated t-value 
with two degrees of freedom were taken from test tables (Richter, 2002).  
 
Table 3.1 Analysis of the effect of variables in the PB-design 
Variable t-test 
Confidence 
level 
Code Designation Low (-) High (+) 
Effect 
t % 
A 
Protective 
effect of Milk 
inoculum 
in MRS 
inoculum in 
milk 
-0,581 -0.581 95 
B Solution 2 MRS 
Saline 
solution 
-0.097 -0.097 n.s. 
C Lysozyme no yes -0.496 -2.666 90 
D 
Effect of final 
pH 
2.5 3.0 -0.457 -2.456 90 
E Dummy - - 0.224 1.204 75 
F Pepsin no yes 0.306 1.645 87.5 
G Dummy - - 0.138 0.742 n.s. 
Veff= 0.03461 S.E. Eff= 0.186038 
n.s.: not significant 
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According to Stowe & Mayer (1966) and Bull et al. (1990), confidence levels greater 
than 85 % are acceptable for this approach. As shown in Table 3.1, both dummy variables 
(experiments code E and G) were not significant, which ereas the other dummy showed 
significance only within a 75 % confidence level. These values reflected a low experimental 
error. The use of either an artificial gastric electrolyte solution (solution 2) or MRS did not 
play a significant role in the viability (confidence level < 85 %, Table 3.1). Lysozyme, more 
acidic conditions (pH 2.5), pepsin and the presence of milk did have a highly significant 
influence (relative significance > 90 %, Table 3.1) on the viability of the strain and were 
therefore selected as important variables to be included in a model stomach passage survival 
trial for the potential probiotic strains in vitro. The effect of these variables correlated well 
with the inhibition data shown in Fig. 3.1.   
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Fig. 3.1 Effect of different variables (presence of milk, lysozyme and pepsin, medium composition and pH) 
on survival expressed as growth inhibition (log  CFU/ml T − log  CFU/ml T ) of L. johnsonii LA1 for 1 h in 
artificial gastric juice medium. Eight experiments were conducted according to the Plackett–Burman design. The 
variables used in each run are specified on the abscise. Error bars indicate standard error. 
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 From run no. 7, it can be clearly seen that the significant variables like absence of 
milk, presence of lysozyme, pepsin and pH 2.5 resulted in the greatest inhibition, i.e. lowest 
survival. The use of MRS broth instead of milk (Fig. 3.1), combined with the absence of 
pepsin and pH set at 3.0, clearly resulted in lowest inhibition (highest survival) even though 
lysozyme was present (run no. 5, Fig. 3.1). 
 
3.1.2 Effect of simulated gastric and intestinal passage on the viability of lactobacilli 
Thirty isolates from children’s faeces, ‘Kule naoto’ and ‘Kwerionik’ were screened for 
their survival under simulated gastro-intestinal conditions. Two L. johnsonii and five L. 
plantarum strains with good survival properties were chosen for further studies of probiotic 
properties (see 3.2 for identification results), all other strains, which did not survive gastro-
intestinal conditions, were not further investigated. The effect of the successive passages 
through artificial saliva and gastric duodenum juices on the viability of the L. johnsonii strains 
is shown in Figure 3.2 A. Strain BFE 6154 showed the highest level of survival with 93 % of 
cells surviving simulated gastric and intestinal transit, whereas only 31.3 % and 11.0 % of L. 
johnsonii strain LA1 (BFE 663, a control strain with known good survival to gastrointestinal 
conditions) and strain BFE 6128 cells survived these conditions. The highest decline in the 
live counts seemed to be due to the effect of gastric juice (determined after one h incubation 
with simulated acid gastric juice  and before addition of artificial duodenum juice), because in 
the following stages of incubation, the counts did not change more than approx. 1 log unit. In 
the case of the positive control strain, L. johnsonii LA1 (BFE 663), its tolerance towards 
gastric juice was higher than that of L. johnsonii BFE 6128, but the strain BFE 663 was more 
sensitive to artificial duodenum juice. As a result, only 31.3 % of the initial inoculum of L. 
johnsonii LA1 survived both conditions (Fig. 3.2 A). In the case of the strains belonging to 
the L. plantarum group, a high variability in their survival was noted. Some strains presented 
the best survival rates in this study, even higher than those observed for the L. johnsonii 
strains, for e.g., L. plantarum BFE 1684 with 98 % survival. L. plantarum K5A included in 
Fig. 3.2 B as a negative control and other strains (results not shown) did not survive the 
simulated gastric and intestinal conditions at all. These strains were therefore not chosen for 
further study.  
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Fig. 3.2 Effect of simulated gastric and intestinal transit on viability of L. johnsonii and L. plantarum 
strains. A: L. johnsonii strains: BFE 663 (LA1) (●), BFE 6154 (○), BFE 6128 (▲). B: L. plantarum 
strains: BFE 5759 (●), BFE 1684 (○), BFE 1685 (▲), BFE 5092 (Δ), ATCC 8014 (■), BFE 5878 (□) 
and K5A (x). Black and white arrows indicate addition of simulated gastric juice at time 0 and 
simulated duodenum juice after 1 h, respectively. Error bars indicate standard error. 
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3.1.3 Resistance of Lactobacillus strains to 0.4 % phenol 
 Resistance to phenol was tested as an additional indicator for survival under intestinal 
conditions (Xanthopoulos et al., 2000). Three reference strains (L. plantarum ATCC 1684, L. 
johnsonii LA-1 and L. paracasei  BFE 675) and the seven probiotic candidate strains (L. 
plantarum BFE 5759, BFE 5878, BFE 1684 and BFE 1685 and L. johnsonii BFE 6154 and 
BFE 6128, Table 3.2), which had survived the in vitro gastrointestinal passage as described 
above (3.1.2), were tested and showed different degrees of sensitivity towards phenol. L. 
johnsonii BFE 663 (LA1) and BFE 6128 were completely inhibited after 24 h, whereas L. 
johnsonii BFE 6154 was considerably inhibited (a reduction of approx. 3 log units CFU/ml) 
(Table 3.2). All L. plantarum strains were less sensitive to phenol. Four of the six strains 
tolerated 0.4 % phenol for 24 h, as their numbers did not decrease (initial inoculum of approx. 
log 7.6 to 8.0). However, none of the strains was able to grow in the presence of phenol 
during this incubation time (Table 3.2). 
 
Table 3.2 Resistance of Lactobacillus strains to 0.4 % phenol 
  
  Viable countsa (log10 CFU/ml) 
  MRS Broth + 0.4%phenol 
 Strain T0 T24 Inhibitionb
Probiotic candidates    
L. plantarum BFE 5759 7.67±0.06 6.28±0.03 1.39 
 BFE 5878 8,02±0.01 7.80±0.19 0.21 
 BFE 5092 8.23±0.05 8.18±0.10 0.04 
 BFE 1684 8.03±0.07 6.69±0.01 1.33 
 BFE 1685 7.98±0.02 7.88±0.02 0.10 
L. johnsonii BFE 6128 7.71±0.03 0.00±0.00 7.71 
 BFE 6154 7.74±0.03 4.72±0.01 3.02 
Reference strains    
L. plantarum ATCC 8014 7.58±0.05 7.14±0.07 0.44 
L. johnsonii BFE 663 7.92±0.11 0.00±0.00 7.92 
L. paracasei BFE 675 8.21±0.03 6.93±0.02 1.29 
 
aLog means counts of three trials (average±S.E.) 
bInhibition = Log10 (initial population) - Log10 (final population) 
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3.2 Selection of strains and identification 
Gram-positive, catalase-negative and rod-shaped bacteria which were able to survive 
the passage through simulated gastric and duodenum juice in the in vitro gastrointestinal 
model, were further identified, and their probiotic characteristics were studied.  
 The selected strains were identified to the species-level by both phenotypic and 
genotypic investigations. The only two strains (BFE 1684 and BFE 1685) selected for further 
studies which stemmed from children’s faeces showed phenotypic properties typical of 
Lactobacillus plantarum strains. Accordingly, these bacteria were rod-shaped, produced DL-
lactate, possessed mDAP in the cell walls and did not produce gas from glucose fermentation 
(Table 3.3). These strains were able to ferment ribose, a pentose sugar, which implies that the 
strains were facultatively heterofermentative lactobacilli. In addition, three strains from 
African fermented dairy products (BFE 5878, BFE 5759 and BFE 5092) also showed similar 
characteristics, indicating that these could also be characterised as presumptive L. plantarum 
strains. These three strains not only fermented ribose, but also an additional pentose sugar, 
i.e., arabinose (Table 3.3). Two other strains (L. johnsonii BFE 6154 and BFE 6128) which 
stemmed from ‘Kule naoto’ exhibited characteristics typical of lactobacilli of the L. 
acidophilus-group. These strains did not produce gas from glucose and did not ferment the 
pentose sugars tested (Table 3.3), indicating that they were obligately homofermentative 
lactobacilli. They did not grow in MRS broth at 15°C but at 45°C. Furthermore, they did not 
contain mDAP in the cell wall and produced DL- lactate (Table 3.3). 
Analysis of the rep-PCR fingerprints showed that the presumptive L. plantarum strains 
(BFE 1684, BFE 1685, BFE 5878, BFE 5759, BFE 5092) clustered very closely at a 
correlation value r = 73.5 %, together with the L. plantarum DSM 20174T type strain and the 
L. plantarum ATCC 8014 and DSM 20686 reference strains, confirming their characterisation 
as L. plantarum (Fig. 3.3). The 16S rDNA gene of one of these strains (BFE 1685) was 
sequenced and showed 99.9 % identity in the nucleotide sequence to the 16S rDNA gene of L. 
plantarum DSM 20174T (result not shown). This also confirmed the identification of these 
strains grouping together in the rep-cluster as L. plantarum. The strains BFE 6128 and BFE 
6154 isolated from African fermented milk grouped together with L. johnsonii DSM 10533T 
type strain at r = 83.2 % (Fig. 3.3), indicating that these strains could also be identified as L. 
johnsonii.  
 
RESULTS 
 
Table 3.3 Phenotypic grouping and key characteristics of Lactobacillus strains (only those relevant for obligately homofermentative and 
facultatively heterofermentative lactobacilli are included): 
Group Aa
Carbohydrates fermented 
S
t
r
a
i
n
 
G
a
s
 
f
r
o
m
 
G
l
u
c
o
s
e
 
m
D
A
P
 
L
a
c
t
i
c
 
a
c
i
d
 
I
s
o
m
e
r
 
N
H
3
 
f
r
o
m
 
A
r
g
i
n
i
n
e
 
G
r
o
w
t
h
 
(
°
C
)
 
1
5
/
4
5
 
A
m
y
g
d
a
l
i
n
 
C
e
l
l
o
b
i
o
s
e
 
G
a
l
a
c
t
o
s
e
 
L
a
c
t
o
s
e
 
M
a
l
t
o
s
e
 
M
a
n
n
i
t
o
l
 
M
a
n
n
o
s
e
 
M
e
l
i
b
i
o
s
e
 
R
a
f
f
i
n
o
s
e
 
S
a
l
i
c
i
n
 
S
u
c
r
o
s
e
 
T
r
e
h
a
l
o
s
e
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BFE 6128 - - DL - -/+ + + - - + - - - - + + + 
BFE 6154 - - DL - -/+ + + - - + - - - - + + + 
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L. plantarum                    
BFE 1684  - + DL - +/+ + - + + + + + + + + - + - - 
BFE 1685 - + DL - +/- + - - + + + + + - + - - + - 
BFE 5878 - + DL - +/- + - + + + + + + + + + + - - 
BFE 5759 - + DL - +/- + - + + + + + + + + + + - - 
BFE 5092 - + DL - +/- + - + + + + + + + + + + + - 
a: obligately homofermentative 
b: facultatively heterofermentative 
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Fig. 3.3 Dendrogram obtained by UPGMA clustering of correlation value r of rep-PCR fingerprint 
patterns of potentially probiotic isolates and appropriate reference strains obtained with primer GTG5. 
T: Type strain. A: L. plantarum cluster, B: L. johnsonii cluster. 
 
 In addition, strains BFE 6128 and BFE 6154 also grouped with L. johnsonii LA1, L. 
amylovorus DSM 20531 and L. gasseri DSM 20243T, which indicates the close relationship 
of these species as they, together with L. acidophilus, L. gallinarum and L. crispatus, make up 
the L. acidophilus-group. The sequencing of the 16S rDNA gene of one of the two strains 
(BFE 6128) confirmed this identification, as this strain showed 99.5 % similarity in the 
nucleotide sequence when compared to the L. johnsonii DSM10533T type strain 16S rDNA 
sequence (result not shown). 
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Fig. 3.5 Production of H2O2 by Lactobacillus spp. under aerobic conditions. Overnight cultures were spotted 
onto ABTS-agar plates containing 0.5 mM 2,2´-azino-bis(3-ethylbenzthiazoline-6)-sulfonic acid and 0.3 units/ml 
horse radish peroxidase. Positive strains were surrounded by a purple halo. L. paracasei BFE 675 did not 
produce H2O2 as indicated by the absence of a purple zone surrounding the colony. 
3.3 Antagonistic activity against pathogens 
In the agar spot test, the indicator strains, Salmonella Typhimurium DSM 5489, E. coli 
ATCC 43895, List. innocua WS 2258, Ent. faecalis DSM 20409, Ent. faecium DSM 13590, 
showed weak to strong inhibition (zone of inhibition of more than 1 mm from edge of 
producer colony up to 10 mm) as listed in Table 3.4. Streptococcus mutans DSM 6178 was 
not inhibited at all by three of the L. plantarum strains tested, inhibited weakly by two L. 
plantarum strains, and medium to strongly inhibited by the L. johnsonii strains tested (Table 
3.4). The indicator strains belonging to the Lactobacillus genus were weakly or not inhibited 
(inhibition zone of less than 2 mm). The inhibitory activity was not due to bacteriocin 
production, because neutralised, cell-free supernatant of the producer culture did not exhibit 
any antimicrobial activity when compared to the effect of live cells in the agar spot test. 
Therefore, the inhibitory activity observed probably depended on production and diffusion of 
organic acids into the medium. Hydrogen peroxide could hypothetically also act as an 
inhibitory substance, but the incubation of the plates under anaerobic conditions discards this 
as a possible cause for the observed inhibition. 
Production of H2O2 under aerobic conditions was also investigated. Only two of the L. 
plantarum strains tested (BFE 5878 and BFE 1684), but  both L. johnsonii strains were able to 
produce H2O2 (Table 3.5). The reference probiotic strain, L. johnsonii LA1 (BFE 663), used 
as a control in investigations of probiotic properties, did not produce H2O2. 
L. plantarum BFE 675 
L .johnsonii BFE 6128 
L. paracasei BFE 675 
L .johnsonii BFE 6154 
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Table 3.4 Agar spot test for detection of antagonistic activitya 
 
a: Inhibitory activity expressed as zone of inhibition surrounding the colony in mm. 
Probiotic 
candidates 
Strains 
S. 
Typhimurium 
DSM 5489 
E. coli 
ATCC 
43895 
List. 
innocua 
WS 2258 
Ent. faecium 
DSM 
13590 
Ent. faecalis
DSM 20409
Streptococcus 
mutans 
DSM 6178 
L. johnsonii
BFE 663 
L. paracasei
BFE 675 
L. casei 
DSM 20011 
L. plantarum BFE 1684 8 4 6 10 14 0 0 0 2 
 BFE 1685 6 4 8 6 20 2 2 0 2 
 BFE 5092 6 2 6 6 12 2 0 2 0 
 BFE 5878 10 4 4 8 12 0 0 0 2 
 BFE 5759 10 4 6 10 14 0 0 0 2 
L. johnsonii BFE 6128 13 4 8 6 8 6 2 0 2 
 BFE 6154 8 2 10 4 12 12 2 0 0 
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3.4 Bile salt hydrolase and β-galactosidase activities 
 All seven candidate probiotic strains were tested for their ability to hydrolyse the 
sodium salt of taurodeoxycholic acid. Bsh positive strains were surrounded by a white 
precipitation zone as shown in Fig. 3.6. All strains possessed bile salt hydrolase activity 
(Table 3.5), and in connection with this, it was noted that all these strains also exhibited high 
resistance to duodenum juice containing 0.5 % bile salts in the gastrointestinal passage model, 
which may be connected with this Bsh activity as suggested by some authors (De Smet et al., 
1995; De Smet et al., 1998; De Boever et al., 2000).  
 Not all the strains in this study were capable of growth on M17 agar medium (Table 
3.5). Only those strains which were able to grow on lactose as the sole C source tested on this 
medium were further investigated for β-galactosidase activity. The highest activity (9.3 
µmol.ml-1 .min-1) was determined for the reference strain L. plantarum ATCC 8014 (Table 
3.5). This strain was followed by the human faecal isolate L. plantarum BFE 1684, which also 
exhibited a high β-galactosidase activity of 8.3 µmol.ml-1.min-1. L. johnsonii strains, on the 
other hand, were not capable of growth in M17 medium containing lactose as sole C source 
(Table 3.5). 
 
 
Fig. 3.6  Examples of a Bsh-negative strain, L. paracasei BFE 675, and a Bsh-positive strain, L. 
plantarum BFE 5759, showing a large zone of white precipitation around the colony. 
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Table 3.5 H2O2 production and enzymatic activities of reference strains and selected 
potentially probiotic L. plantarum and L. johnsonii strains 
 
β-galactosidase 
Strains 
H2O2 
production
Growth in 
lactose as C 
source 
β-galactosidase 
activity 
(µmoles.ml-1 
.min-1
Bsh 
Probiotic candidates      
L. plantarum BFE 5092 - + <D.La + 
 BFE 5878 + + <D.L. + 
 BFE 5759 - + 5.95 + 
 BFE 1684 + + 8.31 + 
 BFE 1685 - - n.d. + 
L. johnsonii  BFE 6154 + - n.d. + 
 BFE 6128 + - n.d. + 
Reference strains      
L. plantarum  ATCC8014 - + 9.3 + 
L. johnsonii  BFE 663 - - n.d. + 
L. paracasei  BFE 675 - + 0.08 - 
 
a: <D.L.: lower than the detection level. n.d.: not determined. 
 
3.5 Antibiotic Resistance 
All strains were resistant to streptomycin and gentamicin, as well as to ciprofloxacin 
(Table 3.6). In contrast, all strains were considered as susceptible to the antibiotics 
erythromycin, ampicillin, penicillin, benzylpenicillin, tetracycline and chloramphenicol 
(Table 3.6), when using the MIC breakpoint values as suggested by SCAN (Chesson et al., 
2002). 
As an example, the E-test results for determination of antibiotic resistance of L. johnsonii 
BFE 6128 is shown in Fig. 3.7. 
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Table 3.6 Antibiotic Resistance of reference strains and selected potentially probiotic L. 
plantarum and L. johnsonii strains 
Minimum inhibitory concentration (µg/ml) 
Strains 
EM GM AB TC CL SM CI PG 
Probiotic candidates         
L. plantarum BFE 5092 1.0 256 0.064 6.0 2.0 256 32 0.38 
 BFE 5878 1.0 256 0.064 6.0 2.0 256 32 0.38 
 BFE 5759 1.0 128 0.032 3 2 256 32 0.75 
 BFE 1684 0.75 48 1.0 0.25 1.5 128 8 0.125
 BFE 1685 0.75 256 0.064 3 2 256 32 0.25 
L. johnsonii BFE 6128 1.0 256 0.047 4 1.5 256 32 0.19 
 BFE 6154 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Reference strains         
L. johnsonii BFE 663 0.25 256 0.19 0.25 1.5 32 32 0.064
L. paracasei BFE 675 0.5 24 0.38 0.75 2 42 12 0.125
Breakpoint valuea 4 1 2 16 16 16 4 2 
 
EM: Erythromycin, GM: Gentamicin, AB: Ampicillin, TC: Tetracycline, CL: Cloramphenicol, SM: 
Streptomycin, CI: Ciprofloxacin, PG: Benzylpenicillin. n.d.: not determined. 
a: breakpoints according to SCAN (2002). 
 
 
BFE 6128
 
Fig. 3.7 E-test for determination of antibiotic resistance of L. johnsonii BFE 6128. This strain was 
sensitive to tetracycline (left) but resistant to streptomycin (right). 
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3.6 Growth of selected probiotic candidates on prebiotics 
 Prebiotics are oligosaccharides which selectively enhance the growth of beneficial 
inhabitants of the gut, such as Lactobacillus spp. and Bifidobacterium spp. These bacterial 
species are able to utilise these sugars, which otherwise cannot be digested in the intestine by 
the human host. To see if the selected Lactobacillus strains of this study were able to utilise 
commercial prebiotics, the growth of these strains on a minimal medium containing prebiotics 
as main carbon source was monitored. In parallel, the growth of these strains in medium 
supplemented with both glucose and prebiotics was also tested in order to see if the presence 
of glucose in limited concentration favoured the growth on prebiotics, and to evaluate the 
effect of residual sugars (2-12 % wt/v) present in the prebiotic preparations. Basal medium 
(BM) was supplemented with 1 % wt/v prebiotic sugar and therefore the highest concentration 
of fructose, glucose or sucrose present in the supplemented medium was approximately 0.1 % 
wt/v. A control growth curve was done in basal medium supplemented with 0.1 % glucose in 
order to determine if the growth observed with the prebiotic sugars was due to the residual 
glucose present.  
  
3.6.1 Growth of L. johnsonii probiotic candidate strains on prebiotics 
 L. johnsonii BFE 6128 and BFE 6154 strains were apparently able to grow on 
Raftiline ST, Raftiline LS and Raftilose (Fig. 3.8), because the growth curves obtained when 
these oligosaccharides were added to basal medium (BM) reached a higher A580nm than on 
BM alone (Fig. 3.8). But when comparing with the growth observed when the BM was 
supplemented with 0.1 % glucose, the highest A580nm of approx. 0.5 obtained on Raftilose and 
Raftiline LS alone were also obtained when grown on BM containing 0.1 % glucose. 
Therefore, it may be assumed that the growth on these prebiotic sugars was actually due to 
growth on the residual sugars. When medium was supplemented with Raftiline ST with and 
without 0.1 % glucose, the growth of both L. johnsonii strains was higher then the growth on 
the respective control curves as shown by the highest A580nm of approx. 0.7 and 0.9, 
respectively.  
 The presence of glucose in limited concentration did not change the behaviour towards 
the prebiotic sugars tested. The only observed change was on growth on Raftilose, where the 
second lag phase disappeared when glucose (in limited conc.) was present. Nevertheless the 
higher growth observed with respect to the growth on Rafitlose + 0.1 % glucose may again be 
   RESULTS 
explained as a result of the residual sugars. In conclusion, only Raftiline ST favoured growth 
of the L. johnsonii strains tested.  
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Fig. 3.8 Growth of L. johnsonii strains on prebiotics. A) L. johnsonii BFE 6128 on basal medium 
(BM) supplemented with 1 % wt/v prebiotics. B) L. johnsonii BFE 6154 on basal medium (BM) 
supplemented with 1 % wt/v prebiotics. (●), medium alone (BM); (○), BM + Inuline (I); (▼), BM + 
Raftilose (R); (   ), Raftiline HP (RHP); (■), Raftiline LS (RLS) and (□), Raftiline ST (RST). C) 
Growth of L. johnsonii BFE 6154 on basal medium (BM) supplemented with 0.1 % glucose and 1 % 
wt/v prebiotics. D) Growth of L. johnsonii BFE 6128 on basal medium (BM) supplemented with 0.1 
% glucose (Gluc) and 1 % wt/v prebiotics.  (●), basal medium +Gluc (G); (○), BM + Inuline + Gluc 
(I+G); (▼), BM + Raftilose + Gluc (R+G); (   ), Raftiline HP + Gluc (G+RHP); (■), Raftiline LS + 
Gluc (RLS+G) and (□), Raftiline ST + Gluc (RST+G). 
 
3.6.2 Growth of L. plantarum probiotic candidates on prebiotics 
 In general, L. plantarum strains did not grow well on prebiotic sugars, but not all 
strains presented the same behaviour and therefore are grouped in three different figures. 
 L. plantarum BFE 5759 and BFE 1685 had a similar behaviour towards utilisation of 
prebiotic sugars. Both strains were not able to grow on Raftilose, Inuline, Raftiline HP nor 
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   RESULTS 
Raftline LS (Fig. 3.9). Only growth on Raftiline ST was superior to growth on 0.1 % glucose 
indicating that growth was supported by Raftiline ST and not by the residual sugars. When 
glucose was present, the utilization of prebiotic sugars did not change (Fig. 3.9).  
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Fig. 3.9 Growth of L. plantarum strains on prebiotics. A) L. plantarum BFE 5759 on basal medium 
(BM) supplemented with 1 % wt/v prebiotics. B) L. plantarum BFE 1685 on basal medium (BM) 
supplemented with 1 % wt/v prebiotics. (●), medium alone (BM); (○), BM + Inuline (I); (▼), BM + 
Raftilose (R); (   ), Raftiline HP (RHP); (■), Raftiline LS (RLS) and (□), Raftiline ST (RST). C) 
Growth of L. plantarum BFE 5759 on basal medium (BM) supplemented with 0.1 % glucose and 1 % 
wt/v prebiotics. D) Growth of L. plantarum BFE 1685 on basal medium (BM) supplemented with 0.1 
% glucose (Gluc) and 1 % wt/v prebiotics.  (●), basal medium +Gluc (G); (○), BM + Inuline + Gluc 
(I+G); (▼), BM + Raftilose + Gluc (R+G); (   ), Raftiline HP + Gluc (G+RHP); (■), Raftiline LS + 
Gluc (RLS+G) and (□), Raftiline ST + Gluc (RST+G).   
   RESULTS 
 In Fig. 3.10 it is shown that neither L. plantarum BFE 5092 nor BFE 5878 were able 
to utilize none of the prebiotic sugars tested, as growth was not higher than that observed on 
0.1 % glucose. When both, the corresponding prebiotic sugar and 0.1 % glucose were present 
there were no changes in utilization of prebiotic sugars. 
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Fig. 3.10 Growth of L. plantarum strains on prebiotics. A) L. plantarum BFE 5092 on basal medium 
(BM) supplemented with 1 % wt/v prebiotics. B) L. plantarum BFE 5878 on basal medium (BM) 
supplemented with 1 % wt/v prebiotics. (●), medium alone (BM); (○), BM + Inuline (I); (▼), BM + 
Raftilose (R); (   ), Raftiline HP (RHP); (■), Raftiline LS (RLS) and (□), Raftiline ST (RST). C) 
Growth of L. plantarum BFE 5092 on basal medium (BM) supplemented with 0.1 % glucose and 1 % 
wt/v prebiotics. D) Growth of L. plantarum BFE 5878 on basal medium (BM) supplemented with 0.1 
% glucose (Gluc) and 1 % wt/v prebiotics.  (●), basal medium +Gluc (G); (○), BM + Inuline + Gluc 
(I+G); (▼), BM + Raftilose + Gluc (R+G); (   ), Raftiline HP + Gluc (G+RHP); (■), Raftiline LS + 
Gluc (RLS+G) and (□), Raftiline ST + Gluc (RST+G).   
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   RESULTS 
 The only prebiotic sugar L. plantarum BFE 1684 appeared to be capable of utilising 
was Raftiline ST (Fig. 3.11) similar to the case of L. plantarum BFE 1685 and BFE 5759 
(Fig. 3.9). Nevertheless, the growth of the strain did not reach the same A580nm, and it seemed 
to be diauxic as indicated by the second lag phase, which may be due to the need of enzymes, 
which may need to be synthesised de novo. 
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Fig. 3.11 Growth of L. plantarum BFE 1684 on basal medium (BM) supplemented with 1 % wt/v 
prebiotics. (●), medium alone (BM); (○), BM + Inuline; (▼), BM + Raftilose; (   ), Raftiline HP; (■), 
Raftiline LS and (□), Raftiline LT. B) Growth of L. plantarum BFE 1684 on basal medium (BM) 
supplemented  with 0.1 % glucose and 1 % wt/v prebiotics. (●), basal medium +Gluc ; (○), BM + 
Inuline + Gluc; (▼), BM + Raftilose + Gluc; (   ), Raftiline HP + Gluc; (■), Raftiline LS + Gluc and 
(□), Raftiline ST + Gluc. 
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3.7 Adhesive properties  
3.7.1 Microbial adhesion to solvents  
The use of three solvents allowed the evaluation of the hydrophobic/hydrophilic cell 
surface properties of lactobacilli and their Lewis acid-base (electron donor and acceptor) 
characteristics (Pelletier et al., 1997; Briandet et al., 1999). As shown in Table 3.7, L. 
plantarum strains BFE 5878, BFE 5092, BFE 5759 and ATCC 8014 and L. rhamnosus GG 
had a low partitioning percentage in the apolar solvent n-hexadecane, indicating that these 
strains possess a hydrophilic surface. L. plantarum BFE 1684 and BFE 1685, L. johnsonii 
BFE 6128, BFE 6154 and LA-1 (BFE 663), L. paracasei BFE 675 and L. casei Shirota (BFE 
688) were characterised by a high affinity to n-hexadecane, indicating the hydrophobic nature 
of their surfaces (Table 3.7). 
 In order to measure the Lewis acid-base properties of the bacterial surface, two 
solvents (chloroform and ethyl acetate) with the same van der Waals properties as n-
hexadecane (Pelletier et al., 1997) were used in order to be sure that the affinity for each 
solvent tested was not due to van der Waals forces. 
 The results of the microbial adhesion to chloroform showed that four L. plantarum 
strains (BFE 5878, BFE 5092, BFE 5759 and ATCC 8014) had a low affinity for this acidic 
solvent, whereas all other strains had a strong affinity for it.  
 When ethyl acetate, an electron donor, was employed for determining the microbial 
adhesion to solvents, adhesion values were noticeably high (ranging from 36.3 to 79.2%) for 
L. johnsonii strains BFE 663, BFE 6128 and BFE 6154. This indicates that these bacteria also 
have an acidic surface character. L. plantarum 1684 and L. rhamnosus GG also showed a 
relatively high adherence value (30 %) to ethyl acetate. The rest of the strains adhered poorly 
to this strongly basic solvent, with values ranging from 0 to 16.8 %, reflecting the non-acidic 
character of these strains. 
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Table 3.7 Adhesion of potential probiotic Lactobacillus strains and Lactobacillus reference strains to 
HT29 cells and to solvents 
 
% Adhesion (±S.E.) to: 
Strains Origin Adhesion indexa n-Hexadecane Chloroform Ethyl Acetate 
Probiotic candidates      
L. plantarum      
BFE 1684 Infant faeces 45.9±5.9
* 60.8±4.4 55.5±4.6 30.4±4.3 
BFE 1685 Infant faeces 69.1±8.8
* 67.6±1.8 77.6±3.4 8.7±3.4 
BFE 5878 Kule naoto 55.5±4.6* 14.7±1.8 20.6±0.7 16.8±0.7 
BFE 5092 Kule naoto 62.7±6.8* 12.0±2.3 22.0±0.7 6.1±1.4 
BFE 5759 Kwerionik 3.7±0.7 7.3±0.4 21.1±0.5 8.3±1.1 
L. johnsonii      
BFE 6128 Kule naoto 100d±n.d.* 68.1±3.7 90.0±1.0 79.2±0.8 
BFE 6154 Kule naoto 100d±n.d.* 79.7±8.7 66.2±5.8 50.4±4.7 
Reference strains     
L. johnsonii BFE 663b LA-1 Nestlé 23.0±3.22
* 74.5±3.6 99.9±0.3 36.3±0.1 
L. plantarum ATCC 
8014 ATCC 24.7±2.6
* 5.7±0.6 11.6±1.2 0±0.0 
L. rhamnosus GGb Valio Ltd. 33.85±4.79* 18.5±1.9 67.1±5.5 30.0±0.8 
L. paracasei BFE 675c Actimel
®, 
Danone 2.38±0.48
 59.6±1.7 100.0±0.3 0±0.0 
L. casei Shirota BFE 
688c Yakult
® 2.62±0.5 40.3±6.8 65.3±0.1 0±0.0 
 
a Adhesion Index: mean ± S.E. (Standard Error) (n=4). Number of bacteria adhering to 100 HT29 
cells. b Positive control strains. c Negative control strains. d More than 100 bacteria per 100 HT29 cells 
were not possible to count, therefore they were given an adhesion index of 100 and no S.E. was 
calculated; n.d.: Not determined. e Means ± standard error of two measurements of three separate 
experiments.* Significantly different (ANOVA, Dunnet’s t-test, P<0.05) from the negative control L. 
casei Shirota.  
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3.7.2 Adhesion of Lactobacillus strains to HT29 cells 
Potentially probiotic Lactobacillus strains were investigated for their ability to adhere to 
the human intestinal epithelial HT29 cells. In addition, four commercial probiotic strains, 
previously well characterised for their adhesion properties (Tuomola et al., 1999; Gopal et al., 
2001) as well as a L. plantarum strain with unknown adhesion properties were used as 
reference strains. L. rhamnosus GG and L. johnsonii (LA-1) served as positive control strains, 
while L. paracasei (Actimel, Danone) and L. casei Shirota (Yakult Ltd.) were used as 
negative control strains and were described as being either adhesive or with a low and non-
specific binding capability, respectively (Tuomola et al., 1999; Gopal et al., 2001). After 
Gram staining of the slides, quantification of adherent bacterial strains, clearly visible as dark 
purple rods on a pale pink cell background, was possible (Fig. 3.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
C D
 
Fig. 3.12 Adhesion of lactobacilli to HT29 cells. A: L. casei Shirota BFE 688 (negative control 
strain), B: L. rhamnosus GG (positive control strain), C: L. plantarum BFE 1685, D: L. johnsonii BFE 
6128. 1000x magnification. 
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L. plantarum BFE 5759 could be characterised as non-adhesive, as its adherence values did 
not differ significantly from those of the negative control (L. casei Shirota, P>0.05, Table 
3.7). L. plantarum ATCC 8014 showed moderate adherence with values differing 
significantly from those of the negative control (L. casei Shirota, P<0.05). All other probiotic 
candidates were classified as strongly adhesive, and they all showed significantly higher 
adherence values when compared to the negative control (P<0.05). Interestingly, the L. 
johnsonii strains BFE 6128 and BFE 6154 isolated from Maasai milk (Kule naoto) showed a 
much higher adhesive index than the positive control strains L. johnsonii LA-1 and L. 
rhamnosus GG, which are described in the literature to adhere well to intestinal epithelial 
cells (Lee et al., 2000). 
 
3.7.3 Competitive exclusion: effect of adherent Lactobacillus strains on the adhesion of 
pathogens to HT29 cells  
L. plantarum BFE 1685 and L. johnsonii BFE 6128 were selected for competitive 
exclusion studies with pathogens because of their strong adhesion to HT29 cells (3.7.2, Table 
3.7). As control strains, the adhesive L. rhamnosus GG and the non-adhesive L. casei Shirota 
(BFE 688) were used. In these experiments, HT29 cells were pre-incubated with lactobacilli 
(5 x 108 CFU/ml) before addition of enterotoxigenic E. coli ATCC 25922, the vancomycin 
resistant Ent. faecium DSM 13590, List. monocytogenes Scott A or S. Typhimurium ATCC 
14028. Adhesion of E. coli was significantly (P<0.01) reduced when HT29 cells were pre-
treated with L. rhamnosus GG or L. johnsonii BFE 6128, and completely abolished when 
cells were pre-treated with L. plantarum BFE 1685. On the other hand, only L. plantarum 
BFE 1685 was able to completely inhibit (P<0.01) Ent. faecium DSM 13590 adhesion, 
whereas neither L. johnsonii BFE 6128 nor the reference strains (L. rhamnosus GG, L. casei 
Shirota BFE 688) tested were able to influence the adhesion of this Enterococcus strain (Fig. 
3.13). 
List. monocytogenes Scott A adhesion was significantly (P<0.01) reduced by all tested 
strains, except for the non-adherent L. casei Shirota (BFE 688). This latter strain did not 
influence the adhesion of E. coli, Ent. faecium or List. monocytogenes strains used in this 
study, but it slightly reduced (P<0.05) the adherence of S. Typhimurium ATCC 14028 cells. 
S. Typhimurium adhesion was also significantly reduced by the presence of L. plantarum BFE 
1685 cells (Fig. 3.13). 
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Fig. 3.13 Adhesion of pathogens to HT29 cells alone or after pre-treatment of HT29 cells with 
potentially probiotic or reference Lactobacillus spp. strains. Results are expressed as means ± S.E. of 
at least four experiments. *Significantly decreased binding when compared to binding on wells without 
lactobacilli (P<0.05, ANOVA, Dunnett’s t test). Binding of the pathogen alone , or after pre-
treatment of HT29 cells with L. rhamnosus GG , L. casei Shirota BFE 688 , L. johnsonii BFE 
6128  or L. plantarum BFE 1685 . 
 
3.7.4 Auto-aggregation of Lactobacillus strains  
 Auto-aggregation was studied on the basis of the sedimentation characteristics of the 
strains because when cells aggregate, they sediment and clear the supernatant. The non-
adherent reference strains L. paracasei BFE 675 and L. casei BFE 688 showed aggregation 
values of less than 20 % (Fig. 3.14), whereas the adherent reference strains L. johnsonii LA-1 
(BFE 663, Fig. 3.14) and L. rhamnosus GG auto-aggregated with a value higher than 20 %. 
Although these strains are both known to adhere well to intestinal epithelial cells, a clear 
difference in auto-aggregation could be observed as L. johnsonii BFE 663 showed much 
higher auto-aggregation values (more than 80 %), while those of L. rhamnosus GG were 
below 40 % (Fig. 3.14). A variation in aggregation values obtained using acidic (pH 4.0) and 
neutral (pH 7.4) PBS was not noted. Only in the case of L. johnsonii strains BFE 6154 and 
BFE 6128, the auto-aggregation was enhanced when tested in their overnight spent 
   RESULTS 
supernatants and it was noticeably higher than that observed in PBS at pH 4.0 (Fig. 3.14). 
Measurements of auto-aggregation on neutralised supernatants was not possible because most 
of the strains continued growing, which led to an increase in A580nm, resulting in negative 
auto-aggregation values (data not shown). 
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Fig. 3.14 Auto-aggregation of potentially probiotic and reference Lactobacillus strains. Overnight 
cultures were washed and resuspended in PBS pH 7.4  , in PBS pH 4  or in MRS spent culture 
supernatant . Absorbance (580 nm) was measured at the beginning (A0) and after a 2-hour-
incubation (A1) at 23°C. Auto-aggregation  % was calculated as: (1 - A1/A0) x 100. 
 
3.7.5 Coaggregation of Lactobacillus  strains with foodborne pathogens  
The scoring system used for the coaggregation test is illustrated in Fig. 3.15. E. coli ATCC 
25922 and S. Typhimurium ATCC 14028 were able to auto-aggregate with scores of 4 and 3, 
respectively (Table 3.8). For coaggregation of pathogens with Lactobacillus spp., the scores 
were reduced by at least one unit in all cases, except for L. johnsonii BFE 6128 and BFE 6154 
strains, which coaggregated with S. Typhimurium with a score of 3 (Table 3.8). After Gram 
staining, it was verified by light microscopy that aggregates comprised Gram-positive as well 
as Gram-negative bacteria.  
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Fig. 3.15 Scoring system for the coaggregation assay. Organisms used to illustrate the different 
scores were S. Typhimurium ATCC 14028 together with L. plantarum BFE 1685 (A) S. Typhimurium 
ATCC 14028 together with L. plantarum BFE 5092 and 10 % spent supernatant from L. plantarum 
BFE 5092 grown in MRS broth at 37°C overnight (B), L. johnsonii BFE 6128 together with L. 
monocytogenes Scott A (C) and S. Typhimurium ATCC 14028 together with L. johnsonii BFE 6128 
and 10% supernatant from L. johnsonii BFE 6128 grown in MRS broth (D). Photographs were taken 
on a Zeiss inverted microscope (200x magnification). The photographs show scores 1 to 4 (1 for small 
and dispersed clumps in some microscopic fields (A), 2 for medium-sized and dispersed clumps (B), 3 
for abundant and medium-sized clumps with turbid supernatant (C) and 4 for very big clumps and 
clear supernatant (D). Scores 3 and 4 were also macroscopically visible. 
 
Three probiotic reference strains (L. rhamnosus GG, L. casei Shirota and L. paracasei BFE 
675) as well as L. plantarum ATCC 8014 and L. johnsonii BFE 6128 and BFE 6154 were 
able to coaggregate with List. monocytogenes Scott A with a higher score than that obtained 
when List. monocytogenes auto-aggregated (Table 3.8). L. plantarum strains coaggregated 
with S. aureus ATCC 25923 to varying degrees. Two of the reference probiotic strains L. 
A B 
D C 
0.5 mm 
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johnsonii LA-1 and L. casei Shirota did not coaggregate at all, whereas L. johnsonii BFE 
6128 and BFE 6154 coaggregated with S. aureus with a score of 4 (Table 3.8). 
When spent culture supernatant of overnight cultures of lactobacilli was added to the 
coaggregation system (1:10) with List. monocytogenes and S. Typhimurium, the 
coaggregation with L. plantarum strains BFE 5878, BFE 5092, BFE 5759, BFE 1685 and 
BFE 1684 and L. johnsonii BFE 6128 increased by one unit (result not shown). In that way, L. 
johnsonii BFE 6128 reached the highest score (4) in coaggregation with these foodborne 
pathogen strains. 
 
Table 3.8 Coaggregationa of potential probiotic Lactobacillus strains with intestinal pathogens 
Strain 
List. 
monocytogenes 
Scott A 
S. aureus 
ATCC 25923
E. coli 
ATCC 
25922 
S. 
Typhimurium
ATCC 14028 
Probiotic candidates     
L. plantarum BFE 5878 1 1 3 1 
 BFE 5092 1 2 3 1 
 BFE 5759 1 2 3 1-2 
 BFE 1684 1-2 1 3 1-2 
 BFE 1685 1 2 3 1 
L. johnsonii BFE 6154 3 4 3 3 
 BFE 6128 3 4 3 3 
Reference strains     
L. johnsonii BFE 663 1-2 0 3 2 
L. rhamnosus GG 3 1 3 2 
L. casei Shirota BFE 688 3 0 3 2 
L. paracasei BFE 675 3 2 3 2 
L. plantarum ATCC 8014 3 3 3 2 
Foodborne pathogens     
List. monocytogenes Scott A 2 - - - 
S. aureus ATCC 25923 - 0-1 - - 
E. coli ATCC 25922 - - 4 - 
S. Typhimurium ATCC 14028 - - - 3 
a Plates were observed with an inverted microscope with a 20 x objective. Scoring system adopted for 
the coaggregation assay: 0, no clumps; 1, small and dispersed clumps in some microscopic fields; 2, 
medium-sized and dispersed clumps, 3, abundant and medium-sized clumps with turbid supernatant; 
4, very big clumps with a clear supernatant (3 and 4 also macroscopically visible).  
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3.8 Interaction of selected probiotic candidate strains with HT29 cells 
3.8.1 HT29 cell viability in coculture experiments  
 None of the probiotic candidate and control strains tested (inoculum: 1 x 107 
CFU/well, ratio: two bacteria to one HT29 cell) significantly modified (P>0.05) the vitality of 
HT29 cells after 24 h incubation, when compared to the negative control (cells cultivated with 
DMEM alone), as assessed by the release of lactate dehydrogenase into the supernatant. 
Bacterial LDH was not released into the medium as corroborated with supernatants of bacteria 
grown on DMEM without HT29 cells. LDH concentration in supernatant of cell monolayers 
disrupted with 2 % Triton-X were considered as 100 % cytotoxicity and used to calculate 
vitality (Fig. 3.16).  
 When HT29 cells were infected with S. Typhimurium (inoculum: 1 x 107 CFU/well, 
ratio: two bacteria to one HT29 cell) for a period of 24 h, the HT29 cells died as indicated by 
a 96-100 % cytotoxicity as determined by measuring LDH released in the supernatant by 
necrotic cells (Fig. 3.16). The monolayers also detached during the washing steps and the pH 
of the medium was acid as indicated by the shift of the pH indicator present in DMEM 
(phenol red). When infection lasted only 4 h, as in the experiments of section 3.9, there were 
no significant changes in vitality of HT29 cells or in the pH of the medium. 
 A similar experiment on cytotoxicity of bacterial strains and components to HT29 was 
done using the MTT assay test (Fig. 3.17). Neither the probiotic candidates, nor the reference 
strains significantly affected HT29 cells vitality (P<0.05). The commercial microbial 
components and TNF-α were not cytotoxic, at least at the concentration used in these assays. 
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Fig. 3.16 Cytotoxicity of bacterial cultures, LPS, LTA, TNF-α and ODN2006 to HT29 cells 
expressed as % cytotoxicity observed after 24 h treatment. A: Probiotic candidates and S. 
Typhimurium. B: reference strains, commercial LPS, LTA, ODN2006 and TNF-α. Cells 
treated with 2 % Triton-X were used as a positive control for 100 % cytotoxicity and cells 
treated with medium alone (DMEM) as a negative control. 
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Fig.  3.17 Cytotoxicity of bacterial cultures, LPS and TNF-α to HT29 cells expressed as % vitality 
observed after 24 h treatment. A: probiotic candidates; B: Control strains, LPS and TNF-α. The 
vitality of HT29 cells treated with bacterial suspensions was studied by means of the MTT test. 
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3.8.2 Modulation of cytokine secretion by HT29 cells 
 Seven potentially probiotic candidate strains and three reference strains (L. rhamnosus 
GG, L. paracasei BFE 675 and L. casei Shirota BFE 688) were tested for their ability to 
induce cytokine secretion in intestinal epithelial cells. IL-1, IL-6, MCP-1, IL-10 and TNF-α 
could not be detected in the supernatants treated with either bacteria or with commercially 
obtained lipopolysaccharide (LPS, 0.1 µg/ml). TGF-β was detected, but it was secreted 
constitutively and no significant (P>0.01) difference could be demonstrated between the 24-
hour-supernatant of the control (cells grown with DMEM without FCS and antibiotics) and 
probiotic-treated samples (5 x 106 CFU/ml in DMEM without FCS and antibiotics). Two L. 
plantarum strains (BFE 5759 and BFE 1685) and one L. johnsonii strain (BFE 6128) 
significantly (P<0.01) induced the secretion of IL-8 when compared to the control without 
bacteria (Fig. 3.18). Nevertheless, when cells were incubated for 24 h together with LPS alone 
(0.1 µg/ml), the levels of this chemokine were much higher (264.02 ± 10.28 pg/ml; Fig. 3.19). 
The two well-known probiotics L. rhamnosus GG and L. paracasei BFE 675 (Actimel®, 
Danone) on the other hand, down-regulated the release of IL-8 as shown in Fig. 3.18. The 
other Lactobacillus strains neither reduced nor enhanced the secretion of this chemokine by 
HT29 cells significantly. 
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Fig.  3.18  Induction of IL-8 secretion (pg/ml) in HT29 epithelial cells by lactobacilli as determined by 
enzyme-linked immunosorbent assay. Values are means ± S.E. of at least three experiments. 
*Significantly different from the control (P<0.01 ANOVA, Dunnett’s t-test).
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 Some of the strains were further tested to determine wether they exerted an effect on 
the response of HT29 cells to LPS (0.1 µg/ml). Indeed, L. plantarum BFE 1685, L. plantarum 
BFE 5878 and L. johnsonii BFE 6128 enhanced the response of HT29 cells to LPS in a 
synergistically way (Fig. 3.19), when incubated together for 24 h. The well studied 
commercial probiotic strain L. rhamnosus GG and the potentially probiotic candidates, L. 
plantarum BFE 1685 and L. johnsonii BFE 6128, were selected for further studies on the 
interaction of lactobacilli with enterocytes based on their IL-8 co-stimulatory properties. 
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Fig. 3.19 Effect of co-stimulation of HT29 cells with LPS and lactobacilli on IL-8 production by 
HT29 cells. 1 x 10  CFU/well and 0.1 µg/ml LPS (from E. coli) were given to HT29 cells and 
incubated for 24 h. Supernatants were collected; centrifuged and IL-8 levels were determined by 
ELISA. Values are means ± S.E. of at least three separate experiments. 
7
Cells incubated only with 0.1 
µg/ml LPS were considered as control.  *P<0.05, ANOVA, Dunnett’s t-test. 
 
3.8.3 Identification of probiotic cellular components responsible for IL-8 induction on 
HT29 cells after 24 h 
 Purified cell walls, LTAs and DNA, as well as sterile-filtered spent supernatant (of 24-
hour bacterial cultures grown in DMEM), lactic acid and cells treated with proteinase K or 
potassium periodate, were tested for their ability to induce IL-8 secretion by HT29 cells after 
24 h incubation as described in section 2.10.3. IL-8 levels (pg/ml) induced by the different 
bacterial components are shown in Fig. 3.20, 3.21 and 3.22. Statistical differences when 
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compared to the untreated control (cells treated with DMEM) were determined by means of 
ANOVA and Dunnett’s t-test (P<0.05). 
 LTAs isolated from L. rhamnosus GG induced a higher production of IL-8 (P<0.05) 
by HT29 cells than the untreated cells (cells treated with DMEM) as shown in Fig. 3.20. The 
sterile-filtered supernatants of 24-hour-old L. rhamnosus GG cultures grown in DMEM were 
also able to induce higher levels of IL-8 secretion (P<0.05), which contrasted with the 
previously shown results of the effect of live L. rhamnosus GG (Fig. 3.18). None of the other 
components tested, significantly influenced IL-8 secretion. 
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Fig. 3.20 Effect of L. rhamnosus  GG cellular components on IL-8 production by HT29 cells. Cells 
incubated only with medium were used as the negative control (basal secretion of IL-8). S. aureus 
LTA was used as a positive control for induction of IL-8 on intestinal epithelial cells. *P<0.05, 
ANOVA, Dunnett’s t-test. 
 
 In the case of L. plantarum BFE 1685, LTAs did not influence the secretion of IL-8 
significantly. Other cellular components (crude cell wall extracts, DNA) and cells treated with 
proteinase K or KIO4 did not exert an effect on IL-8 secretion, either. Interestingly, the 
filtered supernatant of L. plantarum 24-hour cultures significantly influenced the secretion of 
IL-8 by HT29 cells (Fig. 3.21). 
RESULTS 
 
-89- 
 
0
20
40
60
80
100
120
DMEM LTA (S.aureus) LTA Cell wall crude
extract
Cell walls
(SDS)
DNA steril-filtered
supernatant
Prot.K treated
bacteria
KIO4 treated
bacteria
Treatment with L. plantarum  BFE 1685 components (24h)
IL
-8
 (p
g/
m
l)
 
* 
* 
Treatment with L. plantarum BFE 1685 (24 h) 
St ile-fil red 
su rnatant 
LTA           
(S. aureus) 
Fig. 3.21 Effect of L. plantarum BFE 1685 cellular components on IL-8 (pg/ml) production by 
HT29 cells. Cells incubated only with medium were used as negative control (basal secretion of IL-8). 
S. aureus LTA was used as a positive control for induction of IL-8 on intestinal epithelial cells. 
*P<0.05, ANOVA, Dunnett’s t-test. 
 
0
20
40
60
80
100
120
DMEM LTA (S.aureus) LTA Cell wall crude
extract
Cell walls
(SDS)
DNA steril-filtered
supernatant
Prot.K treated
bacteria
KIO4 treated
bacteria
Treatment with L. johnsonii  BFE 6128 components (24h)
Il-
8 
(p
g/
m
l)
 
*
* 
Treatment with L. johnsonii BFE 6128 (24 h) 
St rile-filt red 
su rnatant 
LTA           
(S. aureus) 
Fig. 3.22 Effect of L. johnsonii BFE 6128 cellular components on IL-8 (pg/ml) production by HT29 
cells. Cells incubated only with medium were used as negative control (basal secretion of IL-8). S. 
aureus LTA was used as a positive control for induction of IL-8 on intestinal epithelial cells. *P<0.05, 
ANOVA, Dunnett’s t-test. 
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 On the other hand, LTAs isolated from L. johnsonii BFE 6128 significantly (P<0.05) 
increased IL-8 secretion by HT29 cells. In contrast to the other two strains, L. johnsonii BFE 
6128 spent supernatant did not exert any effects on the levels of IL-8. Other bacterial and cells 
treated with proteinase K or KIO4 components tested did not modulate IL-8 secretion (Fig. 
3.22). 
3.8.4 TNF-α sensitises HT29 cells to probiotic lactobacilli 
 To test the response of enterocytes to probiotic strains in an inflammatory context, the 
effect of pre-treatment of enterocytes with TNF-α on the response to L. plantarum BFE 1685, 
L. johnsonii BFE 6128 and L. rhamnosus GG was tested. As shown before in Fig. 3.16 and 
3.17, neither lactobacilli nor TNF-α affected HT29 cell viability over a period of 24 h.  
 HT29 cells were pre-treated with TNF-α (0.1µg/ml) for 2 h, washed twice with PBS 
and stimulated with lactobacilli (1 x 107 CFU/well). The three lactobacilli strains tested 
exerted a much stronger response on the secretion of IL-8 (Fig. 3.23) than on cells without 
TNF-α pre-treatment (Fig. 3.18). The levels of IL-8 secreted into the medium by HT29 cells 
were also much higher than those of IL-8 induced by TNF-α alone (Fig. 3.23). 
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Fig. 3.23 Effect of TNF-α on the response of HT29 cells (IL-8 secretion in pg/ml) to selected 
lactobacilli [(L. johnsonii BFE 6128 (6128), L. plantarum BFE 1685 (1685) or L. rhamnosus GG 
(LGG)] strains. Cells pre-treated with TNF-α, washed and treated with medium served as control. 
*P<0.05, ANOVA, Dunnett’s t-test. Cells treated only with TNF-α also induced an increased in IL-8 
when compared to cells pre-treated and treated only with medium (DMEM). **P<0.05, ANOVA, t-
test. 
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3.8.5 Effect of lactobacilli on gene expression in HT29 cells 
3.8.5.1 RT-PCR investigation of TLR2-, TLR4-, TLR9- and HBD-2-gene expression 
modulation in HT29 cells by lactobacilli 
 Intestinal epithelial cells were stimulated with L. rhamnosus GG, L. johnsonii BFE 
6128 or L. plantarum BFE 1685 (1 x 107 CFU/well) for 2 h, washed and incubated with 
medium for further 4 h. Non-stimulated cells were treated in the same way but incubated only 
with medium (DMEM). After incubation, RNA was isolated and the expression of TLR2, 
TLR4 and TLR9 was investigated by means of RT-PCR using the primers listed in Table 2.4 
and the RT-PCR programme as indicated in Table 2.2. 
 From the previous results shown in this study, it could be hypothesised that lactobacilli 
may be recognised by their LTAs through TLR2 expression. In the literature, there are some 
discrepancies in the reports of TLR2 expression in intestinal epithelial primary cultures and  
cell lines (Cario & Podolsky, 2000; Hausmann et al., 2002; Melmed et al., 2003; Furrie et al., 
2005). Therefore, it was important to determine if the cell line used in this study was able to 
express TLR2. As shown in Fig. 3.24, the expected RT-PCR product could not be detected 
with this method, neither in untreated cells nor in cells treated with the Lactobacillus spp. 
strains used in this study. 
← 500 bp 
←1000 bp 
← 100 bp 
TLR2 
(638 bp) 
GAPDH 
(306 bp) 
A B C D MM
←300 bp 
 
  
Fig.  3.24 Expression of TLR2 in HT29 cells as determined by RT-PCR using TLR2 specific 
primers. Cells remained unstimulated (A) or were stimulated with 1 x 107 CFU/well of L. rhamnosus 
GG (B), L. johnsonii BFE 6128 (C) or L. plantarum BFE 1685 (D). mRNA was analysed by RT-PCR. 
MM: molecular marker. The expected amplicon sizes are show in parenthesis under the corresponding 
gene. The bands shown with the TLR2 experiments corresponded to primer or primer-dimer bands. 
GAPDH was amplified as control house-keeping gene. 
 
 HT29 cells responded to LPS with an increase in IL-8 secretion. LPS is known to be 
recognised by TLR4 but also by CD14 and LBP (lipopolysaccharide binding protein). To 
confirm that HT29 cells expressed TLR4, the expression of this receptor was investigated by 
RT-PCR as shown in Fig. 3.25. As mentioned before, some Lactobacillus strains seemed to 
synergise with LPS to increase IL-8 when compared to cells not treated with lactobacilli. 
Thus, it was of interest to determine if TLR4 was expressed in HT29 cells, and to see if their 
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levels were modulated by the presence of lactobacilli. The RT-PCR method is a qualitative 
method, but it can also be used in a semi-quantitative way to estimate if there are variations in 
the expression levels of the target gene. As shown in Fig. 3.25, it seems that TLR4 is 
constitutively expressed by HT29 cells, because TLR4 mRNA was detected in non-stimulated 
as well as in stimulated cells. Nevertheless, the intensity of the bands differed, which may 
suggest differences in the levels of expression. A more sensitive method such as real-time RT-
PCR was used later to confirm this (section 3.8.5.2). 
←300 bp 
← 500 bp 
←1000 bp 
 
TLR4 
(449 bp) 
GAPDH 
(306 bp) 
A B C D MM
 
Fig. 3.25 Expression of TLR4 in HT29 cells as determined by RT-PCR using TLR4 specific 
primers. Cells remained unstimulated (A) or were stimulated with 1 x 107 CFU/well of L. rhamnosus 
GG (B), L. johnsonii BFE 6128 (C) or L. plantarum BFE 1685 (D). mRNA was analysed by RT-PCR. 
MM: molecular marker. The expected amplicon sizes are show in parenthesis under the corresponding 
gene. GAPDH was amplified as control house-keeping gene. 
 
 Some studies have reported that DNA from probiotic strains is responsible for some of 
their immune effects (Lammers et al., 2003; Jijon et al., 2004; Rachmilewitz et al., 2004). The 
DNA samples of the three strains investigated here were not able to induce an increase on IL-
8 levels secreted by HT29 cells (Fig. 3.20 to 3.22). The expression of TLR9 was investigated 
by RT-PCR in order to see if this lack of response was due to the absence of TLR9 expression 
in the HT29 cell line. In Fig. 3.26, it is shown that TLR9 is not expressed in non-treated cells 
and it is induced in cells treated with whole cells of Lactobacillus strains. 
←300 bp 
← 500 bp 
TLR9 
(511 bp) 
GAPDH 
(306 bp) 
A B C D MM
← 1000 bp 
 
Fig.  3.26 Expression of TLR9 in HT29 cells as determined by RT-PCR using TLR9 specific 
primers. Cells remained unstimulated (A) or were stimulated with 1 x 107 CFU/well of L. rhamnosus 
GG (B), L. johnsonii BFE 6128 (C) or L. plantarum BFE 1685 (D). mRNA was analysed by RT-PCR. 
MM: molecular marker. The expected amplicon sizes are show in parenthesis under the corresponding 
gene. GAPDH was amplified as control house-keeping gene. 
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 HBD-2 is expressed in epithelial cells as a result of the activation of TLR-pathways 
(Vora et al., 2004). By means of RT-PCR it was not possible to detect the expression of HBD-
2 neither in unstimulated nor in lactobacilli-treated HT29 cells (data not shown). It could 
therefore be inferred that HBD-2 is not expressed by HT29 cell line, at least under the 
conditions tested in this study. 
 
3.8.5.2 Real-time RT-PCR determination of modulation of TLR2-,TLR4-, TLR9- and 
HBD-2-gene expression in HT29 cells by probiotic and potentially probiotic 
lactobacilli 
 As already mentioned, conventional RT-PCR is not quantitative. Therefore, the more 
sensitive and appropriate method for quantifying gene expression is the real-time RT-PCR 
method. For the calibration curves, 10-fold serial dilution series of TLR2, TLR4 and TLR9 
amplicons were used. These amplicons were obtained by amplifying mRNA isolated from 
PBMC which express these genes constitutively. Internal primers were design to amplify a 
smaller fragment (included in these amplicons) during real-time RT-PCR using the cDNA 
obtained by RT-PCR as template. Both the initial RT-PCR products and the amplicons 
amplified with the second pair of primers (Table 2.6) were purified with Quantum Prep PCR 
Kleen spin columns (see 2.3.4.5) and sequenced at GATC Biotech. The sequences of all the 
DNA products correlated with the expected sequences of the target genes. 
 Real-time RT-PCR has a much higher sensitivity than conventional RT-PCR. With 
this technique, it was possible to detect the presence of TLR2 mRNA in HT29 cells. 
Furthermore, the levels of TLR2 were significantly higher (P<0.05) in cells stimulated with 
lactobacilli than in non-stimulated cells (Fig. 3.27). This finding suggests a possible up-
regulation of this gene by lactobacilli. 
 When TLR4 expression was investigated, no differences were observed in the 
expression levels of this receptor neither in non-stimulated nor in lactobacilli-stimulated cells 
(Fig. 3.28). 
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Fig. 3.27 Expression of TLR2 (AU) in HT29 cells as determined by quantitative PCR. Cells remained 
unstimulated (A) or were stimulated with 1 x 107 CFU/well of L. rhamnosus GG (B), L. johnsonii BFE 
6128 (C) or L. plantarum BFE 1685 (D). mRNA was analysed by real-time RT-PCR. Data represent 
results of three independent experiments done in duplicate. *P<0.05, ANOVA, Dunnett’s t-test for 
comparisons with a control (A). 
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Fig. 3.28 Expression of TLR4 (AU) in HT29 cells as determined by quantitative PCR. Cells 
remained unstimulated (A) or were stimulated with 1 x 107 CFU/well of L. rhamnosus GG (B), L. 
johnsonii BFE 6128 (C) or L. plantarum BFE 1685 (D). mRNA was analysed by real-time RT-PCR. 
Data represent results of three independent experiments done in duplicate. P<0.05, ANOVA, 
Dunnettt’s t-test for comparisons with a control (A). 
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 In the case of TLR9 gene expression, the presence of lactobacilli significantly 
(P<0.05) up-regulated the levels of mRNA coding for this receptor as shown in Fig. 3.29. Not 
all the strains exerted this effect with the same intensity. L. johnsonii BFE 6128 up-regulated 
the expression of TLR9 approx. 11 folds, whereas L. rhamnosus GG and L. plantarum BFE 
1685 approx. 5 and 3 fold, respectively. 
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Fig.  3.29  Expression of TLR9 (AU) in HT29 cells as determined by quantitative PCR. Cells 
remained unstimulated (A) or were stimulated with 1 x 107 CFU/well of L. rhamnosus GG (B), L. 
johnsonii BFE 6128 (C) or L. plantarum BFE 1685 (D). mRNA was analysed by real-time RT-PCR. 
Data represent results of three independent experiments done in duplicate. P<0.05, ANOVA, 
Dunnett’s t-test for comparisons with a control (A). 
 
3.8.6 Effect of L. johnsonii BFE 6128, L. plantarum BFE 1685 and L. rhamnosus GG on 
TLR2, TLR5 and TLR9 expression at the protein level in HT29 cells 
3.8.6.1 TLR2, TLR5 and TLR9 expression by HT29 cells without prior stimulation 
with lactobacilli 
 Based on the previous real-time PCR results (3.8.5), it was interesting to determine if 
the changes in expression seen at the mRNA level after stimulation with lactobacilli 
corresponded to expression changes at the protein level. In these experiments, TLR5 was 
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investigated instead of TLR4 because it is known that flagellated bacteria (including both 
Gram-positive and Gram-negative flagellated bacteria) are recognised by this receptor and 
may initiate the activation of intestinal cells through binding to TLR5. The effects of 
lactobacilli on the response of HT29 cells to S. Typhimurium (a flagellated bacterium) is 
described below in section 3.9. 
 TLR2 and TLR5 are known to be located in the cytoplasmatic membranes of cells 
which express these receptors. TLR9 has an intracellular location; it is associated with 
endosomic membranes. For this reason, the method used for detection of TLR9 included a 
permeabilisation step to allow the entry of the detection antibody in the cell to bind to its 
target ligand. In each FACS run 20.000 events (cells passing detector) were measured. Fig 
3.30 A, B and C show the overlayed histograms obtained by marking cells with the specific 
antibodies against each TLR and with the corresponding isotype-control antibodies to discard 
unspecific binding. 
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Isotype control 
antibody 
Isotype control 
antibody 
TLR9 
Isotype control 
antibody 
TLR5 
 
B
 
C  
 
 
 
 
 
Fig. 3.30 Cell surface expression of TLR2 and TLR5, and intracellular expression of TLR9 in HT29 
cells as determined by FACS by labelling HT29 cells with PE-conjugated antibodies against TLR2 or 
TLR5 and with FITC-conjugated antibody against TLR9 (filled peaks). Isotype antibodies were used 
as controls to discard non-specific binding (open peaks).  
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3.8.6.2 Modulation of TLR2, TLR5 and TLR9 protein expression in HT29 cells by 
potentially probiotic lactobacilli 
 L. rhamnosus GG and L. plantarum BFE 1685, but not L. johnsonii BFE 6128 were 
able to increase the TLR2 levels expressed on the membrane of HT29 cells. Fig. 3.31 A and C 
show the increase in mean fluorescence intensity on treated cells as indicated by the shift of 
the peaks to the right, and an increase in the number of cells expressing this receptor. When 
stimulated with L. johnsonii BFE 6128, there was a minimal increase in fluorescence 
intensity, though insignificant, as indicated by the slight shift of the histogram to the right. 
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Fig. 3.31 Modulation of cell surface expression of TLR2 in HT29 cells as determined by labeling cells 
with TLR2 antibody and measuring fluorescence by FACS. The filled peaks indicate the background 
level of expression of TLR2 in HT29 cells. The histogram isotype-antibody (grey-lined open peaks on 
the left) was also overlaid onto the histogram. Three experiments with similar results were performed. 
This figure is representative of one such experiment. 
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 Again, L. rhamnosus GG and L. plantarum BFE 1685 but not L. johnsonii BFE 6128 
were able to increase the TLR5 levels expressed on the membrane of HT29 cells. Fig. 3.32 A 
and C show the increase in mean fluorescence intensity on treated cells as indicated by the 
shift of the peaks to the right. 
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Fig. 3.32 Modulation of cell surface expression of TLR5 in HT29 cells as determined by labeling 
cells with PE-conjugated TLR5 antibody and measuring fluorescence by FACS. The filled peaks 
indicate the background level of expression of TLR5 in HT29 cells. The histogram isotype-antibody 
(grey-lined open peaks on the left) was also overlaid onto the histograms. Three experiments with 
similar results were performed. This figure is representative of one such experiment.  
 
 None of the strains modulated the expression of TLR9 at protein level under the 
conditions tested, as shown in Fig. 3.33 A, B and C, where the peaks of stimulated and non-
stimulated cells overlapped thus indicating no increase in expression. 
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Fig. 3.33 Modulation of intracellular expression of TLR9 in HT29 cells as determined by labeling 
cells with FITC-conjugated TLR9 antibody and measuring fluorescence by FACS. The filled peaks 
indicate the background level of expression of TLR9 in HT29 cells. The histogram isotype-antibody 
(grey-lined open peaks on the left) was also overlaid onto the histograms. Three experiments with 
similar results were performed. This figure is representative of one such experiment. 
 
3.9 Modulation of HT29 cell responses to S. Typhimurium by probiotics 
3.9.1 Effect of lactobacilli pre-treatment of HT29 cells on IL-8 secretion by HT29 cells 
infected with S. Typhimurium 
 Because of the results showing an up-regulation of TLRs by lactobacilli, it was 
hypothesised that the strains tested in this study may have an influence on the recognition of 
an enteric pathogen by increasing the amount of these pattern recognition receptors by 
modulating their gene expression. S. Typhimurium was chosen as model pathogen because of 
its known invasive potential, and because it may be recognised at different levels with 
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different TLRs, i.e. LPS by TLR4, flagellin by TLR5 and CpG motifs in its bacterial DNA by 
TLR9. In order to determine if Lactobacillus strains were able to modulate the response of 
enterocytes to a pathogen, HT29 cells were incubated with 5 x 106 CFU/ml (corresponding to 
a ratio of approx. 5 bacteria to 1 eukaryotic cell) for 2 h. After this time, cells were washed 
with PBS twice, infected with 5 x 106 CFU/ml S. Typhimurium and incubated for further 4 h. 
For comparisons, control HT29 cells were treated only with medium (DMEM) for 2 h, 
washed twice with PBS and infected with S. Typhimurium as described in section 2.6.5.  
 IL-8, whose de novo synthesis is induced by NF-κB as a result of TLR pathways 
activation, was determined in the supernatants as a measure of the responsiveness of IEC to 
bacteria.  All three Lactobacillus strains (L. rhamnosus GG, L. johnsonii BFE 6128 and L. 
plantarum BFE 1685) tested induced a significant (P<0.05) increase in the IL-8 level secreted 
by HT29 cells when compared with the control (cells pre-treated only with DMEM) as shown 
in Fig.3.34 A. 
 Lactobacilli enhanced the response of HT29 cells to S. Typhimurium and this was not 
due to an additive effect, as the levels of IL-8 induced by the Lactobacillus strains after 2 h 
incubation, was negligible (ca. 8.0±2.0 pg/ml) and did not significantly differ from the non-
treated cells as shown in Fig. 3.34 B. This experiment was done in parallel with the one 
shown in Fig. 3.34 A and HT29 cells were subjected to the same washing steps indicated 
before, in order to maintain the same conditions. 
 This effect may be connected to the increased expression of TLR5, which recognises 
the main TLR-ligand of S. Typhimurium: flagellin, observed in HT29 cells stimulated with L. 
rhamnosus GG or L. plantarum BFE 1685 (Fig. 3.32 A and C). In the case of L. johnsonii 
BFE 6128, there must be other mechanisms for the observed IL-8 expression increase, which 
may explain this effect, as the expression of TLR5 at protein level was not influenced, at least 
under the conditions tested here (Fig. 3.32 B). Therefore, the effect of cellular components of 
S. Typhimurium on L. johnsonii BFE 6128 pre-treated HT29 cells was investigated next. 
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Fig. 3.34 Effect of probiotics on the response of HT29 cell in IL-8 production (pg/ml) after 
infection with S. Typhimurium. A: HT29 cells pre-treated for 2 h with a commercial probiotic strain 
LGG (L. rhamnosus GG) or probiotic candidates: BFE 6128 (L. johnsonii) or BFE 1685 (L. 
plantarum) were washed with PBS and treated with S. Typhimurium for 4 h. B: Pre-treatment of HT29 
cell with 5 x 107 CFU/well of LGG, BFE 6128 or BFE 1685 for 2 h after which cells were washed 
with PBS and incubated with DMEM for 4 h. (n=6). *P<0.05, ANOVA, Dunnett’s t-test. 
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3.9.2 L. johnsonii BFE 6128 increases the IL-8 response of HT29 cells to cellular 
components of S. Typhimurium 
 It was shown that L. johnsonii BFE 6128 was able to induce an increased IL-8 
response of HT29 cells to S. Typhimurium (Fig. 3.34 A). The interrelationship between IL-8 
and TLR pathways has been described in Fig. 1.2. Therefore, the enhanced IL-8 secreted by 
HT29 cells should somehow be related to the TLR pathways. As already mentioned, this 
effect could not be explained by an induction of increased expression of TLR receptors at 
protein level, as this strain did not increase the expression of TLR5 nor TLR9 (Fig. 3.29 B 
and 3.30 B). At the mRNA level, this strain also did not influence the TLR4 expression levels, 
when investigated by RT-PCR (Fig. 3.21) but influenced TLR9 mRNA levels. Another 
possibility to approach this question could be the identification of the putative ligand 
stemming from S. Typhimurium to which HT29 cells are sensitised by L. johnsonii BFE 
6128. 
 Thus, in an attempt to identify the component of S. Typhimurium to which L. 
johnsonii BFE 6128 enhanced the innate response of HT29 cells, cellular components from S. 
Typhimurium, which are known TLR-ligands i.e. LPS, flagellin, and DNA, were tested on 
HT29 cells pre-treated with strain L. johnsonii BFE 6128 or pre-treated only with DMEM. 
ANOVA followed by the t-test were done to determine if the differences in IL-8 secretion of 
HT29 cells pre-treated with strain BFE 6128 and HT29 cells pre-treated with medium to the 
mentioned TLR-ligands were significant, as shown in Fig. 3.35. Neither the response to LPS 
nor to DNA from S. Typhimurium were significantly (P>0.05) influenced by the pre-
treatment with L. johnsonii BFE 6128 when compared with cells pre-incubated with DMEM. 
The well known TLR9-ligand ODN2006, which is an unmethylated CpG rich sequence that 
stimulates immune cells by binding to TLR9 (Vollmer et al., 2004; Dalpke et al., 2005; Roda 
et al., 2005), did not exert a significant effect on HT29 cells either.  
 Nevertheless, pre-treatment of cells with L. johnsonii BFE 6128 enhanced the 
response to both whole cells of S. Typhimurium and to flagellin. 
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Fig. 3.35 Effect of L. johnsonii BFE 6128 on the response of HT29 cells measured as IL-8 
production (pg/ml) after infection with S. Typhimurium or its cellular components. HT29 cells pre-
treated for 2 h only with medium (black bars) or with L. johnsonii BFE 6128 (grey bars) after this, 
cells were washed with PBS and treated with S. Typhimurium (S.T.) or their components: LPS (LPS-
S.T.), flagellin (Flagellin-S.T.) or DNA (DNA-S.T.) for 4 h. ODN2006 (ODN) which is an 
unmethylated, CpG  rich  sequence, was also tested. *P<0.05, ANOVA, t-test. 
 
3.9.3 Transcriptomics: modulation of genes involved in TLR pathways 
 These experiments were done to test whether L. johnsonii BFE 6128 was able to 
modulate the expression of other TLRs or molecules involved in TLR pathways, which may 
help explaining the observed increased response of HT29 cells pre-treated with this strain to 
S. Typhimurium (Fig. 3.31 A). For this reason, HT29 cells were incubated with L. johnsonii 
BFE 6128 (5 x 106 CFU/ml) for 2 h. After this time, cells were washed with PBS twice, 
infected with 5 x 106 CFU/ml S. Typhimurium and incubated for further 4 h. HT29 cells 
treated only with medium (control cells), only with L. johnsonii BFE 6128 or only treated 
with S. Typhimurium were also analysed (see 2.6.1). At the end of the incubation period, 
RNA was isolated and expression of genes involved in TLR pathways was quantified by real-
time RT-PCR-based arrays.  
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 Modulation of genes is shown as up- or down-regulation (Fig. 3.36 to 3.43 and Table 
3.9) with respect to the control (HT29 cells treated only with DMEM) as calculated with the 
ΔΔCt method (see  2.9.7).  
 Yuan et al. (2006) described four statistical approaches to analyse, present and 
compare real-time PCR data. As a non-parametric alternative to the t-test, the Wilcoxon test 
for comparisons between two samples to analyse the pools of ΔCt values was used. In this 
study, the Kruskal-Wallis test, which is an alternative to the Wilcoxon test, was also used for 
comparisons among multiple samples. Using realistically small sample sizes, the free-
distribution Wilcoxon test is a more robust and appropriate alternative to the t-test (Yuan et 
al., 2006). The primary assumption by calculating ΔCt is that the additive effect of 
concentration, gene and replicate can be adjusted by subtracting Ct number of reference gene 
(in this case the mean of the Ct value of four housekeeping genes) from that of target gene 
(See equations in section 2.11.6.2). The ΔCt for each treatment and control (cells treated only 
with medium) can therefore be subject to both the Kruskal-Wallis test and the Wilcoxon test, 
which will yield the estimation of ΔΔCt. The results presented here were derived from testing 
the null hypothesis, i.e. that ΔΔCt is equal to 0. If P<0.05, it means that the treatment had a 
significant effect on the expression of the target gene. 
 The quality controls used were the no template control (NTC), which allowed the 
evaluation of possible contaminations of the master mix and the no reverse transcription 
control (NRT), which allowed testing the absence of genomic DNA contamination. Table 2.9 
(in the material and methods section) shows the genes included in the real-time based RT-
PCR array, Table 3.9 in this section shows relevant modulated genes. 
 As a result of the statistical analyses, it became evident that the deviations among 
replicates by analysing the expression of some target genes resulted in a non-significant 
difference between expression of these genes in control cells (treated only with medium) 
compared to treated cells as in the case of the CD14 and LY-86 genes (Fig. 3.36), while for 
others a significant difference of expression could be determined as for example for BTK or 
TICAM1 genes (Fig. 3.36). The lack of significance by the modulation of certain genes with 
an up- or down-regulation higher than 2-fold (Table 3.9), may have been a result of the too 
low sample size (n= 3 for each treatment). As a result, the discrimination sensitivity of the 
statistical test is affected and no significant differences in expression levels can be 
established. This could be improved for some of such genes if a greater sample size was used. 
Unfortunately, due to the prohibitive cost of these arrays this was not possible in this study. 
RESULTS 
 
-105- 
Nevertheless, for some target genes a significant difference could be noted with some 
important results becoming clear. 
  When HT29 cells were pre-treated with medium and afterwards infected with S. 
Typhimurium, a lot of the genes analysed were down-regulated, though not significantly. On 
the other hand, when HT29 cells were pre-treated with L. johnsonii BFE 6128 and afterwards 
infected with S. Typhimurium most of the genes were up-regulated, seventeen of which were 
significantly (P<0.05) up-regulated. This could indicate that the pre-treatment with L. 
johnsonii BFE 6128 of intestinal epithelial cells (HT29 cells) sensitises the cells to initiate 
signal transductions, which lead to the enhanced transcription of genes involved in innate 
immunity that may help responding to the pathogenic strain. 
 
Table 3.9  Up- or down-regulationa of genes involved in TLR pathways in HT29 cells by L. 
  johnsonii BFE 6128, S. Typhimurium or both 
 
Treatment DMEM (2h) + S. Typhimurium (4h)
L. johnsonii BFE 6128 (2h) 
+ S. Typhimurium (4h) 
L. johnsonii BFE 6128 
(2h) + DMEM (4h) 
Grouping Gene Symbol Fold up- or down-regulation Fold up- or down-regulation 
Fold up- or down-
regulation 
BTK -1.14 4.92b 7.23c
CD14 -1.28 1.12 2.46 
LY86    (MD-1) -1.41 4.71 9.70 
LY96   (MD-2) -1.69 2.00 5.38 
MAPK8IP3 2.37 3.01 2.33 
MYD88 -1.08 -1.13 1.14 
PELI1 1.46 1.78 -1.65 
RIPK2 1.67 2.27 -1.61 
Adaptors and 
interacting 
proteins 
TICAM1 1.36 1.84 1.34 
CXCL10 1.66 2.72 -1.74 
IFNA1 1.22 2.00 2.92 IRF Pathway 
IRF1 1.87 2.65 -2.20 
FOS 3.46 7.84 -2.51 
JUN 1.95 3.36 -1.85 JNK/p38 pathway 
MAP3K1 1.12 1.14 -1.40 
CLEC4E -1.79 3.16 7.54 NF/IL6 
pathway PTGS2 1.51 1.39 -2.23 
CCL2 -1.25 2.80 3.75 
CSF2 2.95 10.14 -2.97 
CSF3 1.89 2.65 6.81 
IFNA1 1.22 2.00 2.92 
IL6 -2.83 -1.42 1.80 
IL8 11.38 54.37 -8.75 
IL10 -1.77 3.68 7.58 
LTA 2.28 2.97 9.66 
NFKB1 1.24 1.42 -1.50 
NFKB2 1.46 2.50 -1.78 
NFKBIA 1.57 2.52 -1.91 
NF-кB 
pathway 
TNF 4.44 10.69 4.03 
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IRAK1 -1.29 -21.04 1.07 
IRAK2 1.92 3.02 -2.22 Effectors 
PPARA 1.16 1.33 -1.23 
CD80 1.03 7.65 10.64 
CD86 -1.36 2.28 6.41 
Regulation of 
adaptive 
immunity RIPK2 1.67 2.27 -1.61 
CD180 -1.46 3.56 10.94 
TLR10 -2.29 1.35 2.48 
TLR2 -1.13 3.97 8.76 
TLR5 -1.63 1.21 3.93 
TLR7 -3.14 -1.06 5.74 
TLRs 
TLR9 2.21 2.12 4.77 
Up-regulated 2 8 15 17 15 3 3 18 3 Total number 
of genes Down-
regulated 0 3 12 0 1 3 1 5 10 
 
a Up- (positive values) or down-regulation (negative values) in comparison to the control (HT29 cells 
treated only with DMEM); b light grey (notably regulated up- or down- regulation >2 fold but 
P>0.05); c dark grey significantly regulated (P<0.05) according to the results of the Kruskal-Wallis 
and Wilcoxon tests. 
  
 In the group of genes coding for adaptors and modulating proteins (Fig. 3.36), L. 
johnsonii BFE 6128 alone was only able to significantly (P<0.05) up-regulate the Bruton 
agammaglobulinemia tyrosine kinase (BTK) gene and the Toll-like receptor adaptor molecule 
1 (TICAM1) gene. When cells were pre-treated with L. johnsonii BFE 6128 and afterwards 
treated with S. Typhimurium, Mitogen-activated protein kinase 8 interacting protein 3 
(MAPK8IP3), Pellino homolog 1 (Drosophila) (PELI1), Receptor-interacting serine-threonine 
kinase 2 (RIPK2) and TICAM1 genes were significantly (P<0.05) up-regulated. S. 
Typhimurium alone only significantly up-regulated RIPK2 (Fig. 3.36 and Table 3.9). 
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Fig. 3.36 Modulation of expression of genes coding for adaptors and interacting proteins involved in TLR 
pathways. RNA was isolated from HT29 cells treated only with medium (control cells), from cells pre-treated 
with L. johnsonii BFE 6128 for 2 h and followed with a 4-h incubation with medium (white bars), from cells pre-
treated with L. johnsonii BFE 6128 and followed by a 4-h treatment with S. Typhimurium (grey bars), and from 
* 
* * 
* *
* 
* 
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cells pre-treated with medium for 2 h and followed by a 4-h-incubation with S. Typhimurium (black bars). 
*P<0.05, Kruskal-Wallis test and Wilcoxon test. 
 
 For the interferon regulatory factor (IRF) pathway, two genes, chemokine (C-X-C 
motif) ligand 10 (CXCL10) and interferon regulatory factor 3 (IRF3), belonging to the IRF 
pathway were significantly up-regulated (P<0.05), as shown in Fig. 3.37. 
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Fig. 3.37  Modulation of genes involved in the IRF pathway.  RNA was isolated from HT29 cells treated only 
with medium (control cells), from cells pre-treated with L. johnsonii BFE 6128 for 2 h and followed with a 4-h 
incubation with medium (white bars), from cells pre-treated with L. johnsonii BFE 6128 and followed by a 4-h 
treatment with S. Typhimurium (grey bars), and from cells pre-treated with medium for 2 h and followed by a 4-
h-incubation with S. Typhimurium (black bars). *P<0.05, Kruskal-Wallis, Wilcoxon test. 
 
 For the JNK/p38 pathway, the V-fos FBJ murine osteosarcoma viral oncogene 
homolog (FOS) was down-regulated by L. johnsonii BFE 6128, but up-regulated (P<0.05, 
Fig. 3.38) when both L. johnsonii BFE 6128 and S. Typhimurium were given to the HT29 
cells (Fig. 3.38).  
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Fig. 3.38  Modulation of genes involved in the IRF pathway (B).  RNA was isolated from HT29 cells treated 
only with medium (control cells), from cells pre-treated with L. johnsonii BFE 6128 for 2 h and followed with a 
4-h incubation with medium (white bars), from cells pre-treated with L. johnsonii BFE 6128 and followed by a 
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4-h treatment with S. Typhimurium (grey bars), and from cells pre-treated with medium for 2 h and followed by 
a 4-h-incubation with S. Typhimurium (black bars). *P<0.05, Kruskal-Wallis and Wilcoxon test. 
 
 V-jun sarcoma virus 17 oncogene homolog (avian) (JUN) and Mitogen-activated 
protein kinase kinase kinase 1 (MAP3K1) both belonging to the JNK/p38 pathway, were also 
up-regulated (P<0.05) when cells were pre-treated with L. johnsonii BFE 6128 and then 
infected with S. Typhimurium (Fig. 3.38). 
 Only one gene of the NF/IL-6 pathway was significantly modulated when compared 
with the untreated cells (Table 3.9). This gene was prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclo-oxygenase) also known as COX-2 (PTGS2), which 
was up-regulated (Fig. 3.39) when HT29 cells were pre-treated with L. johnsonii BFE 6128 
and followed by a 4-h treatment with S. Typhimurium, but it was down-regulated when cells 
were treated only with the probiotic candidate L. johnsonii BFE 6128 (Fig. 3.39). 
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Fig. 3.39 Modulation of genes involved in the NF-IL6 pathway. RNA was isolated from HT29 cells treated 
only with medium (control cells), from cells pre-treated with L. johnsonii BFE 6128 for 2 h and followed with a 
4-h incubation with medium (white bars), from cells pre-treated with L. johnsonii BFE 6128 and followed by a 
4-h treatment with S. Typhimurium (grey bars), and from cells pre-treated with medium for 2 h and followed by 
a 4-h-incubation with S. Typhimurium (black bars). *P<0.05, Kruskal-Wallis test, Wilcoxon test.  
 
 For the nuclear-factor κB pathway, three genes, i.e. granulocyte-macrophage colony 
stimulating factor 2 (CSF2) gene, interleukin-8 (IL-8) gene and TNF-α were significantly 
(P<0.05) up-regulated (Fig. 3.40, Table 3.9) when HT29 cells were pre-treated with L. 
johnsonii BFE 6128 and infected with S. Typhimurium. In general, it can be seen that the pre-
treatment of HT29 cells with the probiotic candidate L. johnsonii BFE 6128 induced a higher 
expression of genes involved in the NF-κB pathway in response to S. Typhimurium.  When 
naïve HT 29 cells were infected with this pathogenic strain, these same genes were also up-
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regulated but to a much lesser extent (Fig. 3.40 and Table 3.9). The same phenomenon was 
observed by other genes such as CCL2, CSF3, IFNA1, NFKB1 and NFKB2 also involved in 
these pathway but with a significance P<0.05.  
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Fig. 3.40 Modulation of genes involved in the NF-KB pathway (A and B). RNA was isolated from HT29 cells 
treated only with medium (control cells), from cells pre-treated with L. johnsonii BFE 6128 for 2 h and followed 
with a 4-h incubation with medium (white bars), from cells pre-treated with L. johnsonii BFE 6128 and followed 
by a 4-h treatment with S. Typhimurium (grey bars), and from cells pre-treated with medium for 2 h and 
followed by a 4-h incubation with S. Typhimurium (black bars). *P<0.05, Kruskal-Wallis test, Wilcoxon test. 
 
 Among effector genes associated to TLR pathways (Fig. 3.41), only two genes were 
significantly (P<0.05) modulated, and only when HT29 cells were treated with both strains. 
Interleukin-1 receptor-associated kinase 2 (IRAK2) and peroxisome proliferative activated 
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receptor alpha (PPARA) were significantly (P<0.05) up-regulated. IRAK1 gene was 
markedly down-regultated when HT29 cells were treated with both lactobacilli and S. 
Typhimurium, but the significance of this effect was P<0.05. 
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Fig. 3.41 Modulation of effector genes involved in the TLR pathways. RNA was isolated from HT29 cells 
treated only with medium (control cells), from cells pre-treated with L. johnsonii BFE 6128 for 2 h and followed 
with a 4-h incubation with medium (white bars), from cells pre-treated with L. johnsonii BFE 6128 and followed 
by a 4-h treatment with S. Typhimurium (grey bars), and from cells pre-treated with medium for 2 h and 
followed by a 4-h incubation with S. Typhimurium (black bars). *P<0.05, Kruskal-Wallis test, Wilcoxon test. 
 
 The only gene involved in regulation of the adaptive immune response which was 
significantly (P<0.05) up-regulated by S. Typhimurium alone and when cells had been pre-
treated with L. johnsonii BFE 6128 followed by a treatment with S. Typhimurium was RIPK2 
(Fig. 3.42). This gene is also included in the group of adaptors and modulating proteins. 
Nevertheless, it is worth mentioning that two genes involved in this pathway which code for 
non-classical antigen presenting molecules CD80 and CD86 were also up-regulated, though 
not significantly (P>0.05) by L. johnsonii BFE 6128 alone and by L. johnsonii BFE 6128 
followed by a treatment with S. Typhimurium (Table 3.9). 
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Fig. 3.42  Modulation of genes involved in the adaptive immunity. RNA was isolated from HT29 cells 
treated only with medium (control cells), from cells pre-treated with L. johnsonii BFE 6128 for 2 h and followed 
with a 4-h incubation with medium (white bars), from cells pre-treated with L. johnsonii BFE 6128 and followed 
by a 4-h treatment with S. Typhimurium (grey bars), and from cells pre-treated with medium for 2 h and 
followed by a 4-h incubation with S. Typhimurium (black bars). *P<0.05, Kruskal-Wallis test, Wilcoxon test. 
 
 For the TLR pathways, the CD180 gene was also significantly up-regulated (Fig. 3.42, 
Table 3.9) when both strains were present. Most TLRs were up-regulated in HT29 cells 
treated with L. johnsonii BFE 6128 alone or followed by exposure with S. Typhmurium. In 
contrast, S. Typhimurium alone down-regulated most of the TLRs. Nevertheless, the 
significance of these results was P>0.05, which can be attributed to the low number of 
replicates as mentioned above.  
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Fig. 3.43 Modulation of TLR and TLR-related genes. RNA was isolated from HT29 cells treated only with 
medium (control cells), from cells pre-treated with L. johnsonii BFE 6128 for 2 h and followed with a 4-h 
incubation with medium (white bars), from cells pre-treated with L. johnsonii BFE 6128 and followed by a 4-h 
treatment with S. Typhimurium (grey bars), and from cells pre-treated with medium for 2 h and followed by a 4-
h-incubation with S. Typhimurium (black bars). *P<0.05, Kruskal-Wallis test, Wilcoxon test.  
 
RESULTS 
 
-112- 
 Moreover, the up-regulation of TLRs correlates with the up-regulation of TLR2 and 
TLR9 by lactobacilli described before (Fig. 3. 42) as determined by real-time RT-PCR with 
own-designed primers. 
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4 DISCUSSION 
 The first criterion of this study for selection of new potentially probiotic strains was the 
ability of the strains to survive under simulated gastrointestinal conditions (Table 4.1). This 
ability should ensure that these strains reach the small intestine, which is the intended site of 
action. According to the guidelines for the evaluation of probiotics in food reported by a Joint 
FAO/WHO working group (Chesson et al., 2002), two of the currently most widely used in 
vitro tests are resistance to gastric acidity and bile salts, as based on both survival and growth 
studies. The predictability of these in vitro tests is limited, but the use of sophisticated and 
dynamic, computer models of the gastrointestinal tract, like the one developed by Marteau et 
al. (1997), is beyond the scope of most laboratories. Most of the reported studies have been 
done in acidified MRS (pH 2, 2.5, 3 and 3,5) (Chou & Weimer, 1999; Kociubinski et al., 
1999; Xanthopoulos et al., 2000; Saito, 2004) and in MRS broth containing 0.15 to 0.5 % bile 
salts (Chou & Weimer, 1999; Zarate et al., 2000; Fernandez et al., 2003). Rather than 
evaluating the effect of each component in separate experiments, it should be important to 
evaluate all components (enzymes, low pH, bile salts, duodenum secrete and food vehicle) in 
one system, as the two successive stresses of stomach transit and small intestinal transit might 
interact and thereby affect the survival of the strains in a synergistic way. On the other hand, 
acidified MRS broth does not contain the enzymes released by gastric cells nor by the 
pancreas, and MRS broth represents the optimum medium for growth of lactobacilli.  
Therefore, the Plackett-Burman design was used in this study to determine which 
variables really affect the viability of bacteria in a simple in vitro model of the stomach, 
which was later to be combined with the passage through simulated intestinal conditions. 
According to the analysis of this design, it is necessary not only to test the tolerance to low 
pH, but also the action of enzymes like pepsin and lysozyme. It is also important to consider 
the food vehicle in which the probiotic would be included, as it might exert a protective role 
and enhance the viability of bacteria. For this reason, not only was the effect of pH, but also 
that of pepsin and lysozyme included in the stomach passage model. After one hour 
incubation under simulated gastric conditions, a further treatment followed, with simulated 
intestinal fluids containing bile salts and pancreatin, which is a pool of pancreatic enzymes 
(amylases, trypsin, lipase, ribonuclease and proteases). In this way, both gastric and intestinal 
stresses were successfully combined in a simulated in vitro gastrointestinal model.  
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Table 4.1  Probiotic properties of novel Lactobacillus isolates 
 
Probiotic properties 
Probiotic candidates 
S
e
l
e
c
t
i
o
n
 
c
r
i
t
e
r
i
o
n
 
Safety Technological and functional properties Adhesive properties 
Stimulation 
of innate 
immunity 
P
h
e
n
o
t
y
p
i
c
 
a
n
d
 
g
e
n
o
p
t
y
p
i
c
 
i
d
e
n
t
i
f
i
c
a
t
i
o
n
 
S
t
r
a
i
n
 
S
u
r
v
i
v
a
l
 
u
n
d
e
r
 
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
 
c
o
n
d
i
t
i
o
n
s
 
T
r
a
n
s
f
e
r
a
b
l
e
 
a
n
t
i
b
i
o
t
i
c
 
r
e
s
i
s
t
a
n
c
e
 
O
r
i
g
i
n
 
R
e
s
i
s
t
a
n
c
e
 
t
o
 
0
.
4
 
%
 
p
h
e
n
o
l
 
A
n
t
a
g
o
n
i
s
t
i
c
 
a
c
t
i
v
i
t
y
 
a
g
a
i
n
s
t
 
f
o
o
d
-
b
o
r
n
e
 
p
a
t
h
o
g
e
n
s
 
H
2
O
2
B
s
h
 
β
-
g
a
l
a
c
t
o
s
i
d
a
s
e
 
G
r
o
w
t
h
 
o
n
 
t
h
e
 
p
r
e
b
i
o
t
i
c
 
s
u
g
a
r
 
R
a
f
t
i
l
i
n
e
 
S
T
 
C
e
l
l
 
s
u
r
f
a
c
e
 
h
y
d
r
o
p
h
o
b
i
c
i
t
y
 
C
e
l
l
 
s
u
r
f
a
c
e
 
a
c
i
d
i
c
 
c
h
a
r
a
c
t
e
r
 
C
e
l
l
 
s
u
r
f
a
c
e
 
b
a
s
i
c
 
c
h
a
r
a
c
t
e
r
 
A
d
h
e
s
i
o
n
 
t
o
 
i
n
t
e
s
t
i
n
a
l
 
e
p
i
t
h
e
l
i
a
l
 
c
e
l
l
s
 
(
H
T
2
9
)
 
C
o
m
p
e
t
i
t
i
v
e
 
e
x
c
l
u
s
i
o
n
 
o
f
 
i
n
t
e
s
t
i
n
a
l
 
p
a
t
h
o
g
e
n
s
 
A
u
t
o
-
a
g
g
r
e
g
a
t
i
o
n
 
C
o
a
g
g
r
e
g
a
t
i
o
n
 
w
i
t
h
 
f
o
o
d
-
b
o
r
n
e
 
p
a
t
h
o
g
e
n
s
 
I
n
d
u
c
t
i
o
n
 
o
f
 
I
L
-
8
 
b
y
 
H
T
2
9
 
c
e
l
l
s
 
C
y
t
o
t
o
x
i
c
i
t
y
 
o
n
 
H
T
2
9
 
c
e
l
l
s
 
BFE 1684 +++a - HFe ++b ++ Yh Y Y + +++ ++ + ++ n.d.j + ++ N - 
BFE 1685 +++ - HF ++ ++ Ni Y N ++ +++ +++ + +++ +++ + ++ Y - 
BFE 5759 +++ - Kwf ++ ++ N Y Y ++ ++ + + - n.d. ++ ++ Y - 
BFE5878 +++ - KNg ++ ++ Y Y N - ++ + + ++ n.d. + - N - 
L. 
plantarum 
BFE 5092 +++ - KN ++ ++ N Y N - + + + +++ n.d. ++ + n.d. - 
                    
BFE 6128 +++ - KN -d ++ Y Y N +++ +++ +++ +++ +++ ++ +++ +++ Y - L.  
johnsonii BFE 6154 +++ - KN +c ++ Y Y N +++ +++ +++ ++ +++ n.d. +++ +++ N - 
 
a +++: high, b ++: medium, c+: low, -d: none, eHF: Human faeces, fKw: Kwerionik, gKN: Kule naoto, hY: yes, iN: no, jn.d. not determined. 
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Resistance to bile salts is considered an important property in strains to be used as 
probiotics, however, there is still no consensus about the precise concentration to which the 
selected strain should be tolerant. The physiological concentration of bile acids in the small 
intestine varies from 5 to 20 mmol/l (Hofmann, 1991). Therefore, a concentration of 0.5 % 
oxgall, equivalent to 12.25 mmol/l  bile acids was used in this study, as was also done by 
Kociubinsky et al. (1999). This concentration is higher than the ones (0.3 % and 0.15 %) 
which have previously been used by other investigators of bacterial probiotic properties 
(Chou & Weimer, 1999; Zarate et al., 2000; Fernandez et al., 2003).  
Using this in vitro simulated stomach-duodenum passage, only a few of the 30 strains 
tested, including the reference probiotic strain L. johnsonii LA1 (BFE 663), were able to 
survive the passage under the conditions of this study. L. johnsonii LA1 was used because of 
its known good survival to gastrointestinal conditions in vivo (Holzapfel et al., 1998; 
Salminen et al., 1998). The fact that only seven strains (Table 4.1) out of thirty isolates tested 
together with this reference strain survived the passage through this model validates the 
model, since gastrointestinal conditions are considered to be detrimental to most food-
associated lactic acid bacteria, and because the probiotic control strain indicated survival 
under the conditions tested. Actually, the conditions selected in this in vitro model may have 
been even harsher than in the real situation, where the gastric pH after a meal is of approx. 3, 
and there is a continual removal of the bile salts, leading to fluctuating and often lower bile 
levels. However, this was based on a ‘worst case’ scenario, to determine the most stress 
resistant strains. As already pointed out by various workers in the field (Havenaar et al., 1992; 
McCracken & Gaskins, 1999; Bezkorovainy, 2001; Dunne et al., 2001), as well as a Joint 
FAO/WHO working group (Chesson et al., 2002), in vitro studies can only partially mimic the 
actual in situ conditions in the gut ecosystem. Nevertheless, such in vitro systems are 
powerful tools especially for screening numerous samples. 
Another test for resistance to intestinal conditions used in this study was resistance to 0.4 
% phenol (Table 4.1). Phenols may be formed in the intestine as a result of the bacterial 
deamination of some aromatic amino acids derived from dietary and endogenous proteins. 
These compounds are known to have bacteriostatic properties at least in vitro (Suskovic et al., 
1997). Hence, if they also present this bacteriostatic activity in vivo, bacteria tolerant to 
phenols may have more chances of survival than those which are not. In contrast to the high 
phenol resistance (resistance to 0.4 % phenol) which was previously reported by 
Xanthopoulus et al. (2000) and Suskovi et al. (1997) for L. acidophilus strains, the L. 
johnsonii strains in this study were highly sensitive towards this compound. This was despite 
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the fact that these bacteria are physiologically and phylogenetically closely related. In 
contrast, the results of this study on the phenol resistance of L. plantarum strains suggest that 
the latter were generally moderately tolerant. The significance of the resistance to phenol has 
not been correlated with in vivo data yet. 
Seven new potentially probiotic isolates were selected because of their good survival 
properties for further characterisation (Table 4.1). The selected strains were successfully 
characterised using both phenotypic and genotypic methods, five strains as L. plantarum, and 
the other two as L. johnsonii. These strains were further investigated for their probiotic 
properties as discussed below. Two L. plantarum strains (BFE 1684 and 1685) stemmed from 
faeces of healthy children, indicating the safe origin of the strains and also the ability of these 
strains to survive the passage through the harsh conditions in the gastrointestinal tract (Table 
4.1). The other selected strains (two L. johnsonii and three L. plantarum) stemmed from 
African traditional fermented milk products (Table 4.1). In a previous study conducted by 
Mathara et al. (2004), L. plantarum was the dominating species present in ‘kule naoto’, the 
Maasai traditional fermented milk in Kenya. Although this species has been mainly associated 
to plant-based food fermentations (Holzapfel & Wood, 1995; Stiles & Holzapfel, 1997), it has 
also been reported to be part of the microbiota of African traditional fermented milks (Isono et 
al., 1994; Beukes et al., 2001), and of traditional fermented milks and cheeses from Argentina 
(Medina et al., 2001). L. plantarum is also a normal inhabitant of the gut (Tannock, 1999), 
and therefore it is not surprising, that there are strains able to survive well under 
gastrointestinal conditions. The strain L. plantarum 299v, which was originally isolated from 
the human intestine, is a known probiotic strain that is commercialised mainly in Sweden in a 
lactic acid fermented oatmeal gruel, that is mixed in a fruit drink (Molin, 2001; 
Pathmakanthan et al., 2004). This could be also an interesting alternative for developing a 
probiotic product with no milk or milk constituents using the L. plantarum strains 
characterised in this study. 
The two selected L. johnsonii strains were isolated from Kule naoto, but they were 
present in low numbers in this product and were not a representative important and 
predominant species in the microbiota of this fermented milk (Mathara et al., 2004). They had 
been previously characterised as L. acidophilus (Mathara et al., 2004), but in this study it was 
clearly shown that although they showed phenotypic properties typical of L. acidophilus, they 
actually belong to L. johnsonii species, as assessed by more accurate genotypical methods. L. 
johnsonii also belongs to the normal microbiota of the intestine and is one of the first species, 
after Bifidobacterium spp., which colonises the gut of newborns (Vaughan et al., 2002). The 
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strain L. johnsonii LA-1, which had been isolated from the human intestine, is a probiotic 
strain used world-wide and which has proven gastrointestinal survival (Salminen et al., 1998; 
Felley et al., 2001; Holzapfel et al., 2001). Although the L. johnsonii strains of this study have 
not been isolated from humans, they originate from a traditional ‘domesticated’ environment, 
and associated with fermented milk, they would e most suitable for development of probiotic 
products. 
A major requirement for probiotic strains is that they should be safe for human 
consumption. In order to assure the safety of bacteria used in food, the European Food Safety 
Authority (EFSA) has initiated a ‘Qualified Presumption of Safety’ concept which, similar to 
the GRAS system in the USA, has the purpose of allowing strains with long history of safe 
use and status to enter the market without extensive testing requirements ((EFSA), 2004). 
Antibiotic resistance is one of the safety concerns included in the QPS concept to determine a 
strain’s QPS status. The reason for this is the hypothesis that food bacteria may act as 
reservoirs of antibiotic resistance genes (Chesson et al., 2002; Danielsen & Wind, 2003; Franz 
et al., 2005). In a survey of 62 Lactobacillus starter strains, Danielsen and Wind (2003) found 
a high level of resistance to aminoglycosides for all investigated lactobacilli. Similar results 
were also found by Charteris et al. (1998) and Katla et al. (2001). These authors concluded 
that resistance to aminoglycosides among lactobacilli is a natural, i.e. intrinsic trait, which has 
been attributed to the absence of a cytochrome-mediated electron transport, that mediates 
uptake of aminoglycosides (Charteris et al., 2001). Danielsen and Wind (2003) also suggested 
that resistance to ciprofloxacin appeared to constitute a natural or intrinsic resistance. 
Considering these data, the only antibiotic resistances which were observed for the strains in 
this study, i.e. resistance towards ciprofloxacin and aminoglycosides, were considered to be 
intrinsic or natural resistances. Conversely, the strains selected in this study did not contain 
any of the transferable, acquired resistances which are known to occur among LAB and 
include resistances towards e.g., chloramphenicol, erythromycin and tetracycline (Danielsen 
& Wind, 2003). Therefore, the strains selected in this study do not pose a risk for consumers 
with respect to antibiotic resistance transfer to other gut-associated bacteria (Table 4.1). 
Some variability was noted in the pathogen inhibition profiles of the Lactobacillus strains 
tested. All the probiotic candidates of this study were able to inhibit at least to some extent 
some pathogenic strains associated with food, as indicated by the results of the agar spot test 
(Table 4.1). This antagonistic activity was not due to the production of a bacteriocin, because 
they did not inhibited related strains and the neutralised supernatants did not show inhibitory 
activity. As the plates were incubated anaerobically, the antimicrobial effect was not thought 
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to be due to H2O2 production. Thus, the inhibition of the indicator strains most probably was 
due to the production of organic acids. Under aerobic conditions, both L. johnsonii strains 
BFE 6128 and BFE 6154 strains and L. plantarum strains BFE 1684 and BFE 5878 were able 
to produce H2O2, showing that this is a strain-specific trait, because other strains belonging to 
the same species did not produce H2O2 (Table 4.1). Production of this antimicrobial 
compound by lactobacilli has been described before (Annuk et al., 2003; Servin, 2004) but its 
specific role is still unclear. H2O2-producing lactobacilli are especially found in the vagina of 
healthy women and the presence of these bacteria have been associated with a lower 
frequency of vaginosis as they can, for example, inhibit gonococci (Servin, 2004). H2O2-
producing lactobacilli able to coaggregate with pathogens may exert an antagonistic effect in 
the close proximity, resulting from the coaggregate formation. Therefore, it would be 
interesting to test in vivo if the lactobacilli selected in this study also display these properties 
(coaggregation and H2O2 production) in the vaginal microenvironment. The significance of 
this property in the small intestine has not been reported yet, but we hypothesise that this 
could be possible in a transitional segment of the GIT, such as the duodenum, where the 
conditions are microaerophilic, rather than anaerobic. 
Whether Bsh activity is correlated with high tolerance to bile salts is still under debate. 
While some researchers sustain that deconjugation of bile salts might be a detoxification 
mechanism of vital importance to the Lactobacillus cell, and thus play an important role 
during colonisation of the gastrointestinal tract (Tannock et al., 1989; De Smet et al., 1995; 
Usman & Hosono, 1999; De Boever et al., 2000), others infer that the higher toxicity of the 
deconjugated salts might more strongly affect the viability of the bacterium (Grill et al. 2000). 
Bsh activity is a controversial probiotic property, particularly because the primary bile salts 
can be hydroxylated by 7α-hydroxylating bacteria in the gut (e.g. clostridia) and thus 
converted to secondary bile salts which are pro-carcinogenic (Marteau et al., 1995). Tanaka et 
al. (1999) have found a correlation between the habitat of lactic acid bacteria species and the 
presence of Bsh activity. Thus, lactic acid bacteria isolated from human intestine or faeces 
were Bsh positive, whereas those of food-origin were mostly Bsh-negative (Tanaka et al., 
1999). In contrast, all selected strains of this study exhibited Bsh regardless of their origin 
(fermented milk or human faeces; Table 4.1). Bsh activity is considered a functional property, 
which has also been suggested to be important in lowering serum cholesterol levels (du Toit et 
al., 1998; Pereira et al., 2003). Accordingly, deconjugation of bile acids to primary bile salts 
by Bsh-positive bacteria leads to an increased demand of cholesterol from which bile salts are 
synthesised de novo in the liver, and thus may lead to decreased serum cholesterol. This has 
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been observed in short-term studies using Bsh positive enterococci or lactobacilli (De Smet et 
al., 1998; du Toit et al., 1998; Agerholm-Larsen et al., 2000), although the effect was unclear 
in long-term studies (Richelsen et al., 1996).  
Interestingly, in a study of cholesteremia in a tribe of Maasai conducted by Mann and 
Spoerry (1974), serum cholesterol levels of Maasai men decreased after consumption of large 
amounts of milk fermented with a wild Lactobacillus strain. Though, the significance of those 
results is difficult to extrapolate to people with a typical western life-style diet, the Maasai 
have a quite different diet, which is mostly based on milk and fermented milk, as they rarely 
consume grain or fruit (McAdams Wright, 2006). Four of the strains selected in this study 
based on the property of good survival under gastrointestinal conditions stemmed from ‘Kule 
naoto’, the traditional fermented milk from the Maasai. The four isolated strains possessed 
Bsh activity, and therefore their potential for lowering cholesterol levels should be further 
investigated. The results presented in this study show that not only the isolates of the Maasai 
fermented milk, but all the isolates in this study, including the probiotic L. johnsonii LA1 
control strain, were Bsh positive. This indicates that this property should be a valuable trait 
for these bacteria, which may be connected with either survival or colonisation in the 
gastrointestinal tract. However, the significance of their Bsh activity is not yet clear. Whether 
this trait may play a positive role in reduction of serum cholesterol levels, would need to be 
further investigated in vivo. 
Lactose maldigestion may be improved with therapy, utilising bacteria from fermented 
milk products which contain the lactose cleaving enzyme β-galactosidase (Hove et al., 1999; 
Szilagyi, 2002). Probiotic bacteria such as some of the strains characterised in this study, 
which possess this activity (Table 4.1), might also be used for compensation of lactase 
insufficiency.  Some authors sustain that yogurt bacteria are more efficient for treatment of 
lactose intolerance, because they do not survive gastrointestinal conditions as well as 
probiotic bacteria. Thus, the yoghurt bacteria release the lactase enzyme after disruption of the 
cell wall as a result of bile sensitivity in the small intestine (Gilliland & Kim, 1984; 
Schrezenmeir & de Vrese, 2001). On the other hand, Zarate et al. (2000) have reported that β-
galactosidase activity was severely affected at pH 2. Therefore, if the enzyme is not release 
during the passage through the stomach, the activity of the enzyme is preserved until reaching 
its site of action in the small intestine. This is also supported by a study in humans on the 
improvement of lactose intolerance with fermented milks (Mustapha et al., 1997), where it 
was shown that a L. acidophilus strain, which exhibited the lowest β-galactosidase activity 
and lactose transport but the greatest bile and acid tolerance among the strains tested, was the 
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most effective in improving lactose digestion and tolerance. Thus, Mustapha et al. (1997) 
proposed that bile and acid tolerance may be other important factors to consider when 
Lactobacillus strains are selected for improving lactose digestion and tolerance. Another 
aspect is that lactose can also be used as carbon source for growth by β-galactosidase-positive 
bacteria, and it has therefore been proposed as a potential prebiotic sugar (Szilagyi, 2002). 
However, the use of this sugar as a prebiotic in persons with lactose intolerance would 
obviously not be recommended. In conclusion, strains such as L. plantarum BFE 5759 or BFE 
1684 characterised in this study, with good tolerance to gastrointestinal conditions and high β-
galactosidase activity, should be considered for further in vivo studies as they may contribute 
to alleviate symptoms of lactose intolerance. 
From the seven probiotic candidates investigated in this study, only four (L. johnsonii 
BFE 6154 and BFE 6128 and L. plantarum BFE 1685 and BFE 5759, Table 4.1) were able to 
grow to some extent on the prebiotic sugar Raftiline® ST. A combination of these 
Lactobacillus strains and this compound could, therefore, be used for developing a synbiotic 
product, which would provide the probiotic effects of the selected strains and at the same time 
would support the growth of the lactobacilli contained in the product. In addition, Raftiline® 
ST  would also contribute with the proven ‘bifidogenic effect’ of prebiotics in the gut 
(Bielecka et al., 2002). 
Bacterial attachment to cells of the intestinal mucosa is considered a very important 
criterion for selection of probiotic strains, as it allows bacterial strains to at least prolong their 
transit time through the intestine, allowing them to exert their beneficial interactions or 
possibly colonise the intestine (Lehto & Salminen, 1997a; Blum et al., 1999). Intestinal 
epithelial cell lines have been used extensively to perform comparative studies of adhesion 
properties of probiotic strains (Lehto & Salminen, 1997a; Blum et al., 1999; Lee et al., 2000). 
The human colon carcinoma HT29 cell line used in this study was established in 1964 by 
Jorgen Fogh (Rousset, 1986). This cell line expresses two important differentiation features 
which are characteristic of mature intestinal cells: tight junctions and a typical brush border. 
When cells are grown in the absence of serum, they secrete lysozyme and half of the cells 
differentiate as goblet-like cells (Rousset, 1986). In addition, the time-course of the 
differentiation process, with exponentially dividing cells being undifferentiated and the 
differentiation taking place when cells stop dividing, mimics the situation found in the small 
intestine, with dividing crypt cells being undifferentiated and with the differentiation taking 
place during the crypt to villus migration of non-dividing cells. There are, of course, 
limitations to this model. These cells are not normal but malignant cells, and they do not 
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derive from the small intestine, but from the colon. In spite of these facts, these cells have 
been proven to be useful tools for the investigation of intestinal cell differentiation, function, 
the adhesion and invasion of bacteria and parasites, to name but a few (Rousset, 1986; 
Kerneis et al., 1992; Jung et al., 1995; Blum et al., 1999; Lammers et al., 2002; Lee et al., 
2005). Although mucus-producing epithelial cells in tissue culture are available, this study 
focused on the cell-cell interaction of eukaryotic cells with bacteria from two different points 
of view, i.e. the binding interaction and the elicitation of a cytokine response as a result of this 
binding interaction. For this reason, mucus-secreting cells were not used, as it was also the 
case in most other binding studies, because of the possible interference of mucus with binding 
and signal transduction (Lehto & Salminen, 1997a; Blum et al., 1999; Del Re et al., 2000; Lee 
et al., 2000). However, the role of the mucus in inhibiting binding of bacteria to the epithelial 
cells should not be forgotten. There are several direct and indirect methods for studying 
adhesion potential in vitro, but there is still no consensus about the optimal method that can 
actually predict microbial adhesion in vivo (Blum et al., 1999). Nevertheless, it is widely 
accepted that the level of adhesion of a probiotic strain under a given assay condition (often 
expressed as percentage adhesion) does not constitute an absolute value and has to be 
evaluated in relation to non-adherent strains tested under the same conditions. In this and 
other studies (Tuomola & Salminen, 1998; Tuomola et al., 1999), the L. casei strain Shirota, 
known to adhere weakly to intestinal epithelial cells, was used as a negative control. Another 
relevant point when comparing the binding of different strains, is to maintain the amount of 
bacteria added to the system at similar levels, because the number of bound bacteria is 
influenced by the number of bacteria added to the assay (Tuomola & Salminen, 1998; Lee et 
al., 2000). Both factors, the inclusion of a negative control and the maintenance of the same 
inoculum of probiotic bacteria or probiotic candidates (as determined by plating) were 
considered in the adhesion assay in this study. The inclusion of strains with good adherence 
properties (L. johnsonii  LA-1 and L. rhamnosus GG), which have also been shown to persist 
in the gastrointestinal tract (Holzapfel et al., 1998; Salminen et al., 1998; Alander et al., 1999) 
also contributed to validate the adhesion assay used in this study. Not all the strains tested in 
this study could be described as adherent strains (Table 4.1). However, two L. johnsonii 
strains (BFE 6128 and BFE 6154), isolated from Maasai milk were strongly adherent, as 
expressed by percentage values much higher than those observed for the commercial probiotic 
strains (L. rhamnosus GG and L. johnsonii LA-1) used as positive controls in this study.  
Adhesion of bacteria to animal cells is a much more complex phenomenon than adhesion 
of bacteria to inanimate surfaces. This is because of the complexity of both microbial cell 
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surfaces and eukaryotic membranes, and the ability of living cells to regulate the expression 
of molecules on their surface in response to changes in the environment. Thus, this process 
involves non-specific, as well as specific ligand-receptor mechanisms (Gordon et al., 1985). 
Hydrophobic interactions contribute in the initial adhesion of numerous pathogens to tissues 
(Doyle, 2000). As early as 1924, Mudd and Mudd  (1924) demonstrated that bacteria can vary 
considerably in their degree of hydrophobicity. Furthermore, it was suggested that bacteria 
with high hydrophobic surfaces may reversibly adhere to intestinal cells (van Loosdrecht et 
al., 1987; Del Re et al., 2000; Ehrmann et al., 2002). However, other authors have reported no 
correlation between hydrophobicity and adhesion (Conway & Reginald, 1989; Vinderola et 
al., 2004). The values of the microbial adhesion to solvents test obtained with n-hexadecane 
reflect the hydrophobicity of the bacterial surface, whereas the values obtained with 
chloroform and ethyl acetate in this test can be regarded as a measure of the electron donor 
(basic) and electron acceptor (acidic) characteristics of the cell walls, respectively (Bellon-
Fontaine et al., 1996). The two selected L. johnsonii strains (BFE 6154 and BFE 6128) 
studied showed both a high affinity for the hydrophobic solvent n-hexadecane and for the 
polar solvents chloroform and ethyl acetate (Table 4.1). This indicates that the surface of 
these strains is able to simultaneously interact with charged (hydrophilic) and non-charged 
(hydrophobic) molecules. A relationship between adhesion to intestinal mucus and 
amphiphatic characteristics has been also described (Collado et al., 2006) very recently. Thus, 
it appears that this bivalent nature of the cell surface of the L. johnsonii strains of this study 
may point towards a high adhesion to intestinal epithelial cells, as indicated by the adhesion 
assay results presented above.  
 However, adsorption to surfaces is a non-selective process that is only a part of the 
multistep phenomenon of adhesion. Nevertheless, it is still important, as it brings two surfaces 
close enough to permit possible adhesins and cell receptors to interact with each other 
(Gordon et al., 1985; Abraham et al., 1999). A great variability in adhesion to HT29 cells was 
found among L. plantarum strains (Table 4.1). One of the strains (L. plantarum BFE 5759) 
was non-adhesive, another was moderately adhesive (L. plantarum ATCC 8014) and four 
strains (L. plantarum BFE 5878, BFE 5092, BFE 1685, and BFE 1684) were strongly 
adhesive. Strains which showed poor adhesion to HT29 cells (L. paracasei BFE 675, L. casei 
Shirota BFE 688 and L. plantarum BFE 5759) showed variable values of adhesion to n-
hexadecane and chloroform, but all had low adhesion values to ethyl acetate. The non-
adhesive Lactobacillus strains in this study, therefore, appeared to have a weak acidic surface 
character as indicated by an affinity for a basic solvent (ethyl acetate), a variable 
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hydrophobicity and a moderate to strong basic character (as indicated by an affinity for an 
acidic solvent such as chloroform). In conclusion, the characterisation of the physicochemical 
properties of a particular strain may help explaining how this particular strain interacts at the 
first stages of the multistep process of adhesion to the intestinal cell. A generalisation is not 
possible as it has been shown by this and other studies (van Loosdrecht et al., 1987; Conway 
& Reginald, 1989; Del Re et al., 2000; Ehrmann et al., 2002; Vinderola et al., 2004), that 
there are always exceptions to the rule and no absolute correlation between hydrophobicity 
and adhesion can be established. Most of these studies only studied the hydrophobic character 
of the cell surfaces, but did not investigate the hydrophilic properties (including its acid/base 
properties). In this study, it was shown that lactobacilli with amphiphilic surfaces adhered 
well to HT29 cells. Therefore, it may be inferred, that the amphiphilic character of the 
surfaces allows bacteria to be more versatile in their interactions with complex surfaces, such 
as eukaryotic membranes. 
 Pelletier et al. (1997) reported similarities among the physicochemical surface properties 
of strains of the same species and suggested the use of these properties in a taxonomic 
perspective for microbial classification. The results shown in this study disagree with this 
suggestion, as important variations in the surface properties of bacteria of the same species 
(e.g. L. plantarum) occurred.  
 Strains isolated from traditional fermented products were shown to be capable of 
adhering well to intestinal epithelial cells (HT29) in this study, indicating that not only human 
isolates possess this property. Strains of the same species showed different adhesion 
capability, confirming that adhesion is a strain-specific property as it has been suggested 
before (Jacobsen et al., 1999; Todoriki et al., 2001). In the case of L. johnsonii BFE 6128 and 
BFE 6154, this could be due to the fact that they not only adhered individually, as in the case 
of L. johnsonii LA-1, but also formed big clusters. Some of the L. plantarum strains adhered 
individually and others in pairs or short chains as could be observed microscopically in this 
study. 
 In addition, Del Re et al. (2000) and Kos et al. (2003) suggested that auto-aggregation 
can also be correlated to adhesion to intestinal epithelial cells. Cesena et al. (2001) have 
shown that the gastrointestinal persistence in vivo, as well as the adhesion to epithelial cells in 
vitro, was higher for a L. crispatus strain with an aggregating phenotype, than for its non-
aggregating mutant. Auto-aggregation and coaggregation have also been related to the ability 
to interact closely with undesirable bacteria (Gusils et al., 1999; Ehrmann et al., 2002). In this 
study, strains of L. johnsonii auto-aggregated well and also adhered to intestinal epithelial 
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cells. L. plantarum strains generally auto-aggregated to a lesser extent than the L. johnsonii 
strains (Table 4.1). While most of the L. plantarum strains (BFE 1684, BFE 1685, BFE 5878 
and BFE 5092) adhered well to HT29 cells, L. plantarum strain BFE 5759 was non-adherent, 
even though its auto-aggregation ability was similar to the other highly adherent L. plantarum 
strains. The non-adherent strains L. paracasei BFE 675 and L. casei Shirota (BFE 688) also 
did not auto-aggregate well. Some authors (Boris et al., 1998; Del Re et al., 2000; Ehrmann et 
al., 2002) have suggested that auto-aggregation of probiotic bacteria is strongly related to 
adhesion. Generally, the results of this study also suggested that the majority of bacteria 
which were able to auto-aggregate, also adhered well to epithelial cells, although this was not 
the case for L. plantarum strain BFE 5759. Thus, it may be speculated that auto-aggregation 
may indeed be related to adhesion, but this relationship may not be exclusive, because 
exceptions were noted. Since a general trend between auto-aggregation and the level of 
adherence to intestinal epithelial cells was suggested by the results of this study, the auto-
aggregation test may serve as an indicator of potentially probiotic strains with good adherence 
ability in initial screening experiments. However, since it was clearly shown that there may be 
exceptions to this indicative ability, adherence studies in cell cultures remain of great 
importance and cannot be replaced by auto-aggregation tests.  
 Apart from possibly serving as an indicator to adherence ability, the auto-aggregation 
phenotype is an interesting probiotic property, as it plays an important role in colonisation of 
the oral cavity (Kolenbrander, 1995) and the urogenital tract (Boris et al., 1998), as well as in 
the gastrointestinal persistence of the microorganisms in vivo (Cesena et al., 2001). For L. 
johnsonii strains BFE 6154 and BFE 6128, auto-aggregation was enhanced when tested in 
their own overnight supernatant (at pH of approx. 4.0), and it was considerably higher than 
that observed in PBS at pH 4.0. This indicated that auto-aggregation was not a pH-dependent 
effect but was potentiated by the presence of an auto-aggregating factor in the supernatant, as 
it has been reported before for other lactobacilli (Schachtsiek et al., 2004). It has also been 
hypothesised, that one of the mechanisms through which lactic acid bacteria protect the host 
from infections is by their ability to coaggregate with intestinal pathogens and uropathogenic 
bacteria (Reid et al., 1988; Huis in't Veld et al., 1994). A strong inclination to auto-
aggregation does not imply a strong coaggregation property, but it has been observed that 
strains with high coaggregation ability also show high auto-aggregation (Ehrmann et al., 
2002). This was also supported by our findings, because the strains with the highest 
coaggregation scores also auto-aggregated strongly. However, exceptions were noted because 
L. johnsonii LA-1 (BFE 663), which had high auto-aggregation values, did not coaggregate 
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with S. aureus and only weakly with List. monocytogenes. Previous coaggregation studies 
have been limited to bacteria from human origin. Schachtsiek et al. (2004) were the first to 
report coaggregation of Lactobacillus coryniformis, a food- or feed-associated bacterium, 
with pathogens. Thus, L. coryniformis was able to coaggregate with E. coli K88, 
Campylobacter jejuni and Campylobacter coli, but not with S. Typhimurium, Clostridium 
perfringens and List. monocytogenes. In this study, the first Lactobacillus johnsonii strains of 
food origin able to coaggregate with human pathogens (List. monocytogenes, S. aureus, 
enterotoxigenic E. coli and S. Typhimurium) were reported (Table 4.1),  which coaggregated 
to even a higher degree than the commercial probiotic strains L. rhamnosus GG, L. johnsonii 
LA-1 (BFE 663) and L. casei Shirota (BFE 675). Strains (especially the L. plantarum strains 
because of their inherent fermentative versatility) with this property could be of special 
interest to the food industry, because coaggregates may be formed in the food matrix, and 
thereby prevent the entrapped pathogens from adhering to host cells when ingested 
(Schachtsiek et al., 2004). On the other hand, increased numbers of S. aureus together with 
decreased numbers in lactobacilli and bifidobacteria in the intestinal microbiota of infants 
have been associated with atopic dermatitis (Bjorksten et al., 2001; Watanabe et al., 2003). 
For these reasons, consumption of products enriched with prebiotics and probiotic bacteria 
such as the strains presented in this study, would compensate the intestinal microbial 
imbalance (by increasing the numbers of lactobacilli and bifidobacteria) in patients with 
atopic dermatitis. Furthermore, it could also help excluding S. aureus through coaggregation, 
by preventing the pathogen to adhere to IEC and by inhibiting the pathogen by production of 
inhibitory substances such as organic acids in the close proximity resulting from the formation 
of the coaggregate. Another reason why exclusion of S. aureus would be beneficial is that 
nasal and intestinal carriage of S. aureus in hospitalised patients has been shown to be a risk 
for subsequent infections, especially the emergence of methicillin- and multiresistant S. 
aureus (Vesterlund et al., 2006). The use of probiotic strains, such as the lactobacilli 
characterised in this study, may also serve as a supportive or preventive treatment. 
Diarrhoea acquired in developing countries is caused mainly by viruses and bacteria such 
as enterotoxigenic E. coli, Campylobacter, Salmonella spp. (non-typhoid) and Shigella spp. 
(Yates, 2005). If this acute disease is acquired by people travelling to these destinations, it is 
known as traveller’s diarrhoea. In general, although this disease is rarely life-threatening, it 
results in significant morbidity, as it affects millions of people (Guandalini, 2002). Probiotic 
preparations have been suggested as preventive/supportive therapy and/or post-therapy after 
treatment with antibiotics, to help re-establishing the microbial balance in the GIT and so 
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prevent antibiotic-associated diarrhoea (Isolauri et al., 1991; Kaur et al., 2002; Yates, 2005). 
Enterococcus spp. on the other hand, have been recognised as major opportunistic pathogens 
causing bacteraemia, endocarditis, urinary tract infections in the hospital environment and 
they can act as potential recipients of vancomycin recipient genes (Franz et al., 1999; 
Bertuccini et al., 2002; Klein, 2003). Listeriosis is a food-borne disease, which is 
characterised by meningitis, septicaemia and foetal death (Gahan & Hill, 2005). List. 
monocytogenes is an intracellular parasite, and the GIT is thought to be the primary site for 
entry through epithelial cells (Finlay & Falkow, 1997; Gahan & Hill, 2005). Therefore, the 
inhibition of this invasion step would prevent the further translocation to the spleen and liver, 
where List. monocytogenes cells multiply, and the following bacteraemia. Because of this 
background, and because adhesion is considered the first step of pathogenicity (Finlay & 
Falkow, 1997), two selected Lactobacillus strains were tested for their ability to inhibit 
adhesion to intestinal cells of such important pathogens as vancomycin-resistant Ent. faecium 
DSM 13590, S. Typhimurium ATCC 14028 and List. monocytogenes Scott A, which cause 
considerably morbidity world-wide. 
It is expected that a sufficient amount of a probiotic bacteria must be consumed so that 
the probiotic strains may exert their beneficial effect (Lee et al., 2000). It has also been shown 
that some probiotic strains able to inhibit adhesion of pathogens only do so, when present at a 
higher concentration than the pathogen itself (Mack et al., 1999; Lee et al., 2000). This can 
also be related to the fact that probiotic bacteria are present in probiotic formulations in high 
numbers, and pathogens usually occur in low numbers, and in spite of this, they cause disease 
as their infective dose is generally quite low. For these reasons, higher concentrations of 
lactobacilli were also used in the adhesion inhibition assays of this study. Similar to a 
previous report of an inhibition model with Caco-2 cells (Lehto & Salminen, 1997b), L. 
rhamnosus GG also did not inhibit S. Typhimurium adhesion to HT29 cells in this study. Two 
strongly adherent strains, L. plantarum BFE 1685 and L. johnsonii BFE 6128, however, were 
able to significantly reduce the adhesion of the human pathogens E. coli and List. 
monocytogenes in HT29 cell culture. In addition, L. plantarum BFE 1685 also reduced the 
adhesion of the Ent. faecium and S. Typhimurium strains used in this study. A slight 
inhibition of S. Typhimurium ATCC 14028 by the non-adhesive L. casei Shirota was also 
observed, which seemed not to depend on competitive exclusion for adhesion sites, because L. 
casei Shirota adhered poorly to HT29 cells. Instead, it might depend on another antagonistic 
mechanism such as the production of non-lactic acid molecules with antimicrobial properties 
as has been described before (Fayol-Messaoudi et al., 2005). The spectrum and magnitude of 
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the inhibition of adhesion, as well as the auto-aggregation and coaggregation properties of the 
selected L. plantarum and L. johnsonii strains (Table 4.1), suggest that the mechanisms 
involved in inhibition of adhesion are different. More studies are needed to elucidate if this is 
due to unspecific steric hindrance or a specific mechanism involving adhesins. Adhesion of 
pathogenic bacteria to mucosal surfaces is considered as the first step of intestinal infections 
(Finlay & Falkow, 1997). Nevertheless, the findings of this study demonstrate the ability of 
live lactobacilli, especially L. plantarum BFE 1685 and L. johnsonii BFE 6128, to interfere 
with pathogens through mechanisms such as production of organic acids and H2O2, 
coaggregion and competition for adhesion sites. 
In general, both strains of human origin and strains isolated from food were able to resist 
simulated gastrointestinal conditions, inhibit pathogens, coaggregate with pathogens and 
inhibit their adhesion to IEC (Table 4.1). This may suggest that no host-specificity is needed 
for probiotic activity. 
The intestinal mucosa is the main interface between the immune system and the intestinal 
lumen. It does not only function as a physical barrier, which is constantly exposed to 
exogenous compounds such as food, microorganisms and their metabolites, but it can also 
generate signals for communication with underlying mucosal immune inflammatory cells 
(Haller et al., 2000; Saegusa et al., 2004). Thus, antigen processing and signalling by 
epithelial cells are primary steps of innate and adaptive defence mechanisms in the earliest 
phases after invasion by pathogens. Non-pathogenic bacteria also elicit a response, but their 
mechanism of immune stimulation have been even less elucidated.  
There are contradictory reports about the spectrum of cytokines secreted by intestinal 
epithelial cells (Stadnyk, 1994; Kolios et al., 1999; Stadnyk, 2002; Colgan et al., 2003). This 
could be a reflection of the fact that studies which reported secretion of cytokines such as IL-
10 included intestinal mucosa isolated from biopsies. Such intestinal mucosa not only 
contains epithelial cells, but also different immune cell populations from the epithelial lining 
(such as intraepithelial lymphocytes, Fig. 1.3) and the lamina propria, which are difficult to 
separate from the thin enterocyte layer (Stadnyk, 2002). Vidal et al. (2002) reported TNF-α 
secretion by HT29 cells at very low levels (14 pg/ml) when stimulated with LPS. Jung et al. 
(1995) reported TNF-α secretion (5 to 188 pg/ml) by HT29 cells after exposure to invasive 
Gram-positive and –negative bacteria, but this CK was not secreted after stimulation with 
LPS. In this study, neither LPS stimulation of HT29 cells nor exposure to Lactobacillus 
strains induced TNF-α at the protein level.  
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IL-6 has been shown to be secreted by intestinal epithelial Caco-2 cells stimulated with 
bacteria (Hosoi et al., 2003), but IL-6 was not detected in supernatants of HT29 cells upon 
stimulation with the Lactobacillus strains nor LPS in this study. In addition, IL-6 secretion by 
HT29 cells has not been reported yet. Therefore, the absence of IL-6 secretion in this study 
may be due to inherent variations which occur from cell line to cell line in the repertoire and 
levels of cytokine secretion, which depend in part on the degree of cell differentiation (Böcker 
et al., 2000). In addition, they may also depend on bacterial species/strain specific effects, i.e. 
other strains not tested here may be able to induce IL-6.  
Jung et al. (1995) showed that HT29 cells secreted MCP-1 in response to Gram-negative 
invasive pathogens and to List. monocytogenes, but not in response to LPS. None of the 
Lactobacillus strains of this study were able to induce the secretion of this CHK. 
Under the conditions investigated in this study, it was demonstrated that some strains 
modulated IL-8 levels secreted by HT29 cells in a strain-specific fashion (Table 4.1). Thus, L. 
johnsonii BFE 6128 and L. plantarum BFE 1684 and BFE 5759 enhanced IL-8 secretion, but 
this was considered a weak enhancement when compared to the stimulatory effect observed 
with LPS under the same conditions. This IL-8 induction was not due to cytotoxicity effects, 
as HT29 cell vitality was not affected by lactobacilli under the conditions tested (Table 4.1). 
A similar weak IL-8 induction in intestinal epithelial cell cultures was also previously 
reported for the non-pathogenic Bacillus subtilis natto (Hosoi et al., 2003) and S. cerevisiae 
(Saegusa et al., 2004) bacterial and yeast strains isolated from food. He et al. (2002) also 
found that Bifidobacterium spp. of human origin stimulated other pro-inflammatory CKs in a 
macrophage cell line. In healthy individuals, such a weak immune stimulation might result in 
keeping the immune system alert and in a condition of readiness to react with an 
inflammatory response if challenged by pathogenic bacteria (Saegusa et al., 2004). He et al. 
(2002) have also suggested that the increase of non-pathogenic bacteria with pro-
inflammatory properties, such as bifidobacteria, may contribute to the homeostasis of local 
immunity by preventing local inflammation from being over-suppressed by mainly 
opportunistic and endogenous infective bacteria, which have been found to strongly trigger 
anti-inflammatory CK production. This could be of special interest for aged people, who have 
a distinct aged-related intestinal microbiota with more facultative anaerobic Gram-negative  
bacteria (O'Sullivan, 1999). Nevertheless, it should not be forgotten that a much stronger 
induction of these pro-inflammatory CK by lactobacilli or bifidobacteria alone would destroy 
the balance that they need as normal inhabitants of the intestine to live in harmony with their 
host. In contrast, the typical reaction after invasion of epithelial cells by pathogens is (and 
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should be) in most of the cases a high increase of IL-8, which in vivo may serve as the signal 
for initiation of the acute inflammatory response to eliminate the threat (Schulte et al., 1996; 
Wilson et al., 1998). As already mentioned, pathogenic strains also induce in intestinal cells 
other pro-inflammatory CKs, all involved in initiation and amplification of the immune 
response (e.g. TNF-α, MCP-1, IL-6). It seems that the intestinal epithelium does not respond 
to all bacterial species in the same way, with some bacteria inducing a strong cytokine release, 
and others eliciting a mild or no response. Therefore, it could be hypothesised that the signals 
(a specific array of pro-inflammatory CKs) elicited by IEC to activate immune cells in the 
lamina propria may be differential and hence allow distinguishing between tolerance and 
reactivity. 
However, cytokine responses of epithelial cells are also influenced by immune cells 
(Haller et al., 2000). Therefore, the modulation of the further immune reaction course, which 
involves innate and adaptive components, is generally undertaken by professional immune 
cells of the lamina propria. Accordingly, it is hard to predict the outcome of the observed IL-8 
stimulation by lactobacilli on the further development of an immune response, especially if 
such interactions were tested in cell culture in the absence of immune cells of the lamina 
propria. As an example, the probiotic strain E. coli Nissle 1917, which exhibited anti-
inflammatory properties in animal studies, actually induced pro-inflammatory IL-8 production 
by HT29 cells in vitro (Lammers et al., 2002). Therefore, the data of this study strongly 
suggest that L. plantarum BFE 1685 and BFE 5759, and L. johnsonii BFE 6128 strains 
interacted specifically with enterocytes without assistance from other specialised cells of the 
immune system. However, the further course of this immune stimulation cannot be predicted 
and should be determined in animal experiments or human volunteer studies. 
It is well known that IL-8 secreted by intestinal epithelial cells recruits and activates 
neutrophils, basophiles, lymphocytes and monocytes in the adjacent lamina propria (Schulte 
et al., 1996; Campbell et al., 2001; Beutler, 2004b). This might lead to a pro-inflammatory 
state, which could be harmful when there is already a background of inflammation, as it is the 
case, for example, in intestinal bowel disease. To mimic a pro-inflammatory background, the 
ability of TNF-α (a potent pro-inflammatory CK) to modulate the IL-8 responses of HT29 
cells to lactobacilli was studied. The results showed that IEC were indeed sensitised by this 
pro-inflammatory CK to respond to lactobacilli. In a similar experimental set up, Bai et al. 
(2004) showed that two probiotic strains reduced TNF-α induced IL-8 secretion by HT29 
cells, but the authors did not consider the possibility that the decrease in IL-8 could have been 
a result of protease degradation, as it had been reported before (Horvat & Parmely, 1988; 
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Mintz et al., 1993). Ma et al. (2004) reported that live L. reuteri cells were essential for 
reducing TNF-α-induced IL-8 levels in Caco-2 cells. In contrast, Mc Cracken et al. (2002) 
demonstrated that TNF-α enhanced IL-8 response to L. plantarum 299v, but they found a 
discrepancy between RNA levels and protein levels. Hence, IL-8 mRNA levels were much 
higher in TNF-α pre-treated HT29 cells exposed to L. plantarum 299v than the IL-8 mRNA 
levels induced by TNF-α alone. At the protein level, they found the opposite. In this study, IL-
8 protein levels were higher when TNF-α pre-treated HT29 cells were co-cultured with L. 
plantarum BFE 1685, L. johnsonii BFE 6128 and L. rhamnosus GG. These data are supported 
by a previous report, which showed that leukocytes sensitised Caco-2 cells to non-pathogenic 
E. coli and L. sakei increased the expression of IL-8 mRNA (among other CKs), because the 
principal factor responsible for this was identified as TNF-α produced by the underlying 
leukocytes (Haller et al., 2000). The Lactobacillus strains of this study, as well as the 
reference strain L. rhamnosus GG, would be therefore not be appropriate for treatment of 
IBD, as they enhance the pro-inflammatory activity of TNF-α. However, in vivo studies 
should be done to confirm this in IBD models, such as mice suffering from chemical-induced 
colitis (induced with oxazolone, trinitrobenzene sulfonic acid or dextran sodium sulphate) or 
spontaneous colitis (e.g. in IL-10 knockout mice) (Boirivant et al., 1998; Blumberg et al., 
1999; Rachmilewitz et al., 2002). 
When HT29 cells were co-cultured with lactobacilli and LPS, a synergistic effect was 
seen, as the levels of IL-8 were higher than those observed when HT29 cells were treated with 
LPS alone. Haza et al. (2004) have reported that L. plantarum CBL/J was also able to 
stimulate IL-8 production in the THP-1 human macrophage cell line. However, in contrast to 
the results presented here, IL-8 was not enhanced by incubation with LPS. Haza et al. (2004) 
also tested the influence of both L. plantarum CBL/J and LPS on the production of TNF-α 
and IL-1β by this macrophage cell line and found that the production of these CKs was 
enhanced. 
According to the results of TLR4 mRNA expression, there was no relationship between 
the expression of TLR4, which is activated by LPS, and the effect of lactobacilli on IL-8 
increased secretion in the presence of LPS. Thus, it is possible that lactobacilli influenced the 
secretion of this CHK at a post-transcriptional level, or by influencing the expression of other 
factors involved in TLR4 pathway. 
Because of their adhesive properties, ability to exclude pathogens and stimulate IL-8 in 
HT29 cells, the two probiotic candidates (L. plantarum BFE 1685 and L. johnsonii BFE 6128) 
were further investigated to elucidate their immunostimulatory mechanisms. L. rhamnosus 
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GG was used in these experiments as reference strain. In an attempt to arrive at a better 
understanding of the structural requirements for induction of IL-8  in IEC, the ability of the 
lactobacilli cellular components (DNA, LTAs, cell walls) and pre-treated bacteria (proteinase 
K and KIO4 treatments) to trigger the secreting response in HT29 cells was investigated. 
Whole cells, cell wall components, DNA and soluble factors from L. rhamnosus GG are 
known to elicit pro-inflammatory CKs in human macrophages (Matsuguchi et al., 2003; Pena 
& Versalovic, 2003; Iliev et al., 2005), but the effect of these components in intestinal 
epithelial cells has been less studied. Lammers et al. (2002)  have shown that lactobacilli, 
including L. rhamnosus GG, and bifidobacteria did not induce nor inhibit IL-8 production by 
HT29/19A cells, whereas both cell debris and cell extracts from E. coli Nissle 1917 did. 
Peptidoglycan is the major structural component of Gram-positive bacterial cell walls, and 
was shown to induce localised inflammatory responses augmenting cell- and humoral 
mediated responses (Deng et al., 2004).  
LTAs are membrane-associated amphiphilic macromolecules that are found in many 
Gram-positive bacteria and have been associated with modulation of autolysins, binding of 
cations for enzyme function and electromechanical properties of the cell wall (Debabov et al., 
2000).  LTA is also immunologically active (Tsutsui et al., 1991) and has been shown to 
induce secretion of IL-8 from human blood leukocytes (Deng et al., 2004). In this study, LTA 
derived from L. rhamnosus GG and L. johnsonii BFE 6128 triggered IL-8 secretion by HT29 
cells to levels significantly different (P<0.05) from those produced by naïve cells. In this 
investigation, LTAs were extracted using a gentle extraction procedure, which preserves D-
Ala dipeptides and thus yielding bioactive, pure LTA (Morath et al., 2002). LTA derived from 
L. plantarum BFE 1685 did not modify IL-8 levels secreted by HT29 cells, but its supernatant 
did. A hypothesis to explain this could be that the structural conformation of purified LTA 
differs from the conformation when LTA is inserted in the cells wall. Such conformation 
changes may sometimes influence the immunogenicity of LTA (Bhakdi et al., 1991). 
It was also hypothesised that a soluble factor may exert such an effect, because 
supernatants of L. rhamnosus GG and L. plantarum BFE 1685 also induced IL-8 secretion. 
None of the cell walls extracts induced IL-8 significantly, indicating that the peptidoglycan of 
these strains was not responsible for the lactobacilli stimulation as LTA, membrane and 
proteins were removed during preparation of cell walls with SDS. On the other hand, during 
preparation of crude cell walls, LTA may have lost its immunogenic potential, as it has been 
noted earlier that fatty acids and/or ester-bound alanine are easily lost (Fischer et al., 1980). 
Bacteria treated with proteinase K or KIO4 did not exert any effect on IL-8 induction by HT29 
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cells, either. KIO4 is an oxidant of lipids which may have altered LTA structure. It is also 
possible that certain proteins immersed in the cell wall contributed to the IL-8 induction, 
because the treatment of L. rhamnosus GG, L. plantarum BFE 1685 and L. johnsonii BFE 
6128 with proteinase K eliminated this effect. 
It is well known that bacterial DNA containing numerous repeating unmethylated CpG 
motifs has an immunogenic potential (Takeshita et al., 2004; Pedersen et al., 2005). DNA 
from probiotic bacteria has been reported to modulate the immune function of murine and 
human intestinal epithelia (Jijon et al., 2004; Rachmilewitz et al., 2004) and DNA from 
yogurt starters has been shown to activate B cells (Kitazawa et al., 2003). Akhtar et al. (2003) 
reported that E. coli DNA induced IL-8 in human epithelial cell lines. For these reasons, 
HT29 cells were incubated with DNA from L. rhamnosus GG, L. plantarum BFE 1685 and L. 
johnsonii BFE 6128 to determine if DNA contributed to the IL-8 induction described above. 
However, this was not the case, as no differences were seen with the untreated cells.  
At the mRNA level, whole live L. rhamnosus GG, L. plantarum BFE 1685 and L. 
johnsonii BFE 6128 induced IL-8 as measured by RT-PCR after 2 h coculture with HT29 
cells, after which HT29 cells were washed and incubated with medium alone for 4 h. IEC 
(including Caco-2 and HT29 cell line models) produce antimicrobial peptides (defensins) 
under certain stimuli such as IL-1, LPS or invasive bacteria (O'Neil et al., 1999; Vora et al., 
2004). HBD-2 is an inducible defensins, which may protect the intestinal epithelium from 
pathogen invasion and from potential invaders among the commensal microbiota. E. coli 
Nissle 1917, a probiotic bacterium, has been reported to induce HBD-2 in a Caco-2 cell line 
model (Wehkamp et al., 2004). The Lactobacillus probiotic candidates tested in this study did 
not induce HBD-2 expression in HT29 cells, this may have be due to an strain-specific effect 
only exerted by Gram-negative or invasive bacteria. Another possibility could have been that 
the sensibility of RT-PCR was not high enough. 
TLRs are pattern recognition receptors which recognise microbial components and 
initiate an innate immune response. Contradictory reports about the expression of these 
receptors in IEC have been reported (Cario & Podolsky, 2000; Hausmann et al., 2002; 
Melmed et al., 2003; Otte et al., 2004; Furrie et al., 2005). HT29 cells in this study expressed 
all TLRs at the mRNA level, as investigated with the signal arrays. RT-PCR was not sensitive 
enough to detect TLR2 mRNA, but real time RT-PCR was. The expression of TLR2, TLR5 
and TLR9 in the HT29 cell line was also confirmed at the protein level by FACS analysis. 
TLR2 expression results, together with the IL-8 stimulation potential of LTAs from L. 
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rhamnosus GG and L. johnsonii BFE 6128, strongly suggests that these bacteria stimulate 
innate responses in IEC via their LTAs. 
It has been described that microbial stimuli affect the expression of their cognate TLR 
(Poltorak et al., 1998; Visintin et al., 2001; Hornung et al., 2002). Therefore, it was 
hypothesised in this study, that expression of TLR involved in the recognition of lactobacilli 
may be modulated upon stimulation with these strains. L. rhamnosus GG, L. plantarum BFE 
1685 and L. johnsonii BFE 6128 regulated not only TLR2 but also TLR9 mRNA 
transcription, but they did not influence expression of the TLR4 gene. At protein level, two of 
the three tested strains, namely L. rhamnosus GG and L. plantarum BFE 1685, up-regulated 
TLR2 and TLR5 expression in HT29 cells. 
This is the first time that a modulation of TLR expression by lactobacilli is shown in 
intestinal epithelial cells. This important finding could serve to explain the adjuvant properties 
of some probiotic lactobacilli (Perdigon et al., 1991; Iliev et al., 2005; Ogawa et al., 2005; 
Ogawa et al., 2006) and establish the basis for further studies on development of  mucosa 
vaccine adjuvants, as it has been suggested that TLR signalling pathways are a promising 
mechanism for boosting vaccine responses (van Duin et al., 2006). On the other hand, it may 
also raise attention towards the indiscriminative use of probiotic products for treatment or 
support of IBD, as some strains, such as the strains in this study, may not be adequate for 
patients with a background of chronic inflammation. However, as it has been mentioned 
above, this should be first confirmed in in vivo models of inflammation. 
L. johnsonii BFE 6128 was shown to also enhance the response of HT29 cells towards S. 
Typhimurium. Nevertheless, the increase in IL-8 could not be related to an increase in the 
number of TLR5 receptors (which recognise flagellin). Flagellin has been described as the 
main determinant of Salmonella-mediated NF-κB and pro-inflammatory signalling (Tallant et 
al., 2004). In order to determine if L. johnsonii BFE 6128 was able to enhance the recognition 
of a specific antigen by HT29 cells, different S. Typhimurium derived cellular components 
were tested. Surprinsingly, the increased IL-8 production was only observed in cells 
stimulated with flagellin and with whole S. Typhimurium cells. Thus, the enhancement of the 
secretion of this innate immunity molecule (IL-8) may have been regulated at other levels, 
different than by enhancing TLR5 expression. To further approach this question, RT-PCR 
based arrays were used to evaluate if there were other genes involved in TLR pathways which 
were modulated by lactobacilli. 
Transcriptomic analysis clearly showed that the pre-treatment with L. johnsonii BFE 
6128 followed by an infection with S. Typhimurium activated the transcription of several 
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genes involved in TLR and innate immunity pathways. This was not the case when cells 
treated with S. Typhimurium had not been previously treated with L. johnsonii BFE 6128, nor 
when HT29 cells were treated only with lactobacilli. Among the genes modulated when HT29 
cells had been pre-treated with lactobacilli and then exposed to S. Typhimurium, there were 
genes coding for kinases involved in the transduction of signals upon TLR activation, for 
transcription factors which in turn induce the transcription of other target genes, for CHKs 
involved directly in the recruitment of neutrophils and lymphocytes, for non-traditional 
antigen presenting molecules and for TLR themselves.  
TLR engagement results in activation of the mitogen-activated protein kinases (MAPKs), 
which, together with the NF-κB pathway, transduce extracellular signals to cellular responses. 
Activation of the MAPKs is mediated by a core kinase module comprised of MAP3K, 
MAP2K, and MAPK through sequential protein phosphorylation (Chi et al., 2006). MAP 
kinases are regulatory signal mediators in immunocytes, and play an important role in host 
innate responses. In addition, IL-8 release has been shown to depend in part on MAPK 
activation (Akhtar et al., 2003; Chang et al., 2006). In this study, it was shown that two genes 
coding for the MAP kinases, MAPK8IP3 and MAP3K1 were significantly up-regulated. 
RIPK2 and IRAK2 genes were also up-regulated. RIPK2 (also known as CCK2 or CARD3) is 
a serine/threonine kinase containing a caspase recruitment domain, which is involved in 
multiple receptor signalling pathways that are important for innate and adaptive immune 
responses, but which have not yet been fully elucidated. It has been shown that upon LPS 
stimulation, RIPK2 was transiently recruited to the TLR4 receptor complex and associated 
with key TLR signalling mediators IRAK1 and TRAF6. Furthermore, RIPK2 kinase activity 
was induced by LPS treatment, indicating that it is directly involved in the LPS/TLR4 
signalling (Lu et al., 2005). IRAKs (IL-1 associated kinases) on the other hand, are also 
directly involved in TLR signalling pathways. The transcription of PELI1 (Pellino 1) was also 
up-regulated. Pellino 1 is an adaptor molecule which has been shown to interact with IRAK 
and modulate IL-1 and LPS signalling (Jiang et al., 2003; Schauvliege et al., 2006). Thus, the 
up-regulation of these genes involved in transduction of TLR signalling may have played a 
role in the increases of IL-8 observed when HT29 cells were pre-treated with lactobacilli and 
then, infected with S. Typhimurium.  
Three transcription factors genes, FOS, IRF and NF-κB1 were also up-regulated. The 
early growth transcription factor FOS, together with other members such as JUN complexes 
(whose gene has also been up-regulated) plays a critical role in regulating IL-12 in dendritic 
cells (Agrawal et al., 2003; Dillon et al., 2004). The role of this transcription factor in IEC is 
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less well known. IRF is the essential transcription factor for induction of iNOS by IFN-γ in 
macrophages (Fritsche et al., 2003) but whose function has not yet been defined in IEC. NF-
κB1 is one of the components of the NF-κB pathway, which is the main pathway which 
follows after TLR activation (Kawai & Akira, 2006) and leads to transcription of pro-
inflammatory genes. Therefore, if their up-regulation by lactobacilli, when cells encounter a 
pathogen in IEC could be extrapolated to professional antigen presenting cells, such as 
dendritic cells, the observed up-regulation of genes may have consequences in the further 
development of the immune response by influencing IL-12 and iNOS production. Thus, the 
influence of these lactobacilli on signal transduction in dendritic cells should be further 
investigated. 
It has been proposed, that IEC may also function as alternative antigen presenting cells as 
they express non-classical antigen presenting molecules (Shao et al., 2005). In this study, two 
genes coding for co-stimulatory molecules, CD80 and CD86, were notably up-regulated in 
HT29 cells by pre-treatment with lactobacilli and then followed by treatment with S. 
Typhimurium, though with P>0.05. Nevertheless, the up-regulation of this molecules in 
dendritic cells by lactobacilli and in other antigen presenting cells after TLR activation had 
been described before (Drakes et al., 2004; van Duin et al., 2006). Co-stimulatory molecule-
mediated signalling improves vaccine efficiency (van Duin et al., 2006) and therefore the up-
regulation of CD80 and CD86 genes may represent a mechanism for TLR-ligands and for 
lactobacilli for enhancing the effect of vaccines (Isolauri et al., 1995; Pouwels et al., 1998; 
Suzuki et al., 2004; Mota et al., 2006). 
Intestinal epithelial cells are the first cells which encounter a potential pathogen. They 
are able to recognise it and transduce the signal and express CKs and CHKs, which serve as 
chemical messengers for the immune cells present in the lamina propria (Kolios et al., 1999; 
Stadnyk, 2002). In this study, pre-treatment of HT-29 cells with lactobacilli followed by 
infection with S. Typhimurium led to an increase in IL-8 at the protein level and to the up-
regulation of other CHK and CK genes (CSF2, IL-8, CXCL10 and TNF-α) which also play a 
role in recruiting and activating professional immune cells. CSF2 (granulocyte-macrophage 
colony stimulating factor) prolongs the survival of neutrophils, monocytes and eosinophils, 
and increases the response of those cells to other pro-inflammatory agonists which can further 
amplify the inflammatory response (Wilson et al., 1998). It can also stimulate TNF-α and IL-
1 by monocytes/macrophages (Jung et al., 1995) and influence the initial phase of antigen 
processing and presentation (Siegmund & Zeitz, 2004). IL-8 is a potent neutrophil attractant 
and activator, which may also influence and recruit other cells such as natural killers and 
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basophils (Morohashi et al., 1995; Campbell et al., 2001). The chemokine interferon IFN-γ-
inducible protein-10 (IP-10/CXCL10) is a chemoattractant for various leukocyte subsets. 
Krathwohl  and Anderson (2006) hypothesised that  CXCL10 could stimulate dendritic cells 
to mature and cross-present exogenous antigen to T cells, resulting in a Th1-type immune 
response. TNF-α can stimulate IL-8 and MCP-1 production by monocytes/macrophages (Jung 
et al., 1995). Therefore, the up-regulation of these CK and CHK by pre-treatment with 
lactobacilli followed by infection with S. Typhimurium may serve for recruiting immune cells 
from the lamina propria to the infection site at the very early stages of infection to eliminate 
the threat. This may lead to prevention of diarrhoea caused by S. Typhimurium or to the 
shortening of diarrhoea duration, if the pathogen is eradicated before invasion has occurred. 
In summary, L. johnsonii BFE 6128 sensitised intestinal epithelial cells for recognition of 
S. Typhimurium, and thereby up-regulated innate immune genes which may serve as link 
between the innate and adaptive immunity.  
It has been previously reported that L. rhamnosus GG improved the immunogenicity of a 
rotavirus vaccine (Isolauri et al., 1995) and that serum and intestinal immune responses were 
promoted by lactobacilli (Isolauri et al., 1991; Kaila et al., 1992; Majamaa et al., 1995; 
Guandalini, 2002). There are also many claims about the immune stimulation effects of 
lactobacilli, which include both innate and adaptive immunity components (Kato et al., 1994; 
Isolauri et al., 2001; Perdigon et al., 2002; Ogawa et al., 2006), that have led to the hypothesis 
that lactobacilli may be proper carriers for antigen delivery (Pouwels et al., 1998; Scheppler et 
al., 2002; Mota et al., 2006). Thus, the up-regulation of pro-inflammatory mediators and TLR 
pathways-related molecules can contribute to elucidating the so-called ‘immunoadjuvant’ 
properties of lactobacilli, as well as their contribution to prevention and treatment of bacterial 
and viral diarrhoea. On the other hand, the modulation of TLR expression by lactobacilli may 
open new research directions towards the understanding and developing of new vaccines 
targeting TLR pathways. 
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5 CONCLUSIONS 
In this study, seven strains were selected out of thirty isolates because of their survival 
ability under gastrointestinal conditions, and they were further characterised for their 
probiotic, safety and immunostimulating properties. It was shown that each strain presented 
individual characteristics, which may contribute to their ‘probiotic’ health-promoting effects. 
In the final evaluation of their properties, four strains, L. plantarum BFE 5759, L. plantarum 
BFE 1684, and L. plantarum BFE 1685 and L. johnsonii BFE 6128, are proposed for the 
further development of a multiple-strain fermented milk product containing Raftiline® ST 
would combine the beneficial effect of each probiotic candidate strain, as well as the inherent 
effect of this prebiotic sugar, as has been discussed above. These four strains were able to 
survive gastrointestinal conditions, which indicates that they may reach the site of action, the 
small intestines unharmed. Because of their metabolic properties, they would probably 
contribute to the reduction of cholesterol levels due to the presence of Bsh. In addition, two of 
the strains, namely L. plantarum BFE 5759 and BFE 1684, may also contribute to alleviation 
of lactose intolerance because of their β-galactosidase activity. The four selected strains are 
microorganisms belonging to the risk 1 group because of their long history of safe use and 
they did not have transferable antibiotic resistance, which implies their acceptability 
according to the guidelines of the European Food Safety Association. The selected lactobacilli 
are most promising probiotic candidates as based on their antimicrobial, coaggregative and 
adhesive properties, as they may inhibit or exclude food pathogens by different mechanisms. 
By a coaggregating mechanism with pathogens, lactobacilli may enhance their clearing from 
the gastrointestinal tract, thus preventing them from adhering to IEC and also inhibiting them 
in this micro-environment by producing organic acids and H2O2. Competitive exclusion of 
two of the selected strains, i.e. L. plantarum BFE 1685 and L. johnsonii BFE 6128, have been 
proven in vitro against representative food-borne pathogens, suggesting an important role in 
prevention of enteric infections.  
The ability of these strains to stimulate the production of IL-8 at a low level with their 
LTAs, and possibly also with further un-identified factors, may contribute to maintaining the 
immune system in a state of alert for the possible encounter of pathogens.  
Furthermore, the induction of TLR5 protein expression in IEC supports this hypothesis 
and may increase the IEC capacity of recognising invasive flagellated bacteria such as S. 
Typhimurium already at the early stages of infection. This would mobilise the innate immune 
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response before the pathogen has time to proliferate, gaining time for the adaptive immunity 
to be activated. The significance of increasing TLR2 expression should be further evaluated 
as it might contribute to intolerance by recognising normal inhabitants of the GIT. The 
experiments in this study on the influence of lactobacilli on the response of HT29 cells to S. 
Typhimurium clearly showed that L. johnsonii boosts innate immunity mechanisms against 
this pathogen. Thus, it contributes to the early response against this pathogen by recruiting 
and activating monocytes/macrophages and neutrophils as a result of the enhanced production 
of pro-inflammatory CHK and CKs as well as expression of co-stimulatory proteins.  
However, the colonisation ability and immune stimulatory properties must be validated 
in further in vivo studies. Nevertheless, the importance of in vitro studies should  
underestimated, as they provide a controlled system for the study of underlying probiotic 
mechanisms and are unavoidable steps in the development of new therapeutic agents. On the 
other hand, the screening of multiple strains in vivo without previous knowledge of the 
potential effects and/or hazards of the bacteria being tested should neither be done nor is it 
practicable, first and foremost because of ethical reasons. This, together with the prohibitive 
high costs associated with animal or human studies, is the reason why initial selection studies 
on new probiotic strains are generally first done in vitro. After screening numerous strains for 
their functional properties, those strains displaying interesting probiotic properties are then 
chosen for further in vivo testing and probiotic product development.  
The main objective of this study was to find new probiotic candidates to be used in 
functional fermented milks and the in vitro characterisation of selected strains following the 
criteria for selection of probiotic strains proposed by the a Joint FAO/WHO working group of 
experts in probiotics (Chesson et al., 2002). This objective and the associated aims were 
successfully achieved as ‘multifunctional’ strains were isolated and characterised. Last but not 
least, novel mechanisms involved in the innate immunomodulation were elucidated, providing 
new insights in the communication between bacteria and intestinal epithelial cells as well as 
underlying the sentinel role played by enterocytes. This is the first report on modulation of 
expression of TLRs at the mRNA and protein level by probiotic microorganisms in intestinal 
epithelial cells. 
Therefore, in the final analysis, this study provides a rationale for the further use of the 
selected Lactobacillus strains (L. plantarum BFE 5759, BFE 1684 and BFE 1685, and L. 
johnsonii BFE 6128) as probiotics for therapeutic and preventive purposes. 
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5.1 Outlook 
As the preliminary in vitro tests have shown a definite probiotic potential and 
immunostimulating effects for the lactobacilli selected and characterised in this study, these 
strains are apt to pass to the second step necessary to develop health-promoting products, i.e. 
in vivo animal models. If successful also in these models, it would be necessary to test if the 
effects seen in vitro and in animal models are still observed in humans. 
Double-blind placebo controlled studies may provide further information on the 
beneficial effects of these strains with respect to lactose intolerance, cholesterol lowering, 
prevention of bacterial diarrhoea and immunostimulatory properties.  
The possibility of using these Lactobacillus strains for development of probiotics to be 
use in other compartments of the body such as oral cavity, vagina or the skin should be 
considered. 
To further investigate the mechanisms involved in innate immunity, the use of primary 
intestinal epithelial cells, as well as other cells isolated from human biopsies would provide 
more information about the modulation of TLR-related pathways. The use of reporter-gene 
systems and bacterial mutants would also contribute to gain more insight in these 
mechanisms. 
The results concerning innate immunomodulation by lactobacilli open new research 
possibilities for the use of these bacteria as immunoadjuvants and development of mucosal 
vaccines. 
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LIST OF ABBREVIATIONS 
APC     antigen presenting cell 
ATB     antibiotic 
BSA     bovine serum albumin 
Bsh     bile salt hydrolase 
CD     cluster differentiation 
CHK     chemokine 
CK     cytokine 
COX-2     inducible cycle-oxygenase 
Ct     threshold cycle 
DEPC     diethylpyrocarbonate 
ds     double-stranded 
FACS     fluorescence activated cell sorter 
FCS      foetal calf serum 
FITC     fluorescein isothiocyanate 
GALT     gut associated lymphoid tissue 
GIT     gastrointestinal tract 
GRAS     generally recognised as safe 
HBD-2     human β-defensin 2 
HLA     human leukocyte antigen 
IBD     intestinal bowel disease 
IEC     intestinal epithelial cells 
IEL     intra-epithelial lymphocytes 
IFN     interferon 
Ig     immunoglobulin 
IKK     inhibitor κB kinase 
IL     interleukin 
IRAK     IL-1R-associated kinase 
LAB     lactic acid bacteria 
LDH     lactate dehydrogenase 
LPS     lipopolysaccharide 
LTA     lipoteichoic acid 
MALT     mucosa associated lymphoid tissue 
MAPK     mitogen-activated protein kinase 
MCP-1     monocyte chemoattractant protein-1 
MHC     major histocompatibility complex 
MTT     3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NF-κB     Nuclear factor κB 
NK     natural killer 
NRT     no reverse transcriptase control 
NTC     no template control 
PB     Plackett Burman 
PBMC     peripheral blood mononuclear cells 
PBS     phosphate buffered saline  
PRR     pattern recognition receptor 
QSR     quarter-strength Ringer solution 
RT     room temperature 
SCAN     Scientific Committee for Animal Nutrition 
ss     single-stranded 
TIR     Toll/IL-1R  
TLR     Toll-like receptors 
TNF     Tumour necrosis factor 
Tollip     Toll inhibitory protein 
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